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Abstract

LOW-FLOW DOMICILIARY OXYGEN AS A MECHANISM OF ONGOING
OXIDATIVE STRESS IN COPD PATIENTS
Jill Stulce, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in Health Related Sciences at Virginia Commonwealth University.
Virginia Commonwealth University, 2015
Clarence Biddle, Ph.D., Department of Nurse Anesthesia

Healthcare costs are escalating in the U.S., with a projected 48 trillion dollars by 2021.
More than ever medical researches are obligated to ensure that costly treatment
modalities are safe and effective. Chronic obstructive pulmonary disease (COPD) is a
costly and debilitating disease, ranked as the third leading cause of death in America.
Currently, treatment for COPD consists of anti-inflammatory agents, bronchodilators,
antibiotics and supplemental oxygen when hypoxemia or clinical manifestations ensue.
Oxidative stress is central to the pathology of COPD. Supplemental oxygen has been
substantiated as an instigator of oxidative stress; however, LFDO has not been evaluated
as a mechanism of ongoing oxidative stress in individuals with COPD. Isofuran (IsoF), a
biosynthetic relative of the validated oxidative stress biomarker 8-isoprostane, is
preferentially synthesized during periods of increased tissue oxygen tension. This sort of

specificity allows for refinement in the assessment of supplemental oxygen as a source of
oxidative stress. To address this potential this study evaluated individuals diagnosed with
COPD utilizing LFDO. The study also aimed to determine if IsoF possessed clinical
application in predicting the standard pulmonary function test (PFT) parameters of FEV1,
FVC, FEV1/FVC and FEF25-75. The exhaled breath condensate (EBC) of 52 individuals
with COPD was evaluated for the presence of IsoF. An active control group not receiving
LFDO (n=26) was compared to an active treatment group receiving LFDO for a
minimum of 6 hrs/day (n=26). The groups showed no statistically significant
demographic differences in age, gender, height, weight, ethnicity or smoking history or in
the pulmonary function test parameters of FEV1, FVC, and FEV1/FVC, with the
exception of the FEF25-75 (P=0.03). The active control group generated a mean EBC
IsoF level of 35.81 ± 4.91 pg/ml (± SEM) compared to the active treatment group mean
EBC IsoF level of 51.37 ± 8.27 pg/ml (P=0.057). Currently, no research has been
conducted that defines baseline EBC IsoF levels in healthy or diseased lungs. No
statistically significant differences in mean EBC IsoF levels were noted between the
control and treatment groups; however, the results, in conjunction with the only two
studies available utilizing EBC IsoF as an oxidative stress biomarker, may serve to
provide benchmark information for future research regarding individuals with diseased
lungs, specifically COPD.

Chapter 1- Introduction

Introduction
Americans may be living longer but not necessarily more healthfully. Some lifestyle
choices are rife with consequence. Smoking, over eating and lack of exercise are major players
in our countries overall lack of health and has translated to economic stress. Healthcare
expenditures in the U.S have been growing at an alarming rate for the past several years. Total
health expenditure in the U.S. is defined as the sum of public and private expenditure, and covers
healthcare provision (preventive and curative), family planning, nutrition activities, and
emergency aid. In the 1960’s the healthcare costs constituted approximately 5.2% of the GDP.
During the 70’s healthcare costs increased to 7.2% GDP, or approximately 75 billion dollars.
Currently, 17.3%, or roughly 2.5 trillion dollars, are spent annually on healthcare. A GDP of
20%, or 48 trillion dollars, is projected by 2021 (CMS Report). The United States is on track to
spend one-fifth of tax dollars exclusively on healthcare. There are many factors that contribute to
the escalating costs, such as hospitals, physicians, prescription drugs, nursing/continued care,
private health insurance administrative costs, etc.; however, this study will focus on those areas
whose cost most directly impact health care delivery, hospitals and physicians, which comprise
about 50% of the expenditures are considered the structure and process of healthcare delivery.
When considering an approach to contain escalating costs it is necessary to understand
health trends that contribute most significantly to those costs. According to a report published by
the Agency for Healthcare Research and Quality (AHRQ) (2006), the top five diseases that
1

introduce the greatest economic burden to this country are mood disorders, diabetes, cancer,
heart disease, lung disease and hypertension. One such disease is chronic obstructive pulmonary
disease (COPD), which continues to be one of the top five leading causes of death in America.
Costly treatments, increased hospital stays, loss of functionality leading to inability to work, as
well as requiring in home assistance contribute to the significant expense of this disease. A
deeper understanding of the pathophysiology of the disease, as well as the prescribed
interventions and management, could aid in improving health states and reducing cost of these
major health care categories.
A common denominator exists amongst many disease processes, oxidative stress.
Oxidative stress, free radical induced damage to proteins, lipids and DNA, has been implicated
as a key process in the development of heart, lung, and neural disease, cancer, diabetes, arthritis,
cataracts, and, on a lesser stage, aging. Interestingly, oxidative stress is linked to those disease
categories that introduce the greatest economic burden in the U.S. As such, it is imperative that
researchers gain an intimate understanding of this potentially deleterious process in order to
ameliorate or eliminate its health and economic impact.
Chronic obstructive pulmonary disease is one of the major pulmonary diseases that
proves to be physically, spiritually and economically taxing. It is a progressive and irreversible
respiratory disease primarily linked to oxidative damage caused by airway irritants, most
prominently cigarette smoking. For nonsmokers, long-term exposure to second hand smoke,
chronic asthma, and environmental pollutants are the most significant contributors. As the
leading contributor of COPD, it is of value to understand the mechanisms of destruction induced
by cigarette smoke in the airways in an effort to prevent the destruction. Cigarette smoke
stimulates the generation of reactive oxygen species (ROS), a molecular form of oxygen
involved in oxidative stress, and has been linked to alterations in glutathione (GSH), an intra and
2

extracellular antioxidant present in the lungs (Rahman and MacNee, 1999). Disabling the body’s
protective antioxidant defenses invites oxidative reactions, especially in the presence of
increased ROS. Ultimately, this imbalance results in lung parenchymal damage through
alterations in the lipid bilayers induced by oxidative stress.
For those who smoke, and for those who are chronically exposed to airway mutagens, it
is recommended to undergo pulmonary function testing for early detection of COPD. Early
detection of COPD can produce the greatest opportunity to halt the debilitating disease.
Pulmonary function testing (PFT) is a simple non-invasive method of assessing lung function.
Pulmonary function defects can be grouped into two main categories: obstructive and restrictive.
If expiratory flow is impeded an obstructive disorder may exist; if volume is reduced a restrictive
disorder may exists. Several pulmonary function tests can be performed to assist in predicting
pulmonary status, such as the vital capacity (VC), forced vital capacity (FVC), peak expiratory
flow rates (PEFR), forced expiratory flow rates (FEF), maximal voluntary ventilation (MVV)
and forced expired volume in 1 second (FEV1). The most frequently used parameters in
predicting stages of COPD are the FEV1 and FVC values, both of which are useful in detecting
and quantifying restrictive and obstructive patterns. The FEV1 is the amount of air forcefully
expelled in the first second of exhalation. Forced vital capacity is the amount of air an individual
can forcibly and maximally expel until unable to expel any more. The FEV1/FVC represents a
proportion of an individual’s vital capacity expelled in the first second. When values are
categorized by age, gender, race, and body height and size a meaningful interpretation can be
made. PFTs are effort dependent, therefore, patient compliance and cooperation is required for
accurate result valuation.
The study of oxygen has been a topic of research for literally centuries. It is a perplexing
and curious notion that an element is necessary for life but contributes to morbidity and
3

mortality. Oxygen delivery is a frequently prescribed therapy in both the acute and chronic care
in the U.S. Low flow domiciliary oxygen (LFDO) is a prescribed therapy for those afflicted with
advanced stages of COPD. Due to ethical implications a safety index for oxygen exposure has
not been established. Most of the usable data regarding tolerable limits of oxygen exposure have
been obtained from normal, healthy, young subjects (Klein, 1991). As a result, the effects of
underlying diseases and other factors that may alter inherent oxidative protective mechanisms
remain unknown. For the COPD population the benefits of LFDO therapy are well documented.
Consequences of prolonged exposure to higher concentrations of oxygen has garnered much
research attention; to date, only a handful of research studies have addressed the consequences of
chronic exposure to low concentrations of oxygen with regard to oxidative injury. Petty, Stanford
and Neff in 1971 and Steward, Hood and Block in 1975 both demonstrated histological changes
in post mortem autopsies of those who had been treated with LFDO for several years. Two
studies, both performed in 2004 evaluated 30-minute exposure to 28% oxygen. Phillips et al.
compared healthy subjects and determined a significant (P<0.05) increase in BMAC, a
biomarker of oxidative stress. Carpagnano et al compared healthy subjects to those with COPD
and determined a significant (P<0.05) in 8-IsoP between groups. However, to date no studies
have utilized isofuran, a biomarker synthesized only in the presence of elevated oxygen tensions,
as a mechanism to determine if oxygen is the culprit for the presence of oxidative stress.
A disease process that is a direct result of unchecked oxidative stress, COPD is an ideal
pathology to evaluate to learn more about the potential of LFDO as a mechanism of ongoing
oxidative stress. It would be unfortunate, negligent and medically irresponsible if a prescribed
therapy fostered ongoing oxidative stress in this already fragile population. Eradicating costly
diseases through research and development along with the adherence to healthy lifestyles could
spare the individual and nation at large significant economic, physical and emotional burden.
4

Purpose
Chronic obstructive pulmonary disease, a progressive and irreversible respiratory disease
resulting from unchecked oxidative processes, in advanced states often requires oxygen
supplementation to ameliorate distress. The purpose of this study is to identify if ongoing
oxidative stress is occurring as a result of chronic exposure to low flows of domiciliary oxygen
(LFDO) as evidenced by the validated biomarker, isofuran. Understanding these mechanisms
may lead to a more rational basis for clinical prescription of oxygen.
The goal of this study is to gain insight into the potential of oxygen in order to safely
prescribe and manage oxygen therapy. The objective of this study is to determine if LFDO as a
treatment modality in COPD promotes oxidative stress. The specific aims of this study are to 1)
assess for the presence of isofuran, an oxidative stress biomarker, in the exhaled breath
condensate (EBC) of COPD patients on LFDO; 2) determine if a correlation exists between
standard diagnostic spirometry values and exhaled breath condensate EBC biomarker (isofuran);
3) determine if a correlation exists between length of smoking history, length and concentration
of oxygen exposure and EBC biomarkers (isofuran levels).
Background and Significance
The impact of oxidative stress on the health of U.S. citizens has only recently been
appreciated. Oxidative stress has been linked to the top five diseases, including heart disease,
lung disease, cancer, diabetes, and neural disorders, contributing to the greatest healthcare costs
in terms of treatment, hospitalizations and loss of work (Druss, et al, 2001). While people may be
living longer it may not necessarily be more healthfully (National Center for Health Statistics,
2010).
Chronic obstructive pulmonary disease (COPD) is a progressive disorder resulting in
irreversible lung damage primarily comprised of two disorders: chronic bronchitis and
5

emphysema, and falls as one of the most economically burdensome. Approximately 16 million
Americans have COPD, 14 million with chronic bronchitis and 2 million with emphysema
(WHO, 2002). According to the American Lung Association June 2008 Fact Sheet, 2008 stated
that in 2006 12.1 million U.S. adults (ages 18 years and over) were estimated to have COPD but
that ~24 million U.S. adults have evidence of impaired lung function, indicating an under
diagnosis of COPD.
Smoking is considered the major contributor in developing COPD, be it direct smoking
or indirect second hand smoke exposure (American Lung Association, 2008). Associated health
care costs linked to cigarette smoking up to 2002 had been estimated at ~50 billion dollars
annually. More recent reports from the CDC show the economic costs of smoking to be at $3,393
per smoker, reaching an estimated $157 billion: $81.9 billion in productivity losses due to death
and $75.5 billion due to excess medical expenditures (CDC 2002). COPD is the fourth leading
cause of death and is projected to be the third leading cause of death by 2020 (ALA 2008). The
American Lung Association states that an estimated 800,000 adolescents will start smoking
every year. Statistics like this point to a future of continued and worsening economic and
healthcare challenges as it relates to the management of those who develop COPD.
While smoking is implicated as the initial inducer of oxidative stress in COPD pathology,
continued oxidative stress may be occurring as a result of treatment modalities. Superimposing
further damage on an individual with COPD through chronic exposure to greater than room air
concentrations of oxygen via low flow domiciliary oxygen therapy (LFDO) is neither in the best
interest of the COPD patient nor the community at large. It is well understood that oxygen
therapy for those suffering with advanced stages of COPD benefit from LFDO, however, it needs
to be appreciated if this necessary treatment is a contributing factor to ongoing oxidative stress.
To identify whether or not this phenomenon is occurring as a result can assist in guiding
6

researchers to a better understanding and development of COPD health management modalities,
as well as a better understanding of the untoward effects of chronic exposure of LFDO and the
potentially destructive effects of oxygen free radicals.
Oxidative stress occurs as a result of an imbalance between reactive oxygen species
(ROS) and the system’s ability to neutralize these highly reactive intermediates. This imbalance
of a normal redox state has deleterious effects on the surrounding protein, lipid and DNA
structures as a result of peroxide and free radical production and activity. Oxidative stress has
been linked to aging, autism, Alzheimer’s, cancer, COPD and cardiac disease to name a few
(Halliwell, 2007; Valko et al, 2007; Singh et al, 1995; Ramond et al, 2011; Dean et al, 2011). It
should be understood, however, that ROS are integral in health states as well, such as activation
of the immune system; it is the imbalance of ROS and endogenous antioxidants that result in
pathology (Segal, 2005). Although physiologic changes attributable to oxygen toxicity, such as
decreases in vital capacity, pulmonary compliance, and diffusing capacity, together with
increases in arteriovenous shunting and ration of dead space to tidal volume, early detection of
toxicity requires more sensitive, specific, and preferably easy, tests (Klein, 1991).
In the past decade significant research has been conducted to aid in better understanding
the inflammatory cascades occurring within the body in response to various stressors, such as
oxidative stress (Montuschi, 2007; Barnes, 2006). As a result 8-iso-PGF2α, in addition to many
other nonenzymatically generated prostaglandins, have been identified as a biomarker consistent
with oxidative stress occurring within the lungs (Montuschi, 2007; Barnes, 2006).
More recently, research has demonstrated that isofurans, biosynthetic relatives of the
isoprostanes, are formed under conditions where elevated oxygen tensions exist, allowing for
research to expand in the area of hyperoxia. Both biomarkers can be evaluated in exhaled breath,
making them an ideal to study pathologies occurring within the lungs.
7

Breath analysis is not new to medicine. Hippocrates would assess breath odor to
diagnose disease states; however, not until the 1970’s was it demonstrated by Linus Pauling that
over 250 substances were identifiable in exhaled breath via gas chromoatgraphy mass
spectrometry (GC-MS) (Dweik and Amann, 2008). More efficient devices have been developed
to collect and store exhaled breath for biomarker analysis. Researchers suggest using these
biomarkers to diagnose and prognose, as well as manage disease states (Montuschi, 2007).
The identification of a biomarker sensitive to endogenous changes to oxygen tension
within the body provides an opportunity for researchers to better understand oxidative processes.
Currently there is no information available in the literature that defines basal levels of isofuran in
the exhaled breath of individuals diagnosed with advanced COPD with or without domiciliary
oxygen therapy. This study aims to address this gap in foundational knowledge. It also aims to
gain insight into whether or not chronic exposure to oxygen therapy serves as a mechanism of
ongoing oxidative stress within the lungs of individuals with advanced COPD.
Conceptual Framework
“The well-being of the soul can be obtained only after that of the body has been secured,”
insight provided by Maimonides, a revered 12th century Jewish author, physician and
philosopher, in his three volume series entitled The Guide for the Perplexed, demonstrating an
early appreciation that quality of life is directly linked to physical health (Epstein and Sherwood,
1996). Current appreciation of the effect physical health has on quality of life, through outcomes
research, has expanded to become a multidisciplinary effort involving researchers,
healthcare providers, epidemiologists, economists, sociologists, statisticians and ethicists
(Epstein and Sherwood, 1996).
The idea that quality healthcare can be achieved based on positive health outcomes is
intuitive; however, the practice of relating quality to outcomes has become a prominent strategy
8

and more widely accepted in the past few decades in healthcare delivery (Hammermeister,
Shroyer, Sethi, and Grover, 1995; Jennings and Staggers. 1998). The Donabedian model of
structure-process-outcome will assist in guiding this research endeavor. This model fosters
becoming more attuned to all aspects of health care provision, facilitating a more accurate
interpretation of causal relationships between structure, process and outcomes.
Avedis Donabedian was born to an Armenian family in Beirut, Lebanon in 1919 and
grew up in Palestine, narrowly escaping the Armenian Holocaust. He followed his father’s
footsteps in becoming a physician and eventually became the Chief Medical Officer of the
American University in Beirut. During his tenure there he became frustrated with the limitations
as an administrator and turned his interests to quality health care provision and public health.
Following the Second World War, Donabedian moved to the U.S. from Lebanon and joined the
faculty at the University of Michigan. It was then that he was commissioned with the task of
revising all that had been written on quality assessment and to present it in an organized fashion.
At that time formal writings on quality assessment were limited, allowing Donabedian to tackle
this task in a reasonable amount of time and autonomy. His efforts gave way to the more formal
model of process-structure-outcome phenomenon, or Donabedian’s Triad. Donabedian’s
professional career was dedicated to revising and defining his model and outlining its usefulness
for quality assessment and management (Donabedian 1966, 1968, 1982, 1985, 1992).
Elements of quality assessment. Donabedian’s triad of concepts (structure, process and
outcomes) has been defined in his writings. Structure is conceptually defined in terms of the
setting in which care is provided and refers to the organization of health care resources
(Donabedian, 1966). Structure also includes demographics, the education of providers, the
adequacy of the facilities and equipment, as well as the overall administrative environment.
Process is conceptually defined as the actions that constitute healthcare, to include diagnosis,
9

treatment, preventative care, collaboration of services, and patient education (Donabedian,
1982). Processes can also include the technical aspects of how care is delivered, or interpersonal
processes of how care is delivered (Donabedian, 1980). Donabedian believes the measurement of
process is equivalent to the measurement of quality of care as process contains the most relevant
aspects of healthcare provision (Donabedian, 2003). Outcome is conceptually defined as the end
result of the process of care to include “those things, either favorable or adverse, in the actual or
potential health status of persons, groups, or communities that can be attributed to medical care”
(Donabedian, 1985, p.256) and refers to “states or conditions attributable to antecedent health
care” (Donabedian, 1992). In short, outcome is the measurable or observable result of structure
and process; an assessment as to whether or not a treatment modality offered by providers of an
institution affected the health state of the consumer. Outcome goals are to prevent progression of
poor health, and to restore and maintain health states. Donabedian, (1992) states that quality
outcomes are best achieved when the following attributes are employed: effectiveness (achieving
the greatest improvements in health currently achievable by the best care), efficiency (the ability
to provide appropriate care without diminishing improvements in health), optimality (achieving a
balance between the cost of care and the effects of care on health), acceptability (achieving
conformity with patient preferences), legitimacy (achieving conformity to social preferences and
ethical subscriptions), and equity (conformity to principles guiding the fair distribution of health
care in a population). It is widely agreed upon that defining quality is nearly impossible as each
individuals value judgments differ one to the next. However, it also believed that most likely the
majority equates quality with what the medical community perceives as quality.
Conceptual relationships. The relationship between structure, process and outcome is
antecedent, or causal, in nature. In regards to structure and process, Donabedian states that “the
assumption is made that given the proper settings (structure) and instrumentalities (process),
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good medical care will follow” and, hence, good and desired outcomes (1966, p. 170). Specific
attributes of structure, process and outcomes are considered valid for the purpose of quality
assessment only to the extent that causal relationships can be demonstrated, meaning a quality
outcome is only valid if it can be directly linked to the structure and/or process (Donabedian,
1992).
Structure-Process-Outcome Model used in research. Kunkel, Rosenqvist and
Westerling (2007) implemented the Donabedian model in a qualitative survey research endeavor
of 386 hospital departments in Sweden. The goal of this study was to analyze whether process,
structure and outcome could be used to describe quality systems and whether or not these
components are related. It was concluded that the process-structure-outcome model could be
used to describe and evaluate single quality systems (P=0.095) as well as to compare different
quality systems. They believe it could also serve as an aid to implement a systematic and
evidence based system for working with quality improvements in hospital departments.
Statistical analyses showed that Structure correlated strongly with process (0.72) and outcome
(0.60).
In a two-year prospective study of 288 acute stroke patients across 11 VA medical
centers the structure-process-outcome model was used to examine the quality of health care with
regard to stroke patient outcomes. The goal of the project was to determine if structure of care is
associated with process of care, and if structure of care is associated with stroke outcomes after
adjusting for process. The results demonstrated that both systematic organization (P<0.001) and
technological sophistication (P<0.001) were independent predictors of process of care. Overall,
the full structure-process-outcome model with patient covariates considered, process of care was
statistically associated with 6-month functional outcomes (P<0.01), but structure of care was not
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shown to be statistically significant. In summary, process appears to be more significant of an
indicator for quality outcomes than process (Hoenig et al., 2002).
Model assumptions and limitations. The structure-process-outcome model holds three
major assumptions with regard to validity and usefulness for quality health care assessment: 1)
that quality is defined and outcomes are selected, 2) health is a multidimensional concept; and 3)
multiple causation.
It can be assumed that multiple definitions of quality exist. Valuation is an individualized
phenomenon influenced by many outside forces and variables. According to Donabedian (1982),
quality as an opinion implies valuation and is directly related to the attainment of proposed goals
and objectives. When an individual’s goals and objectives are met congruency of quality is
realized.
The “state” of health is multidimensional in that it is comprised of physical, physiologic,
psychologic, social and spiritual attributes. The influences on each of these attributes are
essentially limitless resulting in extensive outcome possibilities. Intimate understanding of the
whole being facilitates the meeting of individual goals and outcomes.
Attempting to discern causes of healthcare outcomes is challenging, as the variables of
input are vast. Therefore, relying solely on outcome measures cannot provide complete accuracy
to those elements responsible for either positive or negative outcomes. Oversight of structure and
process, both within and between collaborative disciplines must be considered.
Structure-Process-Outcome model guiding this study. Current practices for managing
advanced stages of COPD include the use of low flow domiciliary oxygen therapy for those
individuals who meet prescribing criteria and demonstrate improvement with its use. However,
to date minimal research has been performed to assess whether or not chronic exposure to
oxygen therapy introduces consequences in terms of oxidative injury. In autopsy studies
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performed by Petty, Stanford and Neff (1971) and again by Steward, Hood and Block (1975)
“suspicious” histological changes were noted for those whom had been receiving long term
oxygen therapy. And more recently, two studies performed in 2004 (Phillips et al and
Carpagnano et al) assessed for the presence of oxidative stress through a variety of biomarkers,
all of which demonstrated significant increases following exposure to low concentrations of
oxygen exposure.
Determining the outcome of prescribed LFDO therapy can assist in evaluating the current
structure and process at Phelps County Regional Medical Center.
Research Questions
The research questions guiding this study are:
1.

Does chronic exposure to LFDO contribute to oxidative stress as evidenced by
elevated isofuran levels within the lungs of COPD patients?

2. Does a relationship exist between the FEV1, FEV1/FVC ratio, FEF25-75% and isofuran
levels?
3. Is there a correlation between length of smoking history, and length of oxygen
exposure and concentration of oxygen to isofuran levels?
Hypotheses
The following hypotheses were formulated to address the research questions:
1. Ha: Chronic exposure to LFDO will demonstrate ongoing oxidative stress in the lungs
of COPD patients as evidenced by increased isofuran levels.
2. Ha: A relationship between FEV1 and isofuran levels will be demonstrated in patients
diagnosed with moderate to advanced stages of COPD using LFDO
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3. Ha: A relationship between FEV1/FVC ratios and isofuran levels will be
demonstrated in patients diagnosed with moderate to advanced stages of COPD using
LFDO.
4. Ha: A relationship between FEF25-75% and isofuran levels will be demonstrated in
patients diagnosed with moderate to advanced stages of COPD using LFDO
5. Ha: A positive correlation between oxygen concentration and isofuran levels will be
demonstrated on the day of sampling in patients diagnosed with advanced stages of
COPD using LFDO.
6. Ha: A positive correlation between length of oxygen exposure and isofuran levels will
be demonstrated in patients diagnosed with advanced stages of COPD using LFDO.
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Chapter 2 - Literature Review

Health care provision in America has claimed center stage for over a decade, with
escalating costs with lack of insurance and access garnering the greatest attention. There are
many contributors to the healthcare dilemma in our country; however, for the purposes of this
paper, attention will be given to those aspects dealing with provision of prescriptive therapies of
one of the top 5 impacting disease states, COPD.
There is a history in medicine of implementing treatment modalities only later to learn
that significant consequences may exist to prescribed therapies, contributing to debilitation and
compounding costs. This phenomenon is nearly unavoidable as research limitations are many,
but it remains the responsibility of the scientific research community to monitor implemented
goal directed therapy.
Many subscribe to the fallacy that more is better. We are a country of indulgence, best
demonstrated by an overwhelming epidemic of obesity. While oxygen is absolutely critical to
human health and survival, too much, however, can increase morbidity and mortality. While
oxygen supplementation is necessary during periods of compromised health states, a notion that
more is better is a consequential one. Atmospheric oxygen, approximately 21%, is enough to
sustain all human metabolic processes. The belief that oxygen is innocuous introduces unwitting
consequence to its recipients. Educating healthcare providers about the full potential of oxygen
therapy is imperative.
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Oxygen is one of the most widely, and necessarily, prescribed therapies used in this
country. This fact obligates those responsible for its prescription to better understand its
pathologic potential. An increased understanding of the potential of oxygen exposure may lead to
a more rational basis for its clinical use as well as the development of therapeutic measures
effective in preventing or diseasing the effects of oxygen toxicity. Donabedian’s structureprocess-outcome framework can be utilized to guide this research study in assessing the potential
of low flow domiciliary oxygen therapy in the advanced stages of COPD. In order to begin,
however, to appreciate what is abnormal we must appreciate what is considered “normal.”
Normal Respiratory Function
The human respiratory system is comprised of a series of structural pathways and
specialized tissues operated by musculature for the purpose of drawing oxygen into the body for
delivery to tissues for the manufacturing of energy and the subsequent removal of the waste
products of metabolism through exhalation. The structures involved in this process include nasal
passages (responsible for warming, humidification, and trapping of particles), trachea, bronchi,
and bronchioles, which ultimately terminate into alveolar sacs or alveoli. Alveoli are specialized
membranes that are enveloped in pulmonary capillary beds allowing for an intimate relationship
of gas exchange between the pulmonary circuit and the vasculature. The inward and outward
movement of air in the lungs is made possible by a specialized dome-shaped muscle called the
diaphragm, intercostal muscles, as well as the inherent elastic recoil properties of the lungs and
chest wall.
Alveoli. Alveoli are the terminal sacs within the pulmonary circuit responsible for gas
exchange. The alveoli are comprised of three types of specialized cells: type I and type II
pneumocytes and alveolar macrophages. Type I pneumocytes are thin and flat and comprise
approximately 97% of the alveolar surface. Their thin (~25mn wide), flat construction allows for
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a decreased diffusion distance between the alveoli and the blood. Type II pneumocytes cover
approximately 3% of the alveolar surface, account for ~15% of all parenchymal cells and have a
variety of functions. These specialized cells contain surfactant phospholipids, surfactant A, B
and C, lysosomes, and lysosomal enzymes. The primary function of type II pneumocytes is to
synthesize and secrete surfactant. Surfactant is a lipid-protein mixture, which coats the inner
walls of the alveoli preventing collapse by decreasing the surface tension. Secondary functions of
type II pneumocytes include xenobiotic metabolism, the body’s mechanism of neutralizing
exogenous chemicals/toxins, achieved through the cytochrome P450 system, regulation of
transepithelial ion transport, extracellular matrix protein and growth factors production (to aid in
repair), the release of proteinase and proteinase inhibitors (to regulate turnover of alveolar matrix
proteins), and the expression of cytokines (to mediate inflammation). Type II pneumocytes also
assist in the epithelial repair process by migrating to an area of denudation, proliferation and
differentiation into a specific cell type (Aoshiba and Nagai, 2003). Lastly, alveolar macrophages
are responsible for host defense, immunological homeostasis and tissue remodeling (Lambrecht,
2006).
Alveolar ventilation. Alveolar ventilation is the essential process of oxygenation, the
delivery of oxygen to the tissues, and ventilation, the removal of carbon dioxide via exhalation.
Normal alveolar ventilation depends on respiratory rate and tidal volume, the amount of air
inhaled and exhaled during periods of normal breathing. For the average individual the tidal
volume equals approximately 7ml/kg or toughly 500 ml of air. During normal inspiration the
pressure within the lungs is slightly negative due to the contraction of the diaphragm resulting in
air movement into the lungs. Alveoli, in the absence of disease, are fully open during inhalation.
During exhalation the dynamics contributing to alveolar expansion are lessened and could result
in alveolar collapse. Alveoli resist collapse during the exhalation phase as a result of the presence
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of surfactant, a surface-active lipoprotein present at the air-water interface producing a decrease
in surface tension. Maintaining alveolar integrity during both phases of the breathing cycle
results in ongoing alveolar ventilation.
Oxygen. Oxygen is an element belonging to the 16th group, or the Chalcogen group, on
the periodic table with the atomic number 8 and an atomic weight of ~16 amu. Oxygen is the
most plentiful element on the earth’s surface. It is a colorless, odorless gas that comprises
approximately 21% of earth’s atmosphere. Twenty-one percent of atmospheric oxygen, in the
absence of disease or periods of increased demands, fully supports human metabolic processes
achieved through cellular respiration. The measurement of oxygen is often referred to in terms of
atmospheres absolute, or Ata. Atmospheric oxygen is 0.21 ata at sea level.
Leonardo de Vinci proposed that air consisted of two different gases as it supported both
flames and life. While several prior to 1772 had repeatedly prepared oxygen they failed to
recognize it as an element. The discovery of oxygen was ultimately credited to Priestly in 1774,
achieved by the heating of mercury and lead oxide; Carl Wilhelm Scheele independently
reported this finding as well. Like de Vinci, Priestly too recognized the deleterious properties of
a compound that could support both life and combustion as he made this warning in a six volume
series on the properties of air entitled Experiments and observations on different kinds of air,
“ From the greater strength and vivacity of the flame of a candle, in this pure air,
it may be conjectured, that it might be peculiarly salutary to the lungs in certain
morbid cases, when the common air would not be sufficient to carry off the
phlogistic putrid effluvium fast enough. But, perhaps, we may also infer from
these experiments, that though pure dephlogisted air might be very useful as a
medicine, it might not be so proper for us in the usually healthy state of the body:
for, as a candle burns out much faster in dephlogisticated than in common air, so
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we might, as may be said, live out too fast, and the animal powers be too soon
exhausted in this pure kind of air. A moralist, at least, may say, that the air which
nature has provided for us is a good as we deserve” (Priestly, 1775).
Priestly shared his findings regarding dephlogisticated air with Antoine Lavoisier, a
French colleague known now as the father of modern chemistry, who immediately realized the
significance of this finding. It was Lavoisier who named dephlogisticated air “oxygen,” which
means acid producer, and by 1786 was publicly denouncing the phlogiston theory (Acott, 1999).
Thomas Beddoes, an English physician, followed Lavoisier’s work and in 1794 published
Considerations on the Medical use and on the production of Factitious Air as a result of
collaboration with James Watt, a Scottish inventor and mechanical engineer. This is the first
recorded publication postulating the use of oxygen as a medical therapy, which Beddoes referred
to as “pneumatic therapy” (Stansfield and Stansfield, 1896). Beddoes opened the Pneumatic
Institute in 1799 primarily to treat those with various forms of consumptive disease, such as
tuberculosis or those stricken by environmental toxins. Watts’ expertise in engineering aided
Beddoes in developing purified “aires” for inhaled therapy. The first clinical use of oxygen was
reported in 1868, and considered a treatment for bacterial pneumonia in 1885 (Petty, 2000). The
utilization of oxygen flourished from this point as a therapy.
Cellular respiration. Lungs are the portals of oxygen entry. It is what occurs at the
cellular level within the lungs that sustains life. Cellular respiration is the process of converting
food, oxygen and water to usable physiologic energy. The aerobic chemical reaction C6H12O6 +
6O2 + 6H2O → 12H2O + 6 CO2 + heat (or energy) demonstrates this point. The energy produced
as a result is stored in the form of adenosine triphosphate (ATP). The process occurs in three
phases: 1) glycolysis 2) the Citric Acid Cycle and 3) oxidative phosphorylation, or electron
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transport. The summation of energy produced during cellular respiration has a maximum yield of
36-38 ATP molecules (Voet and Pratt, 2006).
Glycolysis is the splitting of a six-carbon sugar into two molecules of a three-carbon
sugar. As a result of this process two molecules of ATP, two molecules of pyruvic acid and two
high-energy electron-carrying molecules of NADH are produced. In the presence of oxygen this
is the initial step in cellular respiration. Glycolysis occurs within the cellular cytosol while the
remaining processes occur within the mitochondria (Holt, Rinehart and Winston, 2006).
The mitochondria are highly specialized organelles distributed throughout the cytosol of
human cells. A double membrane surrounds the mitochondria. These membranes are
phospholipid bilayers embedded with proteins. The outermost membrane is smooth and contains
the organelle, as well as housing the many proteins that form channels through which a variety of
molecules can move in and out as necessary. The innermost layer is folded into cristae for
enhancing productivity of cellular respiration through increased surface area, and contains the 5
complexes of necessary membrane proteins: NADH dehydrogenase (Complex I), succinate
dehydrogenase (Complex II), cytochrome c reductase (Complex III), cytochrome c oxidase
(Complex IV) and ATP synthase (Complex V) (Holt, Rinehart and Winston, 2006).
The citric acid cycle is initiated by the conversion of two molecules of three-carbon
sugars to acetyl CoA, an essential coenzyme of cellular respiration. Through a series of
intermediate steps several high-energy storing compounds, such as nicotinamide adenine
dinucleotide (NAD+) and flavin adenine dinucleotide (FAD+), are produced as well as two ATP
molecules. The FAD+ and NAD+ molecules are reduced as a result of this process to a form that
carries the high-energy electrons to the next state, FADH and NADH respectively. The citric
acid cycle only occurs in the presence of oxygen; however, it does not use oxygen directly (Holt,
Rinehart and Winston, 2006).
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The electron transport phase of cellular respiration is the stage that directly requires
oxygen. The electron transport “chain” is a series of electron carriers aligned within the
mitochondrial membrane. High-energy electrons are passed to oxygen during enzymatically
initiated oxidative phosphorylation reactions resulting in a proton gradient and ATP production
through the addition of a phosphate to ADP. While oxidative phosphorylation performs the life
sustaining process of producing energy it also produces reactive oxygen species, highly bio
reactive molecules, that contribute to senescence and disease (Kregal and Zhang, 2006).
Cellular homeostasis. The ability of a structure to regulate its environment to maintain
stability is referred to as homeostasis. Cellular homeostasis must be maintained to support
organism viability. Programmed cell death, or apoptosis, is a mechanism of cellular preservation
and, thus, homeostasis. Carl Vogt was the first to describe this phenomenon in 1842, and
continues to evolve. Apoptosis is a multi-step, multi-pathway process that occurs in all cells of
the human body. A lack of apoptotic activity is believed responsible for the formation of many
types of cancers and autoimmune disorders. Apoptosis occurs through cellular signaling, either
intracellularly or extracellularly. Extracellular signals result from the presence of toxins,
hormones, growth factors, nitric oxide or cytokines. Intracellular signals include those induced
by heat, radiation, nutrient deprivation, viral infection, hypoxia and increases in intracellular
calcium concentrations and stress resulting in the binding of nuclear proteins to glucocorticoids.
The mitochondria of the cell play a significant role in regulation of apoptosis. The mitochondria
can achieve cellular homeostasis through the Bcl-2 family, cytochrome c, caspase and Bax
balancing activities. The Bcl-2 family is a group of proteins that regulate outer membrane
permeability and can either be pro-apoptotic (Bax, BAD, Bak and Bok) or anti-apoptotic (Bcl-2
proper, Bcl-xL, and Bcl-w). Cytochrome c is a heme protein involved in apoptosis through the
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binding of protease activating factor-1. Caspase belongs to the cysteine proteases and are
essential in cellular apoptosis, necrosis and inflammation (Menrad et al., 2010).
Oxygen transport/diffusion. The exchange of oxygen and carbon dioxide between the
lungs blood and tissues is controlled by diffusion and driven by concentration gradients.
Dalton’s Law of Partial Pressures illustrates (Ptotal = Pgas a + Pgas b + Pgas c + etc) the total pressure
of all gases is equal to the sum of the partial pressures of each gas. The gas diffusion principle
supported by Fick’s Law demonstrates that a gas diffuses from an area of higher partial pressures
to an area of lower partial pressures. Venous blood returning to the lungs has a lower partial
pressure of oxygen than the concentration within the alveoli facilitating movement of oxygen
from the alveoli into the blood. Poiseuille’s Law describes the relationship between pressure,
flow and radius of communicating structures (Δ P = r4/v). Poiseuille’s law can be applied to the
airways to address impedance of airflow. In the diseased lung, such as emphysema where airway
destruction results in loss of elastic recoil, resistance increases as small airways close during
exhalation. As the radius decreases in diseased airways the pressure required to move the same
amount of air through the small tube increase exponentially making alveolar ventilation less
efficient. When the radii of the airways are reduced by half the resistance is increased sixteen
times.
Finally, transport of oxygen is achieved through the binding of oxygen to the hemoglobin
molecules in the blood. The cardiovascular system is responsible for transporting the
oxygenated hemoglobin molecules in the blood to all the tissues of the body. Alterations in
hemoglobin and/or cardiac output can be deleterious for individuals with airway disease.
Protective mechanisms. The respiratory system has inherent mechanisms to control for
the many particulates and infectious agents that are introduced during inhalation. The nose serves
as a first line defense by trapping particulates over 10 µm in diameter and approximately half of
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all particles of 3 µm aerodynamic diameter (referring to behavior vs. actual size) (Rubin, 2011).
The airway is lined by epithelium that produces a mucociliary blanket responsible for trapping
and ridding the lungs of particles 2-10 µm in diameter. The cilia, finger-like projections on the
mucosal wall, move in a direction toward the trachea to facilitate removal. Once particles reach
the trachea they are expectorated from the lungs through the act of clearing or coughing.
For particles that find their way into the alveoli, alveolar macrophages (AMs) come to
action. Metchnikoff first described the macrophage in the 1800s (Rabinovitch, 1995).
Macrophages are one of the main mediators of the immune response exhibiting multiple
functions, such as phagocytosis (engulfing and ingestion of foreign substances), secretion of
cytokines and chemokines (cell signaling), tumor cytotoxicity, and certain antigen presentation
(the capture of antigens and enabling their recognition by T-cells).
Macrophages are greatly distributed throughout the body and are calcium-mediated
signaling dependent (Hoyal, et al, 1998). They can be found in the lymphoid organs, liver, lung,
gastrointestinal tract, central nervous system, serous cavities, bone, synovium and skin (Monick
and Hunninhake, 2002). As one of the major effector cells of the immune system, macrophages
are found in abundance at sites where organisms interact with the environment. The immense
surface area of the adult human lungs (140 m2) allows for a significant exposure to pathogens
and pollutants on a perpetual basis thereby creating a large reservoir of alveolar macrophages
(AMs) (Gwinn and Vallyathan, 2006). The macrophages found in the lungs are
compartmentalized in airways, interstitium, and intravascular spaces derived from pulmonary
circulating monocytes. Alveolar macrophages are quick responders to many internal and external
stimuli, such as interferon, cytokines, viruses, viral particles, bacteria, airborne pathogens and
particles and changes in calcium (Hoyal et al, 1998). Alveolar macrophages are derived from
bone marrow, undergo a maturation process within the interstitium of the lungs and then enter
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the alveolar space. Alveolar macrophages are effective in handling particles with an aerodynamic
diameter under 2 µm. Through highly adaptive properties AMs provide protection by identifying
offending substances and differentiating to the specific state necessary for pathogen destruction.
Through phagocytosis, an AM engulfs a pathogen, which initiates a series of processes that
culminate in death of the microbe. During phagocytosis, the phagocytic cell undergoes an
increase in glucose and oxygen consumption referred to as respiratory burst, resulting in the
production of reactive oxygen species (ROS). Three main processes commence as a result of AM
initiation: 1) Oxygen-dependent myeloperoxidase-independent intracellular killing. During
phagocytosis, glucose is metabolized via the pentose monophosphate shunt, resulting in the
formation of nicotinamide adenine dinucleotide phosphate (NADPH), a coenzyme used in
anabolic reactions. Cytochrome B from the granulocyte specific granule combines with and
activates plasma membrane NADPH oxidase, a membrane bound enzyme complex found in the
membranes of phagosomes used by neutrophils to engulf microorganisms. The activated
NADPH oxidase uses oxygen to oxidize the formed NADPH with a resultant production of
superoxide anion (O2-). A portion of the superoxide anion is converted to H2O2 plus singlet
oxygen by superoxide dismutase. Also, superoxide anion can react with H2O2 to form a hydroxyl
radical as well as more singlet oxygen. In combination these reactions produce the toxic oxygen
compounds superoxide anion (O2-), H2O2, singlet oxygen (O2) and hydroxyl radicals (OH).
Ultimately, while the formation of free radicals is toxic to microbes, when left unchecked they
contribute to the derangement of the lipid bilayers of the lungs. 2) Oxygen-dependent
myeloperoxidase-dependent intracellular killing. When a particle is absorbed by the phagocyte a
vesicle is formed call a phagosome. The phagosomes bind with lysosomes, organelles containing
digestive enzymes, within the phagocyte forming phagolysosomes. The binding of these granules
with the phagosomes causes release of myeloperoxidase into the phagolysosomes.
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Myeloperoxidase utilizes H2O2 and halide ions (typically Cl-) to produce highly toxic
hypochlorite. Some hypochlorite molecules spontaneously break down to yield singlet oxygen.
Together these reactions produce toxic hypochlorite (ClO-) and singlet oxygen (O2).
Hypochlorites are very strong oxidizing agents. 3) Detoxification reactions. Neutrophils, first
responder phagocytes, and macrophages are able to protect themselves by detoxifying the toxic
oxygen intermediates that they generate. Granulocyte self-protection is achieved in reactions
employing the dismutation of superoxide anion to hydrogen peroxide by superoxide dismutase
and the conversion of hydrogen peroxide to water by catalase. The respiratory burst in AMs is of
significantly greater magnitude than those in other forms of phagocytes, likely due to the life
sustaining and important boundary between the outside world and the body they provide
(Baldridge, 1932; Bellavite, 1988; Nauseef, 2004; Fang, 2011). All aforementioned processes
describe the necessary and life-protecting role of reactive oxygen species.
The susceptibility of the lungs to environmental toxins and the large surface area can
result in an overproduction of reactive oxygen species. Antioxidants exist within the lungs to
balance ROS activity. The most prevalent antioxidant of the lungs is glutathione. Glutathione is
located in the epithelial lining of the lungs and in the lower respiratory tract. It has four major
functions, 1) a major endogenous antioxidant produced by the cells participating directly in the
neutralization of free radicals and reactive oxygen compounds, as well as maintaining exogenous
oxidants, such as vitamins E and C in their reduced form; 2) regulation of the nitric oxide cycle
is critical for life but can be consequential if unregulated; 3) involved in biochemical reactions,
such as DNA synthesis, prostaglandin synthesis, amino acid transport, and enzyme activation;
and 4) iron metabolism.
The protective mechanisms of the human respiratory tract described above are efficient
and effective in defending against infection and pathology of most offending agents. There are,
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however, many diverse organisms that prove challenging for the defenses of the human
respiratory tract, such as adenovirus, respiratory syncytial virus, influenza, measles, pertussis and
tuberculosis (Rubin 2011). Similarly, irritant gases derived from pollution and industrial
accidents also challenge our respiratory defense systems. Environmental oxidants include ozone
and nitrogen oxides, as well as sulfur dioxide. Environmental oxidants, for example, are derived
from the suns interaction with automobile exhaust. Sulfur dioxide is produced mainly through
the burning of fossil fuels. It is believed that the combination of these environmental conditions,
along with cigarette smoke, contributes to pulmonary pathology. For those with existing
pulmonary disease, such as chronic obstructive pulmonary disease, these pollutants can produce
serious morphologic and functional effects.
Respiratory Mechanics
Respiratory mechanics refer to the principles of compliance, elastance, resistance,
impedance, flow, and work of breathing. In respiratory physiology compliance refers ability of a
hollow organ to distend and resist recoil to its natural resting position by overcoming transmural
pressure (Grinnan and Truwit, 2005). Compliance can be expressed by the following equation: C
= ΔV/ΔP, where C = compliance, and ΔV is the change in volume, ΔP is the change in pressure.
The inverse of compliance is elastance (E~1/C). During inflation airway pressure is influenced
by volume, chest wall and lung compliance, and thoracic resistance to flow. Resistance to flow
must be eliminated if compliance is to be measured accurately. This can be achieved by
measuring pressure and volume during a period of no flow. As a result, compliance is
determined by taking static measurements of the distending pressure at different lung volumes
and can be obtained during inflation or deflation. Dynamic compliance can also be calculated.
Compliance can be affected by chest wall and/or lung stiffness.
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Elastance, or elastic recoil, refers to the lungs ability, or the ease, to snap back after the
stretch of inhalation. During expiration the diaphragm relaxes allowing the lungs to recoil and
regain the interpleural pressure experienced at rest. The phenomenon occurs due to the elastic
fibers in the connective tissue of the lungs in conjunction with the surface tension in the alveoli
provided by surfactant (Sherwood, 2007).
Resistance refers to opposition within the respiratory circuit to the inward and/or outward
flow of air. Resistance can be expressed by the following equation Raw = ΔP/V, where
ΔP = Patm – PA, so that Raw = Patm – PA/V (Patm = atmospheric pressure, PA = Alveolar pressure
and V= Volumetric airflow). Determinants of airway resistance, then, are airway diameter and
whether flow is turbulent or laminar (Kirkby et al., 2010).
Flow (Q) is simply the movement of air. Flow is dependent on a pressure gradient (ΔP)
and is inversely related to resistance of flow (R). This relationship is described by the following
equation: Q = ΔP/R. Two types of flow exist within the respiratory circuit: laminar flow and
turbulent flow. The more distal the airway the more laminar the flow becomes. Flow is
influenced by the rate of flow (V), the airway radius (r), the density of gas (p), and the viscosity
of gas (η), while factors, such as length of airways and gas density remain essentially constant. In
the airways governed by laminar flow, resistance is related to the radius (r), airway length (l),
and gas viscosity (η) through Poiseuille’s Law (R=8ηl/nr4). Poiseuille’s law demonstrates the
strong relationship of the radius on resistance, showing that the doubling of the radius decreases
the resistance by 16-fold (Bock, et al, 2000).
Impedance refers to the resistance of airflow as well the energy required to overcome the
elasticity of the lungs and chest wall. Impedance is most accurately assessed through the
measurements of the work of breathing (WOB). Work is defined as the product of pressure and
volume (W = P x V). Since exhalation is generally a passive process WOB is most often
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referring to inhalation. However, diseases processes, such as COPD, that exhibit prolonged
expiratory phase, can significantly increase WOB. As WOB increases metabolic demands,
increased stress is placed on respiratory muscles, which in turn requires increases in cardiac
output. Increases in cardiac output can result in ischemia for those with concomitant cardiac
disease. The goal of mechanical ventilation for those in acute respiratory distress is to support the
vital organs while reducing the WOB. Once the acute phase of distress is resolved ventilatory
support can be weaned until extubation is possible (Grinnan and Truwit, 2005).
Spirometry. The ability to quantify the aforementioned respiratory mechanics of
compliance, resistance, elastance, flow and impedance is particularly useful in detecting,
diagnosing and managing respiratory health and disease states. Quantification occurs through the
use of spirometric measurements. Exposing a potential relationship between spirometric
measurements and the presence of deleterious processes, such as oxidative stress, could hold
merit in early detection and management.
Spirometry, or the measuring of breathing, enables us to assess functional changes within
the respiratory circuit and provide meaning to their numeric value. Spirometry is a tool used to
measure various lung volumes, capacities, flow rates, patterns and gas exchange. Collectively
theses measurements taken for the purpose of assessment are referred to as pulmonary function
tests (PFT). John Hutchinson is credited with the invention of the spirometer in 1846 (Petty,
2002). This early device could only measure vital capacity, the volume of air exhaled after
maximal inhalation. The evolution of the spirometer has resulted in the ability to measure nearly
every aspect of lung function making this device elemental in the diagnosing and management of
COPD and a host of other respiratory ills. It would not be until the 1950’s that spirometric
measurements would be given their due when Barach and Bickerman (1956) edited a
comprehensive text, Pulmonary Emphysema, in which Dayman recognized and described flow
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volume patterns indicative of expiratory airway collapse consistent with emphysema. In 1956,
Hinshaw and Garland would demonstrate a 13.5-liter recording spirometer, showing lung
capacity spirograms that demonstrated the airflow limitations seen with emphysema. The
sophistication of spirometric assessment grew from then and continues today.
Each phase of the respiratory cycle has a corresponding volume or capacity, and flow rate
specific to that given phase. Once adjustments are made for age, gender, height, weight and
ethnicity particular changes in volumes, capacities and/or flow patterns can be predictive of
pathology. Pulmonary diagnoses can be made when obtained values are compared to a “normal”
value. Normal spirometric values vary, depending on environment, culture, gender and physical
stature. In order to achieve an accurate assessment of an individual, obtained results
needs to be compared to a subset of healthy patients with the same/similar demographics. It
should be emphasized that effort is critical when obtaining values for the “normal” and afflicted.
All individuals obtaining PFTs should be instructed on the importance of maximum respiratory
effort and cooperation to ensure accuracy of test results. Tests are often repeated in triplicate to
control for this phenomenon. For those individuals afflicted with COPD respiratory effort is an
issue due to the debilitating effects of the disease, including muscle wasting and cachexia.
Results obtained are compared to the normal volumes, capacities and flow rates of a similar
population (age, gender, height, weight, ethnicity) and given percent of predicted values. Based
on the aforementioned demographics a “normal” PFT value is assigned. Once a value is obtained
it is compared to the “normal” PFT value for that individual. Pulmonary function values nearest
100% are considered most normal. Generally any value less than 80% of “predicted” normal for
said characteristic can be indicative of underlying disease.
The past several decades has brought with it research to determine “normal values” for
lung volumes, capacities and flow rates as it relates to specific demographics, and has greatly
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facilitated interpretation of the results for accurate diagnosing. The relevant variables in this
process are age, gender, body height and habitus, and ethnicity. As it relates to age: as a person
ages the natural elasticity of the lung decreases, translating into smaller lung volumes and
capacities. Also, aging causes decalcification of the skeletal structure resulting in centimeter
changes in the thoracic size and subsequent lung size. In the healthy adult, this does not
necessarily impede daily function; however, for those with respiratory disease, this phenomenon
can be a confounding cofactor. As it relates to gender: typically the lung volumes and capacities
of males exceed those of females even when matched for height and weight. As it relates to body
height and habitus: size has a significant impact on lung volumes and capacities, as such
predictive values have been developed to account for those sizes outside the range of ideal body
weight for given height. Obesity, generally defined as a body mass index (BMI) of > 30 kg/m2,
can often appear during pulmonary function testing as a restrictive disorder due to the physical
impediment placed on the chest wall by the chest and abdominal weight. Standing height is
considered the most important predictor of lung function and is related, to some degree, to the
other demographics that influence forced vital capacity (FVC) values (the forced exhalation
following maximal inhalation), such as weight, presence of disease, scarring, etc. (Cotes, 1993).
Diseases that affect stature, such as kyphosis, scoliosis, osteoporosis, congestive heart failure,
tuberculosis, etc., will predictably decrease lung capacities. Age also has a confounding
influence on the FVC as aging often results in further loss of muscle mass resulting in the
displacement of the diaphragm cephalad causing concomitant decreases in lung volumes and
capacities. As it relates to ethnicity: different ethnic origins have inherent differences in lung
volumes and capacities, as such spirometric software has been adjusted to address the related
differences. These differences appear to be primarily a result of stature and metabolic indices
specific to a given culture.
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Pulmonary function testing can be used for the screening of obstructive or restrictive lung
disease states, documenting obstructive or restrictive lung disease progression, evaluating
therapeutic effectiveness, as a tool for weaning mechanical ventilation, as well as evaluating
patients prior to surgery, especially if patients are > 60 years old, have known pulmonary
disease, are obese, have a history of smoking, cough or wheezing, been exposed to prolonged
surgical times or are undergoing abdominal or thoracic surgeries.
(http://www2.nau.edu/~daa/lecture/pft.htm).
The ability to quantify spirometric measurements aids in assessing lung function.
Spirometric measurements are obtained with a relatively simple apparatus by which a patient
inhales and exhales into a mouthpiece. The force of these two efforts is measured by a
differential pressure transducer, converting the volume and rate of breathing over a specified
amount of time into a quantitative value. Parameters, such as rate of breathing and ventilation,
vital capacity (the maximum amount of air exhaled after maximum inhalation), tidal volume (the
amount of air exchanged during normal breathing), and variations of expiratory volumes (FEV),
vital capacity from a maximally forced expiratory effort (FVC), peak expiratory flow rates
(PEFR), forced expiratory flow rates (FEF), and maximal voluntary ventilation (MVV), and
many others, can be determined. As these values are plotted on a graph inferences can be made
regarding pulmonary functionality.
The forced expired volume in 1 second (FEV1), FVC, and their ratio to each other
(FEV1/FVC) are often initially evaluated to assess lung function. The FEV1 is the volume of air
that can be forcibly exhaled in one second after maximal inhalation and is valuable in assessing
for obstructive disease. Average values for FEV1 in healthy people depend mainly on gender and
age. Results between 80% and 120% of the average predicted value or ~ 75-80% of their vital
capacity (volume of air following maximal inhalation) are considered normal. If the FEV1 value
31

is low (<80%) compared to FEV1% predicted in the normal population in the presence of
maximal effort obstructive disease is highly suggested. The diagnosis of restrictive vs obstructive
disease is further refined when expressed in terms of a proportion to the FVC. A low FEV1
(<75%) in conjunction with a low FEV1/FVC ratio of (70%) is indicative of obstructive disease.
The FEV1 for the patient with restrictive disease will be lower as well but proportional to the
FVC and, therefore, if both the FEV1 and the FEV1/FVC ratio is 85% or greater of predicted
normal, a diagnosis of restrictive disease is highly suggested.
Spirometric results consistent with obstructive disease, such as chronic bronchitis and
emphysema, include changes in the FVC. The forced vital capacity is the amount of air that can
be maximally and forcibly expelled from the lungs after maximal inhalation. For the patient with
obstructive disease expired volumes will be less than normal and require longer amounts of time
to achieve. Spirometric results consistent with restrictive disease, or emphysema, include
changes in the FVC as well; however, the resultant decrease in expired volume is due to a
reduced ability to maximally inhale normal volume due to the mechanical limitations as a result
of the loss of alveolar elastic wall integrity inherent with the disease. Since both chronic
bronchitis and emphysema result in smaller FVC volumes FVC is not a stand-alone diagnostic
indicator of either disease. Concern does not typically occur until the FVC result in 80-85% of
the predicted normal values. Delineations can occur with a post-bronchodilator FVC
measurement. Improvements in the FVC following a bronchodilator suggest obstructive disease,
while no change suggests restrictive disease.
Detection of pulmonary changes consistent with COPD can be made with spirometry
before debilitating stages develop. According to the National Lung Health Education Program,
all persons aged 45 or older who currently smoke, or even those who have quit smoking, should
have spirometric testing (Ferguson et al., 2000). Additionally, those individuals who present
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with symptoms of a chronic cough, sputum production, wheezing or dyspnea that is inconsistent
with the activity being performed should undergo spirometric testing (Ferguson, et al., 2000; Celi
and MacNee, 2004).
COPD
Chronic obstructive pulmonary disease (COPD) is a progressive disorder resulting in
irreversible lung tissue changes. Approximately 14 million Americans have COPD and an
estimated 40 million cases are believed to be undiagnosed (CDC, 2008). COPD is currently the
fourth leading cause of death and projected to be the 3rd leading cause of death by 2020 (Doherty
et al., 2007). COPD kills approximately 120,000 Americans annually (Mannino et al., 2002).
Normal tidal breathing for the average adult occurs approximately 17,000 times per day.
Depending upon the stage of the disease the effort to take those 17,000 breaths increases,
resulting in fatigue, anxiety and general discomfort. As the disease progresses microscopic
changes occur to the multiple organ systems within the body. Identifying a method to detect the
early presence of COPD to thwart its progression is ideal; an effort that would improve quality of
life and lessen the economic burden on the afflicted individual, their family and the healthcare
system.
Descriptions of COPD can be traced back to 1679 in Bonet’s description of the
“voluminous” lungs (Bonet, 1679). In 1769 Morgagni described 19 cases in which the lungs
were “turgid” or dull with air. Baille, an early pathologist, utilized the investigation of post
mortem human tissue to better understand the pathology that may have claimed lives. In his 1795
manuscript, The morbid anatomy of some of the most important parts of the human body, Baille
described the morbid appearance of each organ and correlated autopsy reports with case
histories. Included in this compilation is the first documented observed physical description of
the emphysematous lung.
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Badham first offered clinical understanding of COPD in 1814 when he used the word
“catarrh” to refer to the classic symptoms of COPD, cough and hyper secretion of mucus. He
noted this condition to be disabling. Laennec (1821), a clinician, pathologist and inventor,
eloquently describes emphysema in his Treatise of diseases of the chest, noting that
emphysematous lungs were hyper inflated. Laennec dissected patients he followed during the
course of their illness. Part of his assessment was the utilization of a stethoscope, his own
invention. He described his auscultative assessments in A treatise on the disease of chest and on
mediate auscultation and provided this anecdote,
“The disease which I designate by this title is very little known and has not
hitherto been correctly described by any author. I for a long time thought it
very uncommon, because I had observed only a few cases of it: but since I
have made use of the stethoscope, I have verified its existence as well on
the living as the dead subject, and am led to consider it as by no means
infrequent. I consider many cases of asthma, usually deemed nervous, as
depending on this cause. The chief reason of this affection having been so
completely overlooked is, that it is in some sort of merely the exaggeration
of the natural condition of the viscous.”
Laennec also reported that upon autopsy it was not unusual to find that the lungs did not
collapse for those with symptomatic disease but rather filled up the chest cavity completely on
either side of the heart. Further inspection would show that the lungs were full of air while the
bronchus was filled with mucus. This description appears to describe both bronchitis and
emphysema.
The 1950’s ushered in significant contributions to the understanding of COPD and its
effects on related organs. Dickerson Richards, Nobel Laureate, described the relationship
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between a diseased pulmonary circuit leading and right sided heart failure, or cor pulmonale;
Cherniack described the diseases effect on the acid-base system; Menelee and Callaway
described pulmonary function test results as it related to the emphsymic patient (Petty, 2006).
In an effort to develop a comprehensive and accurate definition of the disease two
historical meetings took place: The CIBA Guest symposium in 1959 and the American Thoracic
Society Committee on Diagnostic Standards in 1962. The definition provided by the American
Thoracic Society (ATS) is the most widely accepted definition and states, “a diagnosis of chronic
bronchitis can be made with the presence of a chronic cough lasting at least three months for at
least two years; and that the diagnosis of emphysema can be made when evidence of enlarged
alveolar spaces and loss of alveolar walls is made.”
These ambiguous definitions prompted continued research in order to better understand
optimal recognition, diagnosis and management. In 1998 a group of committed scientists
encouraged the US National Heart, Lung and Blood Institute and the World Health Organization
to come together to combat COPD. This group is now formally recognized as the Global
Initiative for Obstructive Lung Disease, or GOLD.
Global initiative for obstructive lung disease: GOLD. The Global Initiative for
Obstructive Lung Disease (GOLD), a group of dedicated health care providers, continually work
with healthcare professionals and public health officials to raise COPD awareness and to assist in
improving treatment of the disease worldwide.
The first task undertaken by GOLD was to prepare a consensus report, Global Strategy
for the Diagnosis, Management and Prevention of COPD, published in 2001. Revisions are
continually made to reflect ongoing research (GOLD 2006).
With the goal to provide an individual with the appropriate management therapy, GOLD
developed a classification of COPD by dividing it into 4 stages: mild, moderate, severe and very
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severe. Certain normal values have been assigned as it relates to age, gender, height, weight and
ethnicity. The ratio is used to diagnose obstructive and restrictive disease. Table 1 defines the
stages in terms of pulmonary function test results.
Table 1
Stages of COPD
Stage I
Stage II

Mild COPD
Moderate COPD

FEV1/FVC<0.70
FEV1/FVC<0.70

Stage III

Severe COPD

FEV1/FVC<0.70

Stage IV

Very Severe COPD

FEV1/FVC<0.70

FEV1≥ 80% normal
FEV1 50-79%
normal
FEV1 30-49%
normal
FEV1 <30%
normal, or <50%
normal with
chronic respiratory
failure present

Stages of COPD. In an effort to accurately assess and appreciate an individual’s stage on
the COPD spectrum a series of stages are defined. During Stage I of COPD there may be only
mild airflow obstruction with no awareness of functional decline. Parenchymal, or lung tissue,
changes are typically insidious leaving patients unaware that lung damage is occurring.
Treatment is rarely sought during this stage. Airflow worsens during Stage II as parenchymal
damage worsens and symptoms become increasingly detectable, particularly shortness of breath
upon exertion and cough with sputum production. It is typically during this stage that patients
become aware of the presence of the disease. Upon entering Stage III, or the severe phase of the
disease, the patient experiences airflow obstruction that significantly worsens, shortness of
breath occurs with less and less exertion, and COPD exacerbations becoming more frequent. It
is during this stage that people begin to battle constant fatigue. Stage IV may lead to chronic
respiratory failure, the inability of the lungs to effectively oxygenate and/or ventilate, cor
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pulmonale and death (Leader 2011). To better understand the stages of COPD it is necessary to
understand the physics of the pulmonary circuit and the concomitant changes.
In a review performed by Tuder, et al (2006) a literature search ranging from 1949 to
2005 revealed that 40,309 papers were published on COPD, in which 1637 involved the worked
“inflammation” and 187 involved “protease” or “matrix.” Forty-six papers directly addressed
inflammation and protease imbalance. It is important to consider these factors when formulating
an understanding about the pathology that results in emphysema and chronic bronchitis.
When considering the mechanics of airflow the pulmonary circuit is inherently affected
by tubular diameter and pressure changes, two variables directly impacted by inflammation and
matrix changes within the pulmonary infrastructure. As a result reduced airway diameters
produce increases in resistance, whereas loss of elastic recoil results in diminished pressure on
exhalation. Airway narrowing occurs in chronic bronchitis or asthma, whereas emphysema
exhibits a loss of elastic recoil, resulting in decreased alveolar ventilation and air trapping.
Emphysema. Emphysema is characterized by the loss of alveolar wall integrity resulting
in increases in work of breathing in response to increases in compliance and increases in airway
resistance. Airway mutagens, such as cigarette smoke or environmental pollutants incite
apoptosis, oxidative stress and a protease/antiprotease imbalance resulting in a breakdown in
alveolar infrastructure (Tuder, et al., 2006). Progressive deterioration of wall integrity ultimately
manifests as loss of elastic recoil. Many alveolar sacs will merge into large singular bleb-like
sacs and will lose their pulmonary capillary architecture. The subsequent inability of alveolar
recoil results in outflow obstruction; air becomes trapped in the alveoli resulting in poor gas
exchange (Petty, 2006). Stagnation of air movement means decreased oxygen supply and
retention of carbon dioxide. Low oxygen states within the body are compensated by increasing
hemoglobin concentrations and through hyperventilation.
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As more and more alveoli break down hyperventilation is no longer an effective
compensatory mechanism and worsening hypoxia ensues. Hypoxic vasoconstriction, the
rerouting of blood to functional alveoli, occurs as the body’s last resort to restore equilibrium.
Chronic hypoxic vasoconstriction can result in pulmonary hypertension, or high blood pressure,
within the pulmonary vascular circuitry. A significant consequence of pulmonary hypertension
is right-sided heart failure, or cor pulmonale. The right ventricle must overcome the increased
pulmonary pressure to maintain perfusion pressure. In an already hypoxic environment, the heart
is vulnerable to increased metabolic demands. The accessory musculature of the respiratory
system experience increased oxygen demands as a result of increased work of breathing to
compensate, placing even greater strain on the heart and lungs.
While there are some genetic predispositions associated with emphysema, such as alpha1 antitrypsin disorder, it is most directly linked to smoking. Most individuals diagnosed with
emphysema are over 60 years old and present with a long history of smoking, exertional dyspnea
with use of accessory muscles, tachypnea with a prolonged expiratory phase, minimal
nonproductive cough, and weight loss and cachexia. Cachexia presents a vicious cycle as the
malnourishment contributes to ongoing weakness that in turn contributes to ongoing anorexia.
Those individuals who suffer from advanced stages of the disease may require low flow
domiciliary oxygen therapy (LFDO) therapy to assist in ameliorating symptoms demonstrating
the properties of Dalton’s Law of partial pressure, supporting diffusion through an increase in the
partial pressure of oxygen, and Poiseuille’s Law of increased rates of flow by air being forcibly
delivered into the nasal passages and down the airways.
Chronic bronchitis. Chronic bronchitis is characterized by inflammation of the bronchi
resulting in a copious production of thick mucus, hypertrophy of mucous glands and recurrent
respiratory infections. The mucus produced in this disorder, as well as the chronically inflamed
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bronchioles, creates a physical obstruction to airflow as well as a constant predisposition to
pulmonary infections. Patients who are diagnosed with chronic bronchitis have exhibited
symptoms for greater than three months in a year for two consecutive years in a row. Cough and
sputum production are initially more severe in the winter; however, as the disease progresses, the
productive cough remains present. The chronic obstruction to airflow produced by COPD states
predisposes these patients to low oxygen blood states, or hypoxia, as well as high carbon dioxide
blood states, or hypercarbia (Chiang et al., 2002).
Chronic hypercarbia places the COPD patient at risk of cardiovascular and central
nervous system compromise (Petty 2006). Blood CO2 levels are responsible for communicating
with the respiratory center in the brain to determine rate and depth of breathing. When CO2
levels are chronically elevated respiratory center receptors become desensitized, thus,
dependence on oxygen levels for respiratory stimulation ensues. Although hypercarbia is a
compensatory mechanism to manage respiratory stimulation, elevated levels of CO2 can produce
anxiety, irritability, confusion, stupor, coma, hypertension, hypotension, dysrhythmias and death
(Petty, 2006).
Patients in advanced stages of chronic bronchitis are vulnerable to opportunistic
infections. Low oxygen states, the presence of mucous and compromised respiratory immune
systems puts this patient population at a particular risk for bacterial infections, particularly
Hemophilus influenza and S. pneumonia (Murphy, 2000). Chronic hypoxemia predisposes the
COPD patient to a wide range of complications including metabolic and electrolyte disturbances,
erythrocytosis or polycythemia and, perhaps the most detrimental, pulmonary hypertension and
right sided heart failure, or cor pulmonale (Chaouat, 2008). The development of cor pulmonale is
often accompanied with cyanosis and edema giving the afflicted patient a blue and swollen
appearance, oftentimes referred to as the “blue bloater.” Many patients in the advanced stages of
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the disease are placed on LFDO in an effort to provide them with needed support to maintain
independence and functionality. Oxygenation is impaired in this patient population. Optimizing
oxygenation through LFDO via a nasal cannula has significantly improved symptomatology and
activities of daily living (ADL’s). Patients with advanced COPD often become easily fatigued
and short of breath. Domiciliary oxygen therapy can boost energy levels and lessen labored
breathing by increasing oxygen concentration in the lungs and blood (Croxton et al., 2006;
Sandland, 2008).
Hypoxia. Hypoxia is the state of insufficient oxygen delivery necessary to support
cellular respiration, and cannot be long tolerated. Mechanisms of hypoxia/hypoxemia include
hypoventilation, low inspired oxygen, anemia, right to left shunt, and perfusion/ventilation
mismatching (V/Q mismatch) (Osborne, 2000). There are several causes for hypoventilation:
drugs that depress the CNS, such as narcotics, anxiolytics and sleep aids, trauma to the
brainstem, abnormal spinal cord pathways, and brain stem motor neuron disease, such as
amyotrophic lateral sclerosis (ALS) (Phukan, et al., 2007); diseases affecting the respiratory
muscles, such as Guillain-Barre’ syndrome; diseases of the neuromuscular junction, such as
Myasthenia Gravis; abnormalities of the chest wall, such as scoliosis (Laghi and Tobin, 2003);
and upper airway obstruction, such as epiglottitis. Low inspired oxygen can be a result of altitude
changes or medical mismanagement for a dependent patient. A right to left shunt refers to
phenomena where a “rerouting” of blood results in reduced oxygenation of the blood. This
phenomenon can occur through an anatomic shunt, such as a coronary sinus, where
unoxygenated blood drains into the left heart and mixes with saturated blood. A physiologic
shunt refers to disease states by which blood cannot come into communication with gases within
the alveoli due to filling of the alveolar spaces as seen with pulmonary edema, pneumonia, etc.
Ventilation/perfusion (V/Q mismatch) refers to the disparity between alveoli that are well
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ventilated but poorly perfused, or poorly ventilated and well perfused. This phenomenon can
occur from something as benign as positioning to the presence of atelectasis. Diffusion
impairment refers to interruptions in the rate of diffusion of the gases across the alveolar
membrane. This phenomenon can occur with a variety of interstitial lung diseases. Anemia
results in hypoxemia due to the absence of sufficient oxygen carrying capacity in the form of
hemoglobin. Anemia is prevalent in such processes as kidney disease, uterine fibroid disease and
trauma.
Compensatory mechanisms. In the presence of acute low oxygen states, or cellular
hypoxia, a series of mitochondrial protective mechanisms will occur to maintain cellular
homeostasis. Likely considered the most important rate-limiting step in mitochondrial oxygen
consumption is the decrease in cytochrome c oxidase activity. Cytochrome c oxidase is
responsible for converting molecular oxygen into two molecules of water. The mitochondria, the
site responsible for initiating biochemical processes that determine cell survival or death, will
maintain ATP production temporarily via anaerobic glycolysis. The untoward effects of the
decreased cytochrome c oxidase activity and anaerobic glycolysis is a backlog of protons at all
the redox points along the electron transport chain and the production of pyruvate respectively,
both of which will ultimately result in the build up of cellular acids and eminent cell death
(Galkin et al., 2009, Wheaton and Chandel, 2011).
In the acute phase of hypoxia the release of cytochrome c oxidase allows for the
adaptation to altered oxygen concentrations through the inhibition of proton transportation, thus
decreasing the membrane potential. The decrease in ATP production and a hyper permeable state
of the inner mitochondria is a result of the release calcium and cytochrome c through the Bcl-2associated X (BAX) system, a process that can also lead to caspase activation and programmed
cellular death (apoptosis).
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The maladaptive response of cytochrome c initiated cell death in the presence of
prolonged hypoxia converts to an adaptive process over time by the inhibition of BAX and the
generation of nitric oxide. Nitric oxide binds to a reduced form of cytochrome a3 in the
mitochondria, the same binding site of oxygen, resulting in inhibited cytochrome c activity and
thus reducing oxygen consumption. Furthermore, the presence of nitric oxide changes the
membrane potential due to the increased production of reactive oxygen species (ROS). Oxygen
free radicals, through superoxide dismutase (SOD), are converted to H2O2, which exerts a
protective influence on cellular enzymes, such as the kinase of monophosphate adenine (AMPK)
resulting in cellular energy homeostasis. (Mungai, 2011).
In the presence of chronic low oxygen states cells will continue to adapt through oxygendependent enzymes: the hypoxia inducible factor (HIF)-prolyl and asparaginyl hydroxylases,
prolyl hydroxylases domain (PHDs), and factor inhibiting HIF (FIF). The result of chronic
hypoxia is a “pooling” of PHDs and an over activation of the three PHD isoforms (HIF1α,
HIF2α and HIF3α), mediated by an increase in intracellular oxygen availability (Ginouves,
2008). The desensitization of HIFα triggers a negative feedback mechanism that results in
cellular protection against cell death.
Cigarette smoking. Tobacco use is the leading preventable cause of death globally,
claiming 5 millions deaths annually and a projected 8 million annually by 2030 (WHO, 2011). A
reported 480,000 people die annually in the U.S, with 41,000 of those from exposure to second
hand smoke (US Dept of Health & Human Resources 2013 Report). Cigarette smoke has been
implicated as the single most significant contributor to the development of COPD. Cigarette
smoke induces two particular processes within the lung tissue that contribute to structural
changes associated with COPD: inflammatory responses and oxidative stress. It is, therefore,
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important to consider the implications and role smoking in the development of COPD in order to
better develop appropriate strategies of prevention, treatment, and cure.
In a study by Fletcher and Peto (1977) it was projected that 15-20% of those who smoke
would be vulnerable to the long-term deleterious effects of smoking and would subsequently
develop airflow limitations. The GOLD 2005 Report from the NHLBI/WHO workshop reported
that cigarette smoke-induced airway inflammation is considered to be an important variable in
the pathogenic process of COPD.
When toxicants, such as cigarette smoke, are breathed into the lungs, particles are trapped
in the alveoli and initiate an inflammatory cascade that includes the activation of neutrophils.
Neutrophils contain serine elastase and other proteases that serve to catabolize proteins resulting
in the breakdown of the alveolar infrastructure. Neutrophils also contribute to the development of
reactive oxygen species (ROS), otherwise known as free radicals. Reactive oxygen species
overwhelm lung antioxidant defenses, a situation confounded by cigarette smoke induced
decreases in glutathione, the lungs antioxidant defense, and oxidative stress ensues.
Cigarette smoke has been linked to alterations in glutathione (GSH), an intra and
extracellular antioxidant present in the lungs (Rahman and MacNee, 1999). Disabling the body’s
inherent protective antioxidant defenses invites unchecked oxidative reactions, especially in the
presence of increased ROS. Ultimately, this imbalance results in lung parenchymal damage
causing irreversible alterations in the lipid bilayers induced by oxidative stress.
Cigarette smoke contains ROS with considerable oxidative power, which serves as direct
toxins as well as precursors to other toxins. The primary free radicals, or ROS, in cigarette
smoke are superoxide (O2-), hydroxyl radical (OH), and hydrogen peroxide (H2O2) (Pryor,
1997). Smoking also interferes with α1-antitrypsin activity, a protease inhibitor, by oxidizing
MET358 and MET 351 residues to methionine sulfoxide (Johnson and Travis, 1979) interrupting
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the check and balance system for elastase activity within the lungs (Janoff et al., 1979; Hill et al.,
2000; Sullivan et al., 2005). The combination of increases in elastase activity introduced by
neutrophils, ROS generation compounded with the decreased ability of α1-antitrypsin activity to
control for of these processes can lead to extensive wall destruction.
According to a study by Tuder, et al (2006) cigarette smoke houses over 5000 offending
chemicals. They purport that each puff of cigarette smoke contains ~ 1015 free radicals in the gas
phase and 1018 free radicals per gram of tar, and includes potent oxidants such as hydrogen
peroxide, hydroxyl anion, and organic radicals. Chronic exposure to these deleterious toxicants
result in the disruption of the normal functions of the pneumocyte type I and II cells leading to
increases in epithelial permeability, decreases in surfactant production, and inappropriate
generation of cytokines leading to the initiation of chronic inflammation (Aoshiba and Nagai,
2003). Nitrogen oxide and superoxide radicals are short-lived oxygen free radicals that readily
react to form peroxynitrites. Peroxynitrites are anions with a chemical formula of OONO- that
are oxidizing agents, making it a threat to surrounding cells including DNA and other proteins as
they trigger cellular responses ranging from cell signaling to oxidative injury, inducing cellular
necrosis and apoptosis. Peroxynitrite generation has been implicated in such disease processes as
stroke, myocardial infarction, chronic heart failure, diabetes, circulatory shock, chronic
inflammatory diseases, cancer, and neurodegenerative disorders (Pacher, Beckman and Liaudet,
2007).
Cigarette smoke contains two different forms of free radicals, one in the tar phase and
one in the gas phase. The tar phase contains the long-lived hydroquinones that undergo a redoxcycle to form superoxide radicals and hydrogen peroxides via semiquinones. Semiquinones are
highly reactive free radicals formed by the removal of one hydrogen atom with its electron
during the process of dehydrogenation of a hydroquinone to quinone. This phenomenon results
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in persistent oxidative stress. (Pryor and Stone 1993; Cross et al., 1997; Nakayama 1989) The
gas phase of cigarette smoke contains small oxygen and carbon-centered radicals that are more
reactive than those in the tar phase. It is thought that these free radicals contribute to the
inactivation of α1-antitrypsin proteinase inhibitor (Church and Pryor, 1985).
It has been reported that 85-90% of those diagnosed with chronic bronchitis or
emphysema are smokers, occurring in less than 5% of nonsmokers, and that moderate to severe
emphysema is rare in nonsmokers (ALA COPD Fact Sheet, 2011). According to the CDC,
smoking is the most important preventable cause of death in the United States and is responsible
for over 480,000 deaths each year, with 41,000 of those deaths related to second-hand smoke.
Long-term cigarette smoking is a key contributor to heart disease, peripheral vascular disease,
diabetes, chronic lung disease and strokes, as well as a variety of cancers. Significant focus
should be represented in the structure and process of healthcare delivery systems in order to
affect the best possible outcomes with regard to reducing smoking and its wide array of
implications.
COPD treatment. Diseased lungs impact the overall human experience. As such a
multimodal treatment regimen is employed. The treatment and management of COPD aims to 1)
improve pulmonary function; 2) decrease symptoms; 3) improve exercise tolerance; 4) decrease
exacerbations; and, 5) reduce mortality (WHO, 2013). Simultaneous approaches often optimize
the health state of those afflicted to achieve these goals. Depending on where the individual falls
on the spectrum of the disease dictates how much quality is added back to their life with
management of their disease (Scuirba, 2008).
The global initiative for chronic obstructive lung disease (GOLD) guidelines recommend
a staged approach to the management of COPD; however, the American Thoracic Society (ATS)
and European Respiratory Society (ERS) suggest the continuum of symptoms and FEV1 should
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dictate treatment regimens. All agree, however, that smoking cessation is first and foremost to
any level of recovery.
Smoking cessation is critical in significantly slowing the progression of the disease and
exercise improves overall functionality of respiratory mechanics and oxygen delivery (Shea and
Martinez, 2009). Smoking cessation is the only disease modifying therapy for management of
mild to moderate COPD (Ind, 2005). It has been demonstrated that smoking cessation slows the
accelerated decline of the FEV1 (Fletcher and Peto, 1977; Simmons et al., 2005). According to
the Lung Health Study the rate of decline in FEV1 was reduced by ~50% of those who
permanently quit smoking (Anthonisen et al., 1994). Kanner et al., (2001) reported that those
with COPD who quit smoking experienced fewer exacerbations of their illness.
Respiratory infections are always a significant threat to those with COPD. Those with
chronic bronchitis are particularly vulnerable due to the persistent presence of inflammatory
mucus exudates. As a result microbial pathogens harbor in the lower respiratory tract, disrupt
ciliary function, trigger enhanced mucus secretion, and further damage the epithelium (Sethi,
2000). Recent research suggests the addition of daily antibiotics can significantly reduce the
incidence of acute microbial induced exacerbations and improve the quality of life for COPD
sufferers. The New England Journal of Medicine (2011) published the results of a randomized
clinical trial including 1577 participants, 570 received azithromycin and 572 received a placebo
for 1 year. The treatment group reported a significant (P<0.01) reduction in acute exacerbations.
A small portion of the participants reported small decrements of hearing loss with azithromycin
prophylaxis.
Once the disease has progressed to advanced stages, acute exacerbations of symptoms are
often managed with supplemental oxygen; inhaled beta agonists, long acting beta agonists
(LABA) and anticholinergics to aid in bronchodilation; corticosteroids to reduce inflammation;
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and antibiotics to treat infections (Hunter and King, 2001). Approximately one half of patients
diagnosed with COPD have high concentrations of bacteria in their lower airways (Rave, et al.,
2007; Sethi, et al., 2002). The most frequently offending bacteria include Streptococcus
pneumonia, Hemophilus influenza, Moraxella catarrhalis, Mycoplasma pneumonia, as well as a
variety of viruses (Rave, et al., 2007; Sethi, et al., 2002). It has been suggested that the use of
antibiotics for those with moderate or severe disease with COPD exacerbations have a reduced
risk of treatment failure and death (Ram, et al., 2006).
For patients who cannot be managed successfully with medication therapy, surgery may
be warranted. Three types of surgery are offered to patients with end-stage COPD suffering
from severe symptoms: bullectomy for bullae that compress on more viable tissue; lung volume
reduction surgery (LVRS) to removed ineffective and diseased lung to allow more effective
tissue to function; or a lung transplant. Patients <65 years old with end-stage lung disease in the
absence of other significant disease could be considered for transplantation. Chronic stable
COPD patients who are hypoxemic often require LFDO to assist in maintaining activities of
daily living (Tiep and Carter, 2008).
Low-flow domiciliary oxygen. Low flow domiciliary oxygen therapy has long been in
use as a means of ameliorating respiratory distress and shortness of breath for those afflicted
with chronic lung disease. While the medical community is very aware of the risks associated
with exposure to high concentrations of oxygen, even for relatively short periods of time, the
research is sparse regarding to long-term exposure to low flows of oxygen. Understanding this
dichotomous drug is the responsibility of the healthcare providers.
Following his 1913 scientific expedition to the summit of 14,210-foot Pike’s Peak in
Colorado, the venerable British physiologist, John Haldane wrote, “partial anoxia means not a
mere slowing down of life, but progressive, and perhaps irreparable damage to human structure”
47

(Haldane, 1919). Haldane went on to predict that someday the use of oxygen therapy would
become commonplace in hospitals. In 1956 Cotes and Gibson of the UK were providing
ambulatory patients with supplemental oxygen via portable cylinders. Increased walking time
and improved arterial saturation with the administration of supplemental oxygen was noted
(Cotes and Gibson, 1956). In 1958, Alvan Barach was credited to be the first in the U.S. to
develop transfillable oxygen cylinders, as well as inspiring the advent and continued evolution of
LFDO (Petty, McCoy and Doherty 2005).
In 1980, a major randomized clinical trial took place to determine the effects of nocturnal
oxygen therapy treatment. The study enrolled 203 COPD patients with a blood oxygen level
<50mmHg. The results showed a significant difference (P<.01) in survival outcomes between
those patients on continuous oxygen therapy (COT) and those on nocturnal oxygen therapy
(NOT) only (Timms, et al., 1981).
In 2006 T.J. Ringbaek completed a mixed methods analysis of the domiciliary oxygen
research from 16 different countries between the years of 1994 and 2000 in an effort to better
understand the types of home therapies offered, the adherence to guidelines, the effects of
continuous oxygen therapy (COT), the presence of predictors of survival and hospitalizations of
COPD patients on COT, as well as the effect of nocturnal COT as it related to hypoxemia. Over
17,000 people with advanced COPD were analyzed in this study. Results from this analysis
demonstrated the following: the prevalence of patients on domiciliary oxygen was greater when
prescribed by a general practitioner vs. a pulmonologist; adherence to oxygen therapy was
greater when prescribed by a pulmonologist; the incidence of prescribed domiciliary oxygen
therapy increased between 1995 and 2000 in all evaluated countries; most patients had mobile
liquid oxygen systems; the median survival time of all COPD patients who started domiciliary
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oxygen therapy between 1995 and 1999 was 1.27 years (95% CI; 1.20-1.34) longer than those
compared to those with same diagnosis and no domiciliary oxygen therapy.
Consistently research demonstrates that symptoms of those utilizing LFDO improve
activities of daily living (ADLs), as well as ameliorate shortness of breath; however, there is no
evidence that lung functionality improves or that life is lengthened (Strom, 1993; Dubois, 1994;
Croxton and Bailey, 2006).
The American Thoracic Society has provided the following criteria for the
implementation of LFDO therapy as outlined in Table two.
Table 2
LFDO Prescription Guidelines
PaO2 mmHg

Sa, O2 %

LFDO

Qualifying Condition

≤ 55

≤ 88

Absolute

None

55-59

89

Relative with qualifier

cor pulmonale,
polycythemia > 55%,
History of edema

> 60

> 90

None except with qualifier

Exercise desaturation
Sleep desaturation not
corrected by CPAP
Lung disease with severe
dyspnea responding to O2

PaO2: arterial oxygen tension, SaO2: arterial oxygen saturation; CPAP: continuous positive airway pressure; O2:
oxygen.

The multiple factors that contribute to the morbidity and mortality of COPD have
confounded finding a cure. It remains, however, the responsibility of the research community to
better understand the disease and treatment therapies to bring us nearer to a cure. A step in that
direction includes a better understanding of the dichotomous drug, oxygen. Understanding the
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biochemical risks and benefits of oxygen therapy could result in the discovery of control for
those qualities that contribute to pathology.
Based on information already understood about oxygen utilization, therapeutic guidelines
have been developed. According to the ATS the goal of LFDO therapy is to optimize
ventilation/perfusion (V/Q) matching as a means of correcting hypoxemia, particularly after an
acute exacerbation of symptoms. Prior to initiating LFDO an arterial blood gas (ABG) should be
obtained after breathing room air for 30 minutes. An ABG result will provide insight into arterial
oxygen saturation as well as provide information on the presence of hypercarbia, or respiratory
acidosis. Ventilation/perfusion mismatching can also be calculated by the alveolar-arterial
gradient. The ATS recommends oxygen therapy for 24 hours/day with ambulatory capability.
Exceptions to continuous administration include patients who: 1) are incapable or unwilling to be
mobile; 2) only require oxygen during sleep; 3) require oxygen only during exercise. Liters of
flow are gauged by the ABG result, and can be adjusted according to exertional needs. Flow
rates should be adjusted to a target SpO2 of > 90% during periods of rest. This value should be
calibrated with the initial ABG to assess relationship between SpO2 and PaO2. During sleep flow
rates can be determined by two strategies: 1) the flow can be increased 1 L/min above the
daytime resting prescription; or 2) nocturnal polysomnography or nocturnal pulse oximetry can
be performed to support a more accurate prescription. The latter is especially important for those
patients with cor pulmonale. During periods of exertion flow rates goals should be to maintain a
PaO2 > 60mmHg or SaO2 >90%. Increasing overnight prescription of oxygen flow rates by 1
L/min above the day was challenged in a study by Nisbet et al, (2006) stating overnight
desaturation was not an issue if daytime flow rates were used during sleep.
Consequences of oxygen therapy. While many treatment interventions are effective at
addressing and improving specific symptoms, oftentimes the treatment can predispose a patient
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to undesired consequences. As a supplemental therapy that is prescribed to nearly 800,000
individuals annually at an estimated cost of 1.8 billion dollars it is necessary to appreciate any
consequences that occur as a result of LFDO (Kim, et al., 2008).
It is well understood that high concentrations of oxygen therapy for relatively short
periods of time can result in lung pathology. Chronic exposure of lung tissue to moderate oxygen
concentrations can create pathologic changes such as bronchopulmonary dysplasia (BPD) and
fibrotic scarring resulting in deficiencies in ventilation and oxygenation (Chen, 2007). In
experimental BPD models, ROS-induced damage stemming from exposure to supraatmospheric
oxygen tensions manifested in pulmonary epithelial DNA oxidation, accumulation of HO, lipid
peroxidation, and protein oxidation (Liao et al., 2006; Auten, Whorton and Mason, 2003; Luo, et
al., 1999; Vozzelli, 2004). Human BPD studies strongly support a role for ROS mediated
damage (Ballard, et al., 2008). Plasma-3nitotyrosine, a marker for ONOO- formation, and
protein carbonyls, a marker of protein oxidation, are elevated in premature newborns at the
highest risk for developing BPD. ROS may inactivate antioxidant enzymes, with oxidized or
nitrated proteins critical to lung function (Martin and Walsh, 2004). Retinopathy of prematurity
(ROP) implicates oxygen therapy as central to its pathology. According to a study by Chen and
Smith (2007) excessive oxygen contributes to ROP through regulation of vascular growth factor
suppression. It is also speculated that due to decreased levels of antioxidants in the premature
retina allows for oxygen radicals to accumulate resulting in retinal pathogenesis (Sira,
Nissenkorn & Kremer, 1988).
A standard for directly assessing lung pathology was through the collection and
evaluation of bronchoalveolar lavage (BAL). In a study by Davis, et al (1983) volunteers were
exposed to 50% oxygen for 17 hours after which increased amounts of albumin were measured
in their BAL, demonstrating a pulmonary-capillary membrane compromise. In 1986, Griffith et
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al, conducted a study that yielded similar results in when individuals were exposed to
concentrations of 30-50% oxygen for 45 hour with dose dependent increase in albumin in the
BAL. In the same study, to measure lung epithelial permeability, inhaled technetium-labeled
diethyentriamine pentaacetate was assessed; increases were detected in individuals exposed to
50% oxygen.
Historically it was believed that only high concentrations of oxygen were offensive to
lung parenchyma, however, more recent research demonstrated concentrations as low as 40%
have been implicated as well (Nagatomo, et al., 2012). The 1970’s offered the “60%” rule,
delivering oxygen at 60% or less as an acceptable guideline for management of hypoxemia, after
previous studies of higher concentrations of oxygen clearly demonstrated pathologic
consequences. This practice has been essentially unchallenged due to ethical considerations.
Results from animal studies have provided significant insight into the deleterious effects of
oxygen exposure (Martin and Kachel, 1989); however, in 1989 a study using cultured human
pulmonary artery endothelial cells it was demonstrated that cytotoxicity occurred as early as 8
hours following exposure to 0.95 FiO2, and after 48 hours of exposure to concentrations as low
as 60% (Martin and Kachel, 1989).
Oxygen toxicity causes damage to the lungs through a series of progressive stages.
Initially, epithelial integrity is interrupted resulting in transudate in the alveoli; subsequently,
capillary damage results in exudate between the alveolar sacs leading to fibrosis of the type I
epithelial cells (Campbell, 2002). It is well documented in the literature that interstitial
pulmonary changes occur after exposure to elevated concentrations of oxygen; however, there is
a paucity of research to addresses the consequences associated with chronic exposure to low
concentrations of oxygen.
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An exhaustive Medline data search regarding the risks and benefits of long-term oxygen
therapy revealed 14 studies assessing the value of dating from 1970 to 2010. Multiple variables
were employed with only four studies clearly addressing the presence of an oxidative injury.
In 1971, Petty, Stanford and Neff evaluated 20 patients diagnosed with severe COPD
who were placed on continuous oxygen therapy to correct hypoxemia to a goal of a PaO2
between 50 and 75mm Hg. Multiple blood gases were drawn until desired range was achieved,
which usually resulted in 1-2 L of oxygen per nasal cannula. Survival ranged between 7 and 61
months, with 14 patients dying after an average of 26.7 months. Upon autopsy it was noted that 6
of the deceased showed exudative or proliferative tissue injury commensurate with oxygen
toxicity. Survival was not shortened in those with histologic changes, but quality of life was not
defined. Five patients went on to live an average of 42.4 months with continued excellent
benefit. In 1975, Steward, Hood and Block performed a similar study that evaluated 12 patients
receiving portable oxygen therapy for a mean period of 25.2 months. The overall impression of
the researchers was that oxygen therapy was beneficial. The variables evaluated were pulmonary
function testing, electrocardiogram and cor pulmonale, and hospital admissions. Decline in
pulmonary function tests was not demonstrated, an electrocardiogram exhibited an improvement
in cor pulmonale in 5 patients, and a reduction in hospitalizations for respiratory illnesses. Six
study participants died during the study period demonstrating a 56% survival rate for the
remainder. However, five of the 6 deceased presented with histologic changes consistent with
oxygen toxicity upon autopsy.
A study published in 2004 in the European Respiratory Journal by Phillips et al, aimed to
determine if short-term exposure to a low concentration of supplemental oxygen (28%) had an
induced oxidative stress in nonhypoxic subjects. Breath methylated alkane contour (BMAC) was
the marker utilized in this study. Thirty-one healthy subjects were recruited for this study and
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served as the control and treatment groups in a pre and posttest design. Exhaled breath was
collected prior to oxygen exposure and then after exposed to 28% oxygen at 2L/min via nasal
cannula for 30 minutes while at rest. The results showed a significant (p<0.05) increased in the
oxidative stress biomarker, BMAC.
A similar study performed in 2004 by Carpagnano et al, recruited 23 healthy subjects and
23 subjects with COPD. The control group consisted of 5 healthy subjects and 5 COPD subjects
who breathed ambient air through a facemask for one hour; the treatment group consisted of 18
healthy subjects and 18 COPD subjects (7 of which were receiving domiciliary oxygen
treatment) and exposed them to 28% oxygen via a facemask for one hour. The exhaled breath
was collected from both groups and compared for the presence and quantification of 8isoprostane and interleukin-6, biomarkers of oxidative stress and inflammation. The outcomes of
this study showed a significant increase (p<0.05) in both biomarkers following exposure to one
hour of 28% oxygen.
Oxygen is one of the most widely used therapeutic agents and is a considered a drug in
the truest sense of the word as it has specific biochemical actions, a distinct range of effective
doses, and a well defined consequence at higher doses; however, a therapeutic range as it relates
to dose and time, has not been established. The cost of use is low, yet it has been reported that in
many hospitals the annual expenditure of oxygen therapy exceeds those of most other highprofile agents (Bitterman, 2009). Sufficient evidence-based data does not exist to address the
potential of this dichotomous drug.
Hyperoxia. Oxygen is so central to human existence that it was once intuitive to believe
it incapable of being dangerous, let alone lethal. As such, oxygen was/is administered liberally
within hospital settings, used as a pretreatment prior to deep sea diving or piloting an aircraft,
and even offered at oxygen bars for patrons to imbibe in its protective and healing powers. The
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dangers of prolonged exposure to high concentrations of oxygen are now very well documented.
Oxygen is no longer considered innocuous but rather as a formidable and dichotomous drug that
can give life or take it away. To not adhere to meticulous therapeutic protocols would be medical
negligence. Oxygen continues to be one of the most widely used therapeutic agents but the
margin of safety for various conditions remains to be clearly defined.
Hyperoxia is the term used to describe the presence of excessive oxygen in the lungs and
vasculature for delivery to the tissues of the body. This can occur when inspired oxygen is
delivered at higher than necessary concentrations or at higher than atmospheric pressure, as with
positive pressure ventilation or hyperbaric chambers, and increased fractions of inspired
concentrations. The standard atmosphere is unit of pressure and is defined as being equal to
101.325 kPa or 760 mmHg. The pressure of oxygen of inspired air at sea level is 0.21
atmospheres absolute, or Ata (Saltzman, 1973). Oxygen exposure at 1 atm of pressure, the lung
is the most severely damaged as pulmonary tissue PO2 is the highest in the body. Since
pulmonary tissue PO2 is directly determined by the alveolar PO2 arterial hypoxemia does not
delay the development of pulmonary oxygen toxicity at 1 atm (Nunn, 1987).
While prolonged periods of hyperoxia can cause damage to various structures of the
body, such as the central nervous system (CNS), the retina, hemolysis of erythrocytes,
myocardium, the pulmonary structures are particularly vulnerable to the consequences of
prolonged periods of high-pressure ventilation and increased fractions of inspired oxygen as they
are directly exposed to the offending variables without buffer (Yusa et al., (1987); Gu et al.,
2003; Mengal and Kann, (1966); Sen et al., (2006). Individuals exposed to 1.0 Ata of oxygen for
24 hours will display discernible symptoms of respiratory distress (Saltzman, 1973; Klein, 1990;
Miller et al., 1970). If inspired pressures exceed 2.5 Ata, as possible in a hyperbaric chamber,
neurologic symptoms, such as confusions and coma, will occur abruptly, but are reversible;
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however, pulmonary toxicity is more insidious and, therefore, less reversible (Behnke, 1935). As
early as 1899 J.L. Smith was able to demonstrate that animals exposed to uninterrupted exposure
to one Ata of oxygen for several days would experience respiratory distress, hypoxia and even
death. Upon necropsy these animals displayed severe parenchymal damage.
Paul Bert (1943), a French physiologist, first described central nervous system toxicity in
his publication Barometric pressure: Researches in Experimental Physiology. CNS toxicity is
often referred to, as the “Paul Bert effect.” In his research he showed oxygen was toxic to
insects, arachnids, myriapods, molluscs, earthworms, fungi, germinating seeds, birds, etc. Bert
was able to demonstrate that the deleterious effects of oxygen exposure were a result of increases
in partial pressure vs. concentration, a theory that was essentially unchallenged for decades. In
more recent years a biochemical process resulting in the production of oxygen metabolites has
been implicated as the likely culprit in oxygen toxicity (Klein, 1990).
Oxygen toxicity. The mechanism of oxygen toxicity at the molecular level is now
attributable to free radical interactions with cellular components. As a naturally occurring
phenomenon with physiologic functions, their highly reactive nature makes them formidable
when left unchecked. The oxygen molecule is normally susceptible to univalent reduction
reactions within the cell to form a superoxide anion and hydrogen peroxide. While both of these
compounds can have direct toxic effects, they interact to form more dangerous species through a
process called the Fenton reaction, a reaction resulting in the formation of radicals from
nonenzymatic processes. Due to the deleterious potential of free radicals, or reactive oxygen
species, a complex and layered defense of enzyme systems and low-molecular weight radical
scavengers exists.
It is difficult to fully appreciate the whole process of oxygen toxicity in humans for
obvious ethical reasons. As a result, most studies conducted regarding this deleterious process
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have utilized animal models, including ultrastructural morphometry, or the measurement of an
external form. Human studies consist of autopsies following a severe illness requiring high
concentrations of oxygen, usually delivered by high-pressure ventilation. In animal models
researchers have been able to track oxygen toxicity from the mild to severe stages; however, only
the end stages have been studied in humans during autopsy. Fortunately, relevant relationships
exist between the animal and human studies with regard to morphologic changes (Lambertson,
1971; Crapo, et al., (1980); Crapo, 1986; Kapanci, et al., (1969); Thet & Parra, (1986); Kapanci,
et al., (1972). In most species, exposure to 100% oxygen at 1 atm for 24-72 hours is associated
with the initial phase of injury in all species.
It has been proposed that the alveolar destruction that occurs as a result of oxygen
toxicity is compromised of multiple processes: apoptosis, oxidative stress, and protease
antiprotease imbalance. In the pages that follow these mechanisms will be addressed in an effort
to better understand the cascade of events that result in COPD.
During periods of hyperoxic pathologic conditions, a large influx of ROS is produced,
disrupting the balance between oxidants and antioxidants, making surrounding tissues vulnerable
to pathologic changes. Exposure time, atmospheric pressure, and fraction of inspired oxygen
(FiO2) determine the cumulative oxygen dose predisposing toxicity (Mach, et al., 2010).
Pulmonary capillary endothelial and alveolar epithelial cells are targets for ROS. The
earliest morphologic changes seen in the initial, or inflammatory, phase involve subtle changes
in endothelial cell structure, which result in pericapillary accumulation of fluid. If left unchecked
interaction can result in excessive edema, alveolar flooding, hemorrhage, and collagen, elastin,
and hyaline membrane deposits (Yee, et al., 2006; Kan, Lee and Kim, 2005; Pagano and
Barazzone-Argiroffo, 2003). The initial phase is associated with, or rapidly followed by,
accumulation of thrombocytes, macrophages and neutrophils in the lungs accompanied by the
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release of soluble mediators of inflammation resulting in ongoing edema and cellular signaling
(de los Santos, et al., (1987); Barry & Crapo, (1985); Fox, et al., (1981); Rinaldo, et al., (1988);
Forman, York & Fisher, (1960); Ozawa, et al., (1988)). The hemoglobin-oxygen buffering
mechanisms fail when the PAO2 reaches a critical level and the tissue PO2 rises above hundreds
of mmHg. At high levels of oxygen, protective endogenous antioxidant enzyme systems become
overwhelmed by ROS resulting in cell death (Mantell, et al., (1999).
Pulmonary oxygen toxicity can be explained occurs in 5 phases: 1) Initiation: during this
phase there are increases in production of toxic oxygen metabolites, depletion of antioxidant
stores, decreases in flow of tracheal mucus lending to infection and no obvious evidence of lung
injury; 2) Inflammation: during the inflammation phase damage occurs to the pulmonary
capillary endothelial lining, increases in inflammatory mediators rush to site of insult and the
development of pulmonary edema ensues; 3) Destruction: during the destruction phase there is
amplified damage to the endothelial lining with the accumulation of platelets, neutrophils, a
continued release of inflammatory mediators, and this is the phase most associated with
mortality; 4) Proliferation: the proliferation phase becomes evident after prolonged exposure to
oxygen concentrations between 60-85% with hypertrophy occurring to the remaining pulmonary
capillary endothelial cells, increases in monocytes, increases in type II pneumocyte activity, or
surfactant production; 5) Fibrosis: permanent lung damage occurs during this phase as collagen
deposition occurs in the lung interstitium, increases in the thickness of the pulmonary interstitial
space and increases in interstitial fibrosis (Mensack and Murtaugh, 1999).
The pulmonary epithelial surface is vulnerable to a destructive inflammatory response.
Inflammation damages the alveolar capillary barrier leading to impaired gas exchange and
edema. Reactive oxygen species induces pulmonary secretion of chemo attractants, and
cytokines stimulate macrophage and monocytes mobilization and accumulation into the lungs,
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leading to further ROS production, extending injury. As highly reduced cell layers become
increasingly oxidized and levels of antioxidants fall, ROS-induced activation of signal
transduction pathways regulates cellular responses of adaptation, repair or cell death by
apoptosis, oncosis, or necrosis (Romashko, et al., 2003; Kannan, et al., 2006).
Cellular response to ROS signaling occurs as a result of mitogen-activated protein kinase
(MAPK), toll-like receptor 4 (TLR4), signal transducers and activators of transcription (STAT),
and nuclear factor kappa beta (NFkß) communicating with the DNA of the cell and eliciting a
response. The MAPK pathway regulates cell death genes, stress and transformation and growth
regulation. The TLR4, STAT pathways are associated with survival gene expression and
antioxidant response. The NFkß pathway is an up-stream signal for inflammation and survival
genes: antioxidant enzymes, Bcl-2, hemeoxygenases, and heat shock proteins (Mach, et al.,
2010).
Oxidative stress. Oxidative stress occurs as a result of the cumulative effects of an
excess of reactive oxygen species (ROS). Prolonged exposure to higher than normal
concentrations and partial pressures of oxygen than the lungs are normally exposed to will result
in the production of ROS (Fridovich, 1998). Conditions that precipitate oxidative stress through
different ROS producing mechanisms include pneumonias, sepsis, acid aspiration, hyperoxia,
high-pressure ventilation, pulmonary contusion, reperfusion injury and/or bleomyocin exposure
(Matute-Bello, Frevert and Martin, 2008). When the body is unable to control for an excess of
these highly bioactive intermediates that result from these pathologic processes significant
cellular damage and pathology can ensue. Ironically, the precipitating conditions typically
require prolonged oxygen exposure as a support therapy placing them at an even greater risk of
oxidative damage.
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Research regarding high concentration oxygen exposure in healthy patients has not
demonstrated permanent results when exposure was less than 24 hours. In a 1970 study
performed by van der Water et al, nine young healthy men were exposed to 100% normobaric
oxygen for 6-12 hours. Following this exposure the alveolar-arterial 02 gradient, pulmonary artery
pressure, total pulmonary resistance, cardiac output, pulmonary vascular volume, and CXR were
evaluated with no pathologic findings noted. However, unpublished research conducted on
exceptionally fit pilots that routinely inspired 100% oxygen immediately pre flight suggests the
pilots experienced symptoms consistent with inflammatory lung injury, such as cough, substernal
chest pain and burning. Pulmonary function tests in this group indicated that pathologic changes
had occurred in those who had participated in repeated, pre-flight, short-term inspiration of high
oxygen concentrations (Vacchiano, personal communication).
The symptoms primarily observed in conscious patients with oxygen toxicity is
tracheobronchial irritation resulting in a cough and substernal discomfort. The onset of
symptoms of tracheal irritation occur ~4-22 hours after the start of oxygen exposure (Comroe et
al., 1945). According to Sackner et al, (1975) these symptoms precede changes in pulmonary
function tests.
Historically, the most commonly used index of oxygen toxicity in humans has been vital
capacity (VC) (Comroe, et al., (1945); Caldwell, et al., (1966). Vital capacity is measured as the
total volume of expired air from the lungs following maximal inhalation. Early respiratory
physiologists reported that subjects who were suspected to have suffered oxygen poisoning had
concomitant decreases in their VC (Comroe et al., 1945; Caldwell et al., 1966, Clark and
Lambertsen, 1971). However, more current research has abandoned this index as a primary
indicator as too many variables confound accuracy.
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Hyperoxic lung damage. Oxygen exposure at concentrations greater than 50%
administered between 4 and 22 hours can induce lung injury between (Bitterman, 2009) via two
mechanisms: 1) the formation of cytotoxic oxygen free radicals; and 2) absorption atelectasis
(Carvalho et al., 1998). The formation and activity of oxygen free radicals is the topic of interest
for this research study and, therefore, will be addressed exclusively.
Most research addressing the subject of pulmonary oxygen toxicity has been performed
almost exclusively on animal models for obvious ethical reasons. Research performed on
humans is typically carried out during autopsy (Klein, 1990). In most species, exposure to 100%
at one atm for a period of 24-72 hours results in the initial phase of lung injury. Normally this
phase displays no outward symptoms of injury but is characterized by increases in production of
oxygen metabolites, such as reactive oxygen species, through the recruitment and activation of
neutrophils (Jamieson et al, 1986; Rinaldo et al., 1988, Vacchiano et al., 1997; Wheaton and
Chandel, 2011). The presence of neutrophils in the lungs is commensurate with parenchymal
damage (Crapo et al., 1980; De los Santos et al., 1987, Steinberg, K.P. et al., 1994; Reutershan et
al., 2005). Neutrophils release inflammatory mediators, which, in this environment, result in the
production of reactive oxygen species via various oxidases (Zmiljewski et al., 2008; Wheaton
and Chandel, 2011). The ROS also mediate increased mucous production, decreased ciliary
function, fibroblast injury, gene expression of pro-inflammatory mediators (TNG-a, IL-8, IL-1,
NO), and diminished pulmonary mechanics and lung repair (Barnes, 1990; Barnes, 1996;
Keatings et al., 1996; Barnes, 2004; Cross, et al., 1994; Macnee and Rahman, 1999).
The major cellular mediators in pulmonary oxygen toxicity are considered alveolar
macrophages (AMs), neutrophils (PMNs), and vascular endothelial cells (VECs) (Vacchiano,
Osborne and Temple, 1997). The consequence of cytotoxic free radical activity is fibrotic
changes to the parenchyma. Parenchymal fibrosis results in disrupted wall integrity and
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impaired gas exchange. Alveolar macrophages have been implicated as the initial metabolic
source producing reactive oxygen species (Vacchiano, Osborne, and Temple, 1997; Grommes
and Soehnlein, 2011).
The discontinuation of hyperoxic exposure can result in three ways: 1) Type II
pneumocytes proliferate to begin restructuring of the alveoli; 2) fibroblast proliferation that may
lead to interstitial fibrosis, and 3) development of pulmonary hypertension as a result of the
derangement of large and small arterial walls (Coflesky, et al., (1987); Shaffer, et al., (1987).
The role of oxidative stress is now widely recognized as a key component of airway
inflammation in a variety of pulmonary ailments (Riedl and Nel, 2008). Through the excessive
production of ROS structural cellular damage occurs through the oxidation of proteins, lipids and
DNA (Riedl and Nel, 2008). Continued attention needs to be given to this pervasive process as it
undermines the human infrastructure making it vulnerable to disease and discomfort.
Acute Respiratory Distress Syndrome. Ashbaugh et al, (1967) were the first to describe
and report a syndrome with a set of pulmonary pathologies that presented with such symptoms as
diffuse lung infiltrates and respiratory failure and referred to as adult respiratory distress
syndrome (ARDS). During that time those who identified this syndrome included cases of battle
trauma, severe sepsis, pancreatitis, and massive transfusions. Following ongoing research,
Ashbaugh and Petty (1971) refined their definition to include clinical features of severe dyspnea,
cyanosis refractory to oxygen therapy, decreases in pulmonary compliance, atelectasis,
pulmonary vascular congestion and hemorrhage, pulmonary edema and hyaline membranes at
autopsy.
By 1988 a 4-point physiologic quantification system was introduced to stratify lung
injury: 1) level of positive end expiratory pressure (PEEP); 2) P/F Ratio (ratio of arterial oxygen
concentration to the fraction of inspired oxygen; 3) static lung compliance; and 4) degree of
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pulmonary infiltrations on chest x-ray (CXR). Other considerations with this point system
included the examination of nonpulmonary organ dysfunction (Murray et al., 1988).
Shortcomings, however, existed with this definition as it did not clearly delineate ARDS from
cardiogenic pulmonary edema or offer predictive outcomes. In 1994 the American-European
Consensus Conference Committee (AECC) developed the now widely accepted definition of this
collection of phenomenon and changed the name to acute respiratory distress syndrome to reflect
that all are vulnerable to the possibility of experiencing this pathologic process.
The current definition of ARDS is as follows: acute onset, bilateral pulmonary infiltrates
on CXR, pulmonary capillary wedge pressure (PCWP) <18 mmHg, P/F ratio <200. Adult
respiratory distress syndrome occurs in four stages: exudative (acute phase), proliferative,
fibrotic and recovery, if recovery is possible. Management of ARDS includes oxygen,
mechanical ventilation, fluid therapy and a variety of medications to combat and support the
various manifestations associated with the pathology. Ventilatory management, to include
elevated oxygen concentrations, serves a dichotomous role. The patient will not survive without
positive pressure ventilation and increases in supplemental oxygen, however, these treatments
introduce potentially irreversible sequelae. Higher concentrations of inspired oxygen at
atmospheric pressure are associated with pulmonary oxygen toxicity.
Reactive oxygen species. Reactive oxygen species (ROS) are free radicals containing
oxygen in multiple forms to include oxygen ions, peroxides, superoxides, dioxylgenals and
ozone. Free radicals are atoms, molecules or ions characterized by unpaired electrons in their
outer orbits, making them highly reactive. Oxygen free radicals are continuously being produced
intracellularly by oxidation-reduction reactions (Southorn and Powis, 1988).
Normal cellular metabolic processes are the major source of ROS production, with
electron transport chain of the mitochondria the largest contributor. ROS generation also occurs
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endogenously during activation of circulating inflammatory cells or phagocytes, or exogenously
due to interactions with noxious chemicals (Kirkham and Rahman, 2006).
It should be understood that ROS have essential homeostatic responsibilities, such as
regulation in signal transduction cascades, cellular phosphorylation, gene expression, and DNA
synthesis (Upham and Trosko, 2009). Specific roles of ROS are dependent upon location,
neighbors and timing (Auten and Davis, 2009). Of particular value, as it relates to this study, is
the role of ROS in the antimicrobial activity of phagocytic cells for host defense (Fang, 2011). In
contrast, however, in an unregulated environment, all components of the cell (lipid, protein and
DNA) are vulnerable to irreparable changes (Bowler and Crapo, 2002). The lipid bi-layer is
particularly vulnerable to the activity of oxygen free radicals due to the presence of multiple
double bonds lending to increased reactivity. The oxidative degradation of lipids is referred to as
lipid peroxidation.
Due to the unique molecular structure of oxygen and its abundance within cells oxygen
has powerful potential. It readily accepts free electrons generated by normal oxidative
metabolism within the cell, producing ROS. Processes causing uncoupling of electron transport
can further enhance ROS production. However, other entities, such as the endoplasmic
reticulum-bound enzyme systems, cytoplasmic enzyme systems, and the surface of the plasma
membrane contribute. Contributions by multiple enzyme systems, such as the cytochrome P450
monoxygenase system, xanthine oxioreductase system, nitric oxide synthases, and several others
involved in the inflammatory process (cyclooxygenase and lipoxygenase), can also increase the
generation of ROS. While several forms of ROS are produced, concern of over the production of
the more toxic radicals, such as HO, especially in the presence of reduced transition metals such
as iron, exists. Also, important to note, rapidly reacts with nitric oxide to form peroxynitrite
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(ONOO-), a strong nitrating and oxidizing compound. These highly reactive species can react
with membrane lipids to cause more complex radicals through the initiation of lipid peroxidation,
the non-enzymatic degradation of lipids.
The endogenous production of O2- arises from NADPH oxidases (NOX 1-3) at low
levels in the smooth muscle and vascular endothelium, with dual oxidases 1,2, and 4 in the
epithelial cells. Reactive oxygen species have an important role in regulating nitric oxide
availability, influencing airway and vascular reactivity (Auten and Davis, 2009).
Free radical induced oxidative stress has been implicated in many disease processes such
as cardiovascular, pulmonary, autoimmune, inherited metabolic disorders as well as cancers and
aging. However, the lungs and pulmonary vasculature are particularly vulnerable to the effects of
free radical mediated tissue injury due to the increased presence of unsaturated fatty acids (the
substrate for lipid peroxidation) and exposure to higher concentrations of oxygen than any other
organ in the body (Torres, 2004).
Numerous pathways are initiated when stress is experienced leading to free radical
production. A cascade of free radical activity leads to lipid peroxidation, protein oxidation, DNA
damage, all of which contribute to pathology and cell death (Kappus and Sies, 1981; Bowler and
Crapo, 2002).
Reduction-oxidation reaction. Reduction-oxidation, or redox, reactions are those that
refer to chemical reactions in which atoms have their oxidation state changed. Oxidation state
refers to the charge an atom would have if all bonds to atoms of different elements were 100%
ionic, the chemical bond created by the attraction of opposite charges. The increase in the
oxidation state of an atom as a result of a chemical reaction with a net loss of electrons is
referred to as oxidation. The decrease in the oxidation state of an atom as a result of a chemical
reaction with a net gain in electrons is referred to as reduction (Voet, Voet and Pratt, 2006).
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Metabolic redox reactions within the body can result in the formation of molecules that
are missing electrons. When a system is overwhelmed and there is an imbalance of antioxidants
present new molecules are formed. In an effort to neutralize, these highly reactive and unstable
molecules (or free radicals) will react with the first available source, such as DNA, lipid
membranes, often resulting in irreparable damage and cell death (Kappus and Sies, 1981).
The direct effects of ROS on signaling pathways include redox-sensitive transcription
factors, such as HIF, Nrf-2, and Nf-κB, as well as through direct effects through the inactivation
of NO-based signaling (Auten and Davis, 2010).
To demonstrate the pathologic potential of unchecked ROS an example is provided. The
developing retina is especially sensitive to ROS-mediated damage, contributing to retinopathy of
prematurity in newborns. Vascular growth into the developing posterior retina is normally driven
by redox-sensitive pathways that upregulate vascular endothelial growth factor (VEGF).
Following birth, the neonate experiences increases in oxygen tension that suppresses VEGF. In
the premature infant the suppression of VEGF in conjunction with altered autoregulation of
retinal blood flow, as well as a deficiency in antioxidants, results in cessation of angiogenic
budding, while apoptosis of developing vessels occurs secondary to the formation of ROS and
nitrogen species (Gu, et al., 2002; Gu, et al., 2003; Saugstad, 2006).
Antioxidant systems. All aerobic organisms have enzymatic and non-enzymatic cellular
defenses, collectively referred to as antioxidants, to maintain cellular homeostasis. Regulation of
ROS activity is provided by antioxidants (Bowler and Crapo, 2002; Southorn and Powis, 1988).
Antioxidants are both water-soluble and lipid soluble. Water-soluble antioxidants
generally react with oxidants in the cell cytosol and the blood plasma. Lipid soluble antioxidants
protect cell membranes from lipid peroxidation. With regard to function there are four main
classifications: 1) Preventative, which suppress the formation of ROS, 2) radical scavenging,
66

which suppress chain initiation and/or halt propagation reactions, 3) repair and restore, such as
proteases, and 4) those that allow for adaptation that occurs when the signal for the production
and reactions of ROS induces oxidant formation and transport (Rahman, Biswas & Kode, 2006).
The enzymatic antioxidants include superoxide dismutase (SOD), catalase, glutathione
peroxidase, glutathione S-transferase and thioredoxin (Kirkham and Rahman, 2006). The nonenzymatic antioxidants include low molecular weight compounds, such as glutathione, urate,
ascorbate, α-tocopherol, bilirubin, and lipoic acid, and high molecular weight compounds, such
as the proteins albumin and transferrin.
Glutathione (GSH), a tripeptide thiol, is the primary intra and extracellular antioxidant in
the lungs and is markedly up regulated in the presence of oxidative stress (Barnes, 2004; Rahman
and MacNee, 2000; Deneke and Fanburg, 1989; Meister and Anderson, 1983). Alterations in
alveolar and lung GSH metabolism are recognized as a central feature of many inflammatory
lung diseases, such as COPD (Rahman and MacNee, 1999).
A delicate balance must be maintained between ROS production and the antioxidant
defenses to ensure cellular stability. The balance is disturbed by conditions of hyperoxia,
inflammation, or ischemia-reperfusion, or in the presence of impaired antioxidant defenses, such
as seen with smoking (Auten and Davis, 2009). Mechanisms of ROS-related cell death include
direct injury to proteins, lipids, and nucleic acids. For example, nitrosylation and protein
oxidation impair a variety of enzymatic process and growth factors leading to cellular
dysfunction (Stadtman and Levine, 200). Lipid peroxidation has been linked to cell death
through the effects on cellular phospholipids through the activation of sphingomyelinase and the
release of ceramide, which result in apoptosis (Fruhwirth and Hermetter, 2008). Nucleic acid
oxidation has been linked with physiologic and premature aging as well as DNA strand breaks,
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which leads to necrosis and/or maladaptive apoptosis (Auten, Whorten and Mason, 2002). The
ability of the cell to handle changes determines whether or not it is adaptive or maladaptive.
In the proper location and concentrations, ROS can function as second messengers and
activate multiple signal transduction pathways within the cell, such as growth factors, cytokines
and calcium signaling. Possibly through the production of lipid peroxide intermediates, ROS can
activate protein kinases, which phosphorylates and releases to Bcl-2-related proteins sequestered
within cells (Parinandi, et al., 2003; Lei and Davis, 2003). The release of these key proteins can
activate the Bax system resulting in apoptosis.
Significantly high levels of O2- are generated by NOX in phagocytes, such as the
neutrophils and microphages (~1000-fold higher than nonphagocytic cells) (Auten and Davis,
2009). Blocking neutrophil influx induced by hyperoxia resulted in mitigating oxidative DNA
damage, HO formation, and O2- accumulation, while simultaneously enhancing alveolar
development (Auten, Whorton and Mason, 2002; Belik, et al., 2004; Auten et al., 2001; Ning et
al., 2006). It has been demonstrated that when the NADPH oxidases are genetically ablated
reduction in pulmonary ROS accumulation occurs; however, this has not been proven to be
protective as accompanying inflammation ensues (Gao et al., 2002; Yao et al., 2008).
Lipid Metabolism
Lipid metabolism can occur from both enzymatic and nonenzymatic processes. In the
increased presence of reactive oxygen species enzymatically driven lipid metabolic pathways
may be bypassed for the nonenzymatic lipid peroxidation pathway (Voet, Voet and Pratt, 2006).
Enzymatic lipid metabolism. Enzymatic lipid peroxidation occurs when
cyclooxygenase and lipoxygenase control the peroxidation of various fatty acid substrates. These
cyclooxygenase derived fatty acid substrates include prostaglandins. Enzyme generated products
mediate specific bioactivities via receptor-dependent pathways that are under tight regulation.
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Cyclooxygenase is the precursor to prostaglandin synthesis, and are pro-inflammatory. Nonsteroidal anti-inflammatory drugs (NSAIDS), such as ibuprofen or naproxen, are cyclooxygenase
(COX) inhibitors, antagonizing prostaglandin synthesis, thwarting inflammation and relieving
associated pain perception.
Non-enzymatic lipid metabolism. An overabundance of ROS can lend to non-enzymatic
lipid peroxidation, the metabolism of fatty acids, primarily arachidonic acid, resulting in the
oxidative degradation of lipids. This is a process by which free radicals readily bind with
electrons of the lipids in cell membranes resulting in cellular damage (Repetto, Semprine and
Boveris, 2012). Since this process does not involve cyclooxygenase no current therapies are
available to ameliorate the inflammatory response caused by these mediators.
Lipid peroxidation most readily affects polyunsaturated fatty acids due to the presence of
multiple double bonds that are positioned between methylene groups and highly reactive
hydrogen atoms. Products of ROS initiated non-enzymatic lipid peroxidation are
proinflammatory prostanoids, which can generate more radicals that are capable of releasing
damaging enzymes (Auten and Davis, 2010). Radical reactions consist of three main steps:
initiation, propagation, and termination (Repetto, Semprine and Boveris, 2012).
Initiation is the step in which a fatty acid radical is produced. Of these the most notable
initiators in living cells are reactive oxygen species, such as OH and HO2, which readily bind
with a hydrogen atom to form water and a fatty acid radical (Porter, Caldwell and Mills, 1995).
Propagation is the step by which the newly formed unstable fatty acid radical readily
binds with molecular oxygen to form an unstable peroxyl-fatty acid radical. This process
continues, or propagates, producing a different fatty acid radical and lipid peroxide, or cyclic
peroxide if it reacts with itself (Porter, Caldwell and Mills, 1995).
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Termination occurs when two radicals react to form a non-radical. This can only occur
when the concentration of radical species is high enough to potentiate the interaction between
two radicals. When a radical reacts with a non-radical the interaction will always produce a
radical, thus the chain reaction phenomenon. Organisms have evolved to protect themselves by
speeding up termination through scavenging free radicals with antioxidants, such as vitamin E
(α-tocopherol), as well as the enzymes superoxide dismutase, catalase and peroxidase (Porter,
Caldwell and Mills, 1995).
The location the initial hydrogen atom abstraction takes place along the carbon chain
determines the by-product produced. By-products of ROS generated non-enzymatic lipid
peroxidation include isoprostane compounds, which are non-classical eicosanoids, such as 8-IsoPGF2α, a biomarker now used extensively to assess for the presence of oxidative stress in a
variety of conditions. In conditions where increased oxygen tensions exist, the formation of
isofurans is favored over 8-Iso-PGF2α (Fessel, et al., 2002). The isofurans are a more sensitive
indicator of oxidative injury. These biomarkers can be detected in multiple media: serum, urine
and exhaled breath.
Eicosanoids
Eicosanoids are oxidative derivatives of 20-carbon chain essential fatty acids (EFA),
specifically omega-3 (ω -3) and omega-6 (ω-6), which are primarily responsible for immune and
inflammatory responses as well as serving as central nervous system messengers. Eicosanoids
are comprised of four main families: prostaglandins, prostacyclins, leukotrienes and
thromboxanes, all of which have bioactive subcategories. Prostaglandins, prostacyclins and
thromboxanes comprise a group called prostanoids. Eicosanoids are not stored in cells but rather
are synthesized in response to hormonal stimulation. Synthesis occurs through a series of steps.
Initially, a fatty acid substrate, such as arachidonic acid, is released from cellular phospholipids
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via phospholipase A2; the free fatty acids are then acted upon by either cyclooxygenase 1 or 2
(COX1 or COX2) forming a hydroperoxide. The newly formed hydroperoxide is then reduced
through a peroxidase reaction resulting in PGH2, an unstable intermediate from which all other
prostanoids are derived via various enzymatic reactions (Voet, Voet and Pratt, 2006).
Prostanoids. Prostanoids are biologically active lipids formed from cyclooxygenases or
prostaglandin synthases acting on the 20-carbon EFA chain by adding two oxygen molecules as
two peroxide linkages and forming a 5-carbon ring approximately midway in the structure.
Prostanoids are comprised of prostaglandins, prostacyclins and thromboxanes, all of which have
a specific role with regard to the immune/inflammatory response and homeostasis. Prostanoid
activity is achieved through autocrine and paracrine stimulation, meaning they exert their
activities through cellular signaling among same cells and adjacent cells, respectively.
Homeostatic functions of prostanoids include cytoprotection of gastric mucosa, regulatory
influence on the renal, cardiovascular, and pulmonary physiology, protein metabolism and
gestation and parturition regulation; however, they are involved in pathologic processes, such as
inflammation, cardiovascular disease, cancer, dementia and Alzheimer’s as well as aging to
name a few (http://lipidlibrary.aocs.org/Lipids/eicprost/file.pdf).
Prostaglandins. Prostaglandins were identified in the 1930’s and named so as they were
thought to originate in the prostate gland. It was discovered by the 1960’s that prostaglandins
exist in nearly all cells of the human body as a result of the biosynthesis of specific EFAs. While
cellular concentrations of prostaglandins are low-level, measuring only in nanomoles, their
biologic activities are profound.
An important chemical distinction of prostaglandins is the 5-carbon ring positioned
between the 8 and 12 carbons. Dependent upon subgroups, the prostaglandin family is
comprised of at least 11 variations: PGA, PGB, PGC, PGD, PGE, PGFα, PGG, PGH, PGI, PGJ,
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and PGK. Further distinctions can be made by the absence or presence of double bonds, denoted
by the subscript 1, 2, or 3. Typically, double bonds are located with the alkyl substituents. The
number of double bonds is directly related to the fatty acid precursor. For example, PGE1, PGE2
and PGE3 are derived from linoleic, arachidonic and eicosapentaenoic acids respectively
(http://lipidlibrary.aocs.org/lipids/eicprost/file.pdf). Greek subscripts α and β are used with the
PGF series to describe the stereochemistry of the hydroxyl group on carbon 9
(http://lipidlibrary.aocs.org/Lipids/eicprost/file.pdf).
Thromboxanes. Thromboxanes are lipid molecules in the eicosanoid family responsible
for clot formation and vasoconstriction following endothelial trauma. The two major
thromboxanes are thromboxane A2 and B2. Platelets contain an enzyme, thromboxane-synthase
A, which converts arachidonic acid into thromboxane. Thromboxane promotes platelet
aggregation, facilitated by vasoconstriction (Voet, Voet and Pratt, 2006).
Prostacyclins. Prostacyclins are lipid molecules and, though considered independent
mediators, in eicosanoid nomenclature are referred to as PGI2, derived from ω-6 arachidonic acid,
and are, therefore, grouped with prostanoids. Prostacyclins are produced in endothelial cells
from prostaglandin H2 (PGH2) via prostacyclin synthase. The primary function of prostacyclin in
the inflammatory cascade is inhibition of platelet aggregation and vasodilation, balancing
thromboxane activity and resulting in homeostasis. Unopposed thromboxane activity could result
in significant vascular consequence (Voet, Voet and Pratt, 2006).
Non-classical Eicosanoids
Isoprostanes. Isoprostanes (IsoPs) are prostaglandin F2-like compounds formed in vivo
in abundance as a result of non-enzymatic lipid peroxidation of EFAs, primarily arachidonic
acid, in the presence of oxidative stress. Reactive oxygen species attack the fatty acid,
prostaglandin, resulting in the chemically altered compound with a prostane ring, making up a
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series of isomers named F2-isoprostane. Isoprostanes possess powerful inflammatory,
vasoconstrictive and hyperalgesic properties capable of significant pathology. These compounds
were discovered as a result of reevaluating plasma samples from health subjects stored at -20C
for several months, while the peak times were the same on the chromatogram the peak levels had
increased by ~100-fold. This occurred as a result of autoxidation, a non-enzymatic free radical
metabolism, of plasma lipids during storage. Further investigation confirmed these compounds to
be isomeric to PGs and possess an F-type cyclopentane (prostane) ring, leading to the
nomenclature F2-isoprostanes (Morrow, et al., 1990).
Since that time over a thousand studies have been performed using the 8-isoprostane as a
biomarker of oxidative stress and are considered accurate markers of lipid peroxidation in both
animal and human models of oxidative stress with the isoprostane 8-iso-PGF2α consistent with
pulmonary oxidative stress are (Barnes, 2006) during periods of normoxia and the isofurans
(IsoF) in circumstances where elevated oxygen tension levels are present (Roberts et al, 2004).
The production of isoprostanes is self-limiting making isofurans a better biomarker of oxidative
stress in the presence of hyperoxia.
Isofurans. Isofurans, like isoprostanes, are a result of non-enzymatic free radical
metabolism of arachidonic acid but are differentiated by a substituted tetrahydrofuran ring. IsoPs
and IsoFs share a carbon-centered radical as an intermediate. The generation of IsoPs at the
carbon-centered radical undergoes a 5-exo cyclization to form a cyclopentane ring; IsoFs are
generated when the carbon-centered radical interacts with molecular oxygen, which is why IsoF
formation is favored during periods of increased oxygen tension. Elevated oxygen
concentrations, greater than 21%, favor isofuran over isoprostane production, such as during
periods of hyperoxic therapies or with disorders of the mitochondria where oxygen utilization is
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impaired (Roberts et al., 2004). This unique differentiation allows for more sensitive evaluation
of pathologic processes meeting these criteria.
In a study by Fessel et al, (2002) steps were taken to determine the mechanism of
formation of IsoPs compared to IsoFs when assessing for hyperoxic induced oxidative stress, as
noted with hyperoxia-induced acute lung injury, retinopathy of prematurity, etc. In the pathway
for IsoP formation a carbon-centered radical must undergo intramolecular rearrangement to form
a cyclopentane ring. Competition from molecular oxygen in this reaction prevents the formation
of an IsoP. The researchers presumed this limited IsoP formation at higher oxygen
concentrations. Fessel and colleagues hypothesized that an independent pathway would be
modulated by higher oxygen tensions. To test the hypothesis they measured IsoP and IsoF
formation in vitro from the oxidation of arachidonic acid in the presence of increasing oxygen
tensions. It was concluded that IsoPs and IsoFs increased comparably up to 21% oxygen
as oxidation requires the presence of oxygen; however, IsoF formation continued to increase
significantly as oxygen tension increased to 100% with a ratio of ~6:1 IsoF to IsoP formation.
Further experiments were then undertaken to assess for in vivo IsoF formation. Using the wellestablished liver oxidant injury animal model CCl4-treated rats was utilized to assess for IsoF
formation. The results showed much lower levels of IsoFs than IsoPs. Concerned that this may
be due to the fact that liver tissue has a low oxygen tension they opted to repeat the experiment
in rat kidney and brain tissue. These results were 2-2.3 fold higher than the IsoFs measured in the
liver. Finally, the researchers wanted to look specifically at the formation of IsoFs vs. IsoPs in
the lungs following high concentrations of oxygen exposure. After 3 hours of 100% oxygen
exposure there was no significant difference between IsoP levels between the treatment and
control groups; however, IsoFs increased 5-fold.
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To date eight regioisomers of IsoFs have been identified from which 256
enantiomerically pure IsoFs can be formed (Fessel et al., 2002). An IsoF-type compound has
been identified as an enzymatic oxidation product of arachidonic acid and has been synthesized
in the lab (Pace-Asciak, 1971; Bild et al., 1978; Just and Oh, 1981).
In order to provide clarity, standard rules for chemical nomenclature have been applied
and conform to prostaglandin conventions. Isofurans are abbreviated to IsoFs, consistent with
their biosynthetic relative the IsoPs. The IsoFs have been divided into eight classes based on the
position of the isofuran ring and the alkene of the allylic alcohol. Consistent with prostaglandin
standards, the C-1 will always be the carboxylate carbon; the number of the first carbon of the
ring then will denote the position of the isofuran. Consistent with organic natural-product
nomenclature, the position of the alkene of the allylic alcohol is represented by the ∆ symbol
followed by a superscripted number of the first carbon of the alkene. Eight families of IsoFs are
recognized. These families are further subdivided and differentiated based on two considerations:
the relationship of the alkyl groups of the tetrahydrofuran ring (syn vs. anti), and the relationship
of the ring hydroxyl to the adjacent alkyl group (cis vs. trans) resulting in 32 differentiated
subgroups, each comprised of eight enantiomerically –pure diastereomers.
F2-IsoPs and IsoFs can be quantified in a variety of human and animal fluids and tissues.
The detection and measurement of these molecules in plasma and urine demonstrate global
oxidative stress in vivo while quantification of F2-IsoPs and IsoFs in a tissue sample or in a
specific fluid such as exhaled breath condensate represents local, organ-specific oxidative stress.
Currently the only methodology used to detect and quantify isofurans is the GC/MS. A
“standard” per se is not available but rather the retention times generated from the oxidation of
arachidonic acid are considered consistent with the presence of isofuran (Roberts & Fessel,
2004).
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Exhaled Breath Condensate
It is a goal of the healthcare community to discover safe and effective methods of
assessing for the presence and/or severity of disease processes with the least amount of risk and
discomfort to the patient. For those with debilitating respiratory diseases, traditional means of
collecting tissue samples could exacerbate distress states. The advent of exhaled breath analysis
has opened the door to a safe, effective and non-invasive analysis of some significant disease
states.
Exhaled breath is the air exhaled from the lungs and consists primarily of water vapor
with particles of aerosolized airway-lining fluid (ALF). Aerosolized airway-lining fluid is
comprised of volatile and non-volatile compounds. Many of these compounds can be indicative
of a variety of physiologic or pathologic process occurring within the body.
The concept of evaluating exhaled breath dates back to 400 B.C. when Hippocrates, the
“father of medicine” described fetor oris and fetor hepaticus as a symptoms of disease states
(Duveen and Klickstein, 1955). In the mid 1800’s, Nebelthau determined the presence of acetone
in the breath of diabetics (Hubbard, 1920). In 1874, Francis Anstie, an English physician, spent a
significant portion of his career trying to better understand the effects of alcohol on the body. As
such he was the first to demonstrate that alcohol could be collected into a rubber football bladder
from the exhaled breath of one whom had been imbibing.
In 1927, Dr. Emily Bogen, a practicing physician in Los Angeles during the time of
Prohibition felt compelled to accurately diagnose the presence of alcohol in those persons
involved in car collisions, which were on the rise at that time, to avoid wrongfully accusing and
punishing the innocent. As a result, she developed a breath-collecting device, similar to Dr.
Anstie’s, to measure the presence and degree of alcohol for those persons involved in car
accidents (Bogen, 1927). During that same year in Chicago, Illinois, McNalley, a coroner76

chemist, invented a breathalizer that evaluated changes in color of air moving through chemicals
in water (Popular Science, 1927).
In 1938 Dr. Rolla Harger, a professor of biochemistry and toxicology at Indiana
University, developed the Drunkometer, considered the first roadside breath-testing device to be
used by police. The exhaled breath would pass over and interact with potassium permanganate
resulting in a color change. The degree of color change was directly related to the degree of
intoxication. In 1954 Robert Borkenstein, an Indiana police captain, was credited with
developing a more practical and portable device that does not require recalibration, allowing for
ease of use.
In the1970’s Linus Pauling opened wide the field of breath analysis when he
demonstrated over 250 identifiable substances in exhaled breath via a gas-liquid partition
chromoatgraphy mass spectrometry (Dweik and Amann, 2008; Corradi and Mutti, 2012). Over
80 organic compounds have been identified as directly related to just smoking (Fillpiak, 2012).
Chromatography and spectrometry expanding the exploration of exhaled breath for detection and
measurement of compounds and the subsequent development of exhaled breath collection
devices and assays. As a result of an ongoing evolution of this technology over 5000 compounds
can be measured in exhaled breath to date.
Although it had been established for centuries that chemical evidence exists, and is
measurable, in exhaled breath and that exhaled breath is the greatest source of insensible water
loss, the use of EBC to assess for physiologic and pathologic processes did not occur until 1980
when researchers from the former Soviet Union began to publish reports of its use. Sidorenko et
al (1980) published an article entitled Surface-active properties of the exhaled air condensate, a
new method of studying lung function. However, it would be well into the 90’s before the United
States would begin to explore the value of EBC.
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Collection of exhaled breath condensate is a non-invasive method of collecting
aerosolized air particles from the lungs in order to assess for the presence of ongoing pathology.
EBC contains a variety of biomarkers including hydrogen peroxide, ammonia, leukotrienes,
nitrogen oxides, peptides, cytokines, isoprostanes and isofurans that represent such processes as
airway and lung redox pathology, acid-base imbalances, degree and type of inflammation in
acute and chronic asthma, COPD, adult respiratory distress syndrome, occupational disease,
cancers and cystic fibrosis (Hunt 2002; Horvath et al, 2009).
Respiratory diseases as well as the prescribed therapeutic regimens influence the degree
of biomarker concentration obtained (Horvath 2005). While precise assessment of individual
solute concentrations cannot be made it can provide useful information when concentrations
differ between health and disease states (Hunt 2007).
EBC collection devices. Several commercially available collection devices have been
developed to procure the exhaled breath condensate for biomarker analysis; however, the
concepts of obtaining a collectate are the same amongst them. The exhaled air passes through a
condensing unit resulting in the accumulation of fluid, or condensate. Care to avoid salivary
contamination should be always be taken. Approximately 1-3 milliliters of collectate are required
to guarantee ability to assay in duplicate or triplicate. In general it requires ~10-15 minutes of
tidal breathing to acquire this volume. During normal tidal breathing the levels of aerosolized
particles ranges between 0.1-0.4 particles/cm3 with a mean diameter of 0.3µm. The amount of
aerosolized particles from the respiratory tract is dependent upon airway velocity and surface
tension within the extracellular lining fluid (Mutlu et al., 2001).
The most widely used EBC collection devices utilized in the United States are the
EcoScreen® and the RTube™. Both devices collect exhaled breath through tidal breathing into a
mouthpiece where the exhalant is guided into a cooling chamber for condensation. The
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EcoScreen® is a large nonportable device that requires access to an electrical outlet to operate
the cooling chamber. The EcoScreen® requires 30 minutes to reach the cooling standard, in
between patient cleaning of the mouthpiece and condensing chamber, accessing the cooling
chamber (oftentimes requires some thawing for removal from chamber), and seven minutes for
sample collection. The RTube™ does not require cleaning of its parts as the device is single use
and disposable; multiple samples can be obtained with single patient use and issues with thawing
sample for storage are not encountered. While the EcoScreen® is better able to maintain a
constant temperature than the RTube™ the portability and ease of use of the RTube™ makes this
device extremely advantageous. These features make the RTube™ the device of choice for this
research project.
Concerns, such has condensing temperatures and adherence to the collection unit wall,
have been raised regarding factors introduced by the collection devices that may alter the
composition and, therefore, measurability of biomarkers in the condensate. In a study by Czebe
et al (2008) three condensing units were evaluated to determine the efficacy of the EcoScreen®,
RTube™ and Anacon condensers as well as to test the influence of condensing temperature. The
results of this research effort demonstrated that condenser type influences sample pH, total
protein and leukotriene concentrations with the samples from the EcoScreen® being more
alkaline and contained more protein while the RTube™ and Anacon correlated with regard to
condensing temperature affects on pH but not protein content. The researchers concluded that
adherence of the biomarkers to condenser surface and condensing temperature may play a role in
biomarker variability.
Montuschi (2007) evaluated the EcoScreen®, EcoScreen II®, and the RTube™ with
regard to methodological differences. Each poses benefits and limitations. The EcoScreen® and
EcoScreen II® are able to maintain temperatures to preserve the sample until analysis can occur.
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The EcoScreen® offers an added benefit of respiratory parameters measurability. The
EcoScreen® II has the ability to collect EBC derived from the airways or the alveoli at the same
time. This may allow for the study the origin of biomarkers in the lung compartments.
The RTube™ offers the advantage of portability making collection possible nearly
anywhere; the device also prevents salivary contamination (Hunt, 2002) and has a condensing
sleeve that can be cooled to any temperature. Limitations of the process of using this device
include maintaining temperature during storage and travel; for those compounds that are
chemically unstable this can present a problem.
Exhaled breath condensate pH is typically low in patients with a variety of diseases
inducing airway inflammation, such as cystic fibrosis, COPD, asthma, etc., (Dupont et al, 2006;
Hunt et al, 2000; Borrill et al., 2005; Ojoo et al., 2005). In a comparative study performed by
Koczulla et al., 2009, in which results were repeated on two different days comparing the
EcoScreen® and the RTube™ for pH analysis results showed no significant differences
(P=0.754). The results of the study demonstrated repeatability and reproducibility in healthy
controls, COPD and asthma patients as well as subjects experiencing a common cold. In a
similar study by Prieto et al, 2007, significantly higher pH values in EBC were noted when
obtained with the RTube™ compared to the EcoScreen®.
Rosias et al (2006) evaluated condensers to determine if the properties of the condensing
units interacted with eicosanoids and proteins resulting in values that were at the lower limits of
detection. Albumin and 8-IsoP were evaluated for adherence to five different condensing unit
coatings: silicone, glass, aluminum, polypropylene and Teflon. Results of this study showed that
in vitro silicone and glass coatings yielded a higher recovery of both albumin and 8-IsoP. In vivo
the same was true for 8-IsoP with regard to silicone and glass while albumin was only detectable
in glass.
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According to a follow up study by Rosias et al, (2008) on biomarker reproducibility in
EBC, an optimized glass condenser provided more EBC volume and biomarker detection;
however, biomarker reproducibility in the EBC of healthy adults was not influenced by
condenser type (glass, silicone, EcoScreen® or optimized glass). With regard to bioactive lipids
it has been demonstrated that polypropylene condensers should be considered to avoid the
concern of absorption that can occur with others (Mutlu, et al., 2001).
In a letter to the editors, Sapey et al, (2008) provided five challenges to the interpretation
of the findings in the 2008 Rosias study. Sapey and colleagues questioned the validity of basing
the coefficient of variation (CV) on the mean of spiked samples stating such methods artificially
lowers the CV and, therefore, does not provide a true representation of the inherent variability of
measuring mediators near the lower levels of detection of said assay. Secondly, they contend that
the use of CV is not always the ideal way to express variability stating, “When mean values are
low, CV values can be abnormally high.” Thirdly, the Rosias study stated a “matrix effect is seen
when samples are spiked with 10 pg/ml of mediator but not at 100 pg/ml; Sapey and colleagues
contend that spikes of these concentrations would mask a matrix effect. Fourthly, they did not
find it sensible to address other sources of variability when the assay itself has high variability;
and finally, Sapey and colleagues took issue with the lack of definition of a lower limit of
quantification for any assay as they believe that the lower limit of quantification is central to the
measurement of mediators as well as adhering to strict methodologies as it pertains to a given
biomarker.
Standard for assessing alveolar lining. Historically, pathologic processes occurring
within the lower respiratory tract were evaluated by invasive methods such as bronchoalvealor
lavage (BAL), sputum induction and bronchoscopy. Bronchoscopy is used to visualize the
proximal and distal airways; to control alveolar hemorrhage; sampling of fluids; collecting
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tissues through biopsy; identifying tumors; exploring lesions; investigating hilar lesions;
assessing mechanical difficulties; inspecting the nasopharynx and larynx; and removal of foreign
bodies, etc., (Stocks, et al., 2005). The BAL requires the instillation of saline into the smaller
airways to collect ALF for assessment. The invasive nature of these maneuvers typically requires
sedation and, though rare, carries the risk of hypoxia, dysrhythmias, pneumothorax, bleeding,
infection, bronchospasm, laryngospasm, fever and even death (Zimmerman and Klein, 1997;
Morrow and Agent, 2001). The advent of exhaled breath collection allows for non-invasive
sampling making these ideal collection devices in a fragile patient subset (Montuschi, 2007). No
research supports any such risks to patients utilizing exhaled breath condensing devices.
Comparing EBC biomarker concentrations to established techniques, such as BAL, could
be useful in establishing standards and interpreting results. However, to date few studies exist
that compare the two collection media. Interpreting BAL has its own limitations, such as the
large range of normal values for each substance being measured resulting in a lack of sensitivity
in detecting disease. Additionally, abnormalities detected in BAL fluid are rarely related to a
specific interstitial lung disease. The BAL is fraught with false positive and negative results.
The actual technique utilized to collect BAL may result in tissue damage confounding the results
of the collectate (Leroy et al., 2008).
In a study by Jackson et al. (2007) 48 subjects participated in a study to compare EBC
values to BAL values for 8-IsoP, nitrogen oxides, pH, hydrogen peroxide, total protein,
phospholipids and keratin. The results demonstrated significantly higher concentrations of 8IsoP, nitrogen oxides and higher pH (P<0.001) in EBC. No difference was demonstrated
between EBC and BAL with regard to hydrogen peroxide concentration. Total protein was noted
to be significantly higher in BAL (P<0.001). Phospholipids were also higher in EBC, but no
significance for keratin was detected. No significant correlation was noted between EBC and
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BAL for any of the biomarkers listed. However, in a study by Piotrowski et al, (2007), a positive
correlation (r=0.68) was demonstrated between BAL and EBC 8-isoprostane and LTB4.
In that same year Piotrowski et al, evaluated 28 patients diagnosed with sarcoidosis and
compared the results to a control of 17 healthy subjects. Enzyme-linked immunoassay with
utilized to detect 8-IsoPs in EBC and BAL, as well as a cell count, percentage, and number and
activity of cells. Results demonstrated a significant elevation of 8-IsoP in the EBC of the
sarcoidosis group and a positive correlation between EBC and BAL media (r = 0.68, P<0.0001)
with regard to EBC 8-IsoPs and BAL CysLT may support a possible prognostic value.
Methodological considerations for EBC collection. In 2005 the American Thoracic
Society (ATS) and European Respiratory Society (ERS) Task force on EBC convened to develop
guidelines for the collection and measurement of exhaled biomarkers. Since that time several
reports (Grob, et al., (2008); Davis, et al., (2012); and Rosias, 2012) have been published,
however, with little to add to the original report. Due to the inherent nature of the biomarker
molecule being assessed, the varying storage practices and the specimen assessment tool (assays
vs mass spectrometry) a singular methodology for EBC collection and biomarker detection has
been elusive. Provided below are areas considered to have potential influence on the collection,
maintenance, concentration and detection of biomarkers in exhaled breath.
Duration and temperature of condensate collection. Generally, 10 minutes of tidal
breathing will produce 1-3 mL of EBC. Considerations may need to be made for individuals with
shortness of breath and fatigue easily. According to the report, no differences could be
determined in biomarker concentrations of H2O2, nitrite/nitrate, 8-isoprostane, adenosine and
MDA in studies utilizing 10, 15 or 20 minute collection periods for EBC sampling.
Gessner et al, (2001) demonstrated that not only was EBC volume linearly related to the
volume expired, but also to the total protein and urea content. This finding suggests that these
83

accumulated in the collection device by a similar mechanism as expired water vapor, but is not
necessarily accurate for all substances present. Therefore, Gessner and colleagues suggest that
maybe a volume target should be the goal rather than an amount of time.
Condensation is best achieved when breathing into a cooled collection device. Note
should be taken that the act of breathing through a device will inherently increase its
temperature. The solubility of volatile mediators may be influenced by temperature. Collection
temperatures should be maintained and recorded.
Ambient air. Ambient air may contain molecules that may influence EBC composition
through the following mechanisms: 1) directly contribute to EBC levels; 2) react and, therefore,
change or consume molecules trapped in EBC; and 3) lead to inflammatory and biochemical
changes in the airway that are reflected in EBC composition.
Breathing pattern. When assessing for mediators in individuals with respiratory disease,
breathing patterns were considered. According to the ATS/ERS Task Force “breathing pattern”
differences did not contribute to significant differences in mediator levels. However, in a report
by Montuschi (2007) flow dependence maybe an indicator of where biomarkers originate, in the
airways or the alveoli. Concentrations of EBC biomolecules dependent upon expiratory flow
rates are believed to originate from the airways (Schleiss, et al., 2000). In contrast, the lack of
flow dependence would indicate that a biomolecule is mainly derived from the alveolar region
where flow has a minor role (Schleiss, 2000). Hydrogen peroxide is flow rate dependent
(Schleiss, et al, 2000) whereas 8-isoprostane would primarily be detected from activity in the
alveoli (Montuschi, et al., 2003; Carpenter, et al., 1998).
Airway health and lung function. Exhaled breath condensate volume does not depend on
lung function parameters including FEV1 and FVC in either normal subjects or in those
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diagnosed with COPD. Currently there is no supporting evidence that changes in airway health
cause any difference in mediator release or dilution of EBC.
Age, gender, height and weight. The largest amount of information available on
biomarkers that affect the EBC is on H2O2. This mediator does not seem to be age dependent in
children but does express higher concentrations in older than younger adults. This is likely
attributable to senescence as well as any pathology. Body height and weight do not seem to have
a relationship to EBC volume and H2O2; however, it is recommended that further research be
conducted using other biomarkers. A study performed by Basu, et al, (2009) performed in three
countries, Sweden, Poland and Italy, it was demonstrated a slight increased in isoprostane
production in men when compared to women. No studies were identified that linked height and
weight to changes in biomarker associated with lipid peroxidation.
Food and drink. To date there is no established data that links volatile mediator
concentrations to food and/or drink consumption. However, no systematic studies have been
performed. For the purposes of this study those individuals who ingest antioxidant supplements
will be blocked when performing statistical analyses.
Circadian rhythm. Time of day appears to be relevant for H2O2 in the EBC of normal
subjects and those with COPD. Further research studies are recommended to determine if this
translates to biomarkers consistent with lipid peroxidation.
Tobacco smoking. Information regarding smoking is only available on cigarette smoking,
not pipe, cigar or e-cigarette smoking. The effects of EBC biomarkers regarding the absence or
presence of a filter, or specific brands have not been evaluated. Both acute and chronic smoking
causes increases in H2O2, isoprostane, nitrate and nitrotyrosin levels, as well as increases in
chemotactic activity. In patients with COPD, no difference was observed in the mean EBC
H2O2 and 8-isoprostant levels between smokers and non-smokers (Horvath, 2005). The
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ATS/ERS recommend study participants refrain from smoking for at least three hours prior to
EBC analysis. Studies on the influence of continued smoking in the presence of diagnosed
COPD do not demonstrate significant increases 8-isoprostane levels following acute smoking
consumption (Montuschi, et al., 2000).
Systemic disease. The Task Force deems it important to consider the potential effect of
systemic diseases, including extrapulmonary diseases, with regard to EBC mediators. In the
report prepared by Horvath (2005) it was stated that 20-fold increases in EBC H2O2 levels were
detected in uremic patients.
Current research suggests the synthesis of isofuran occurs during periods of increased
cellular oxygen concentrations. Clearly this occurs as a result of delivery of supplemental oxygen
therapy, but also can occur as a result of pathology that damages the mitochondria. In a report by
Fessel et al, (2004) it was demonstrated that mice exposed to 100% oxygen conditions esterified
isofurans were detected in the lungs, whereas isoprostane levels remained the same. It is
theorized that diseases with mitochondrial dysfunction cellular tensions of oxygen increase due
to the diminished capacity of the mitochondria to consume oxygen. This notion bore out in a
study that discovered that isofurans, but not isoprostanes, are significantly increased in the
substantia nigra in brains from patients with Parkinson’s and Lewey body disease (Fessel et al,
2003). Other mitochondrial/neurodegenerative diseases that should be considered would include
Alzheimer’s, amyotrophic lateral sclerosis, and Huntington’s disease.
The origin of biomarker synthesis remains a confounding variable in EBC research.
Further research is recommended in this area. Developing methodologies that tightly address this
conundrum are recommended. For purposes of this study all systemic diseases will be recorded.
Salivary contamination. Saliva contains many of the mediators present in lower airways.
Care needs to be taken to avoid sample contamination. Many devices include a saliva trap to
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control for this confounding phenomenon. The RTube™ offers a saliva trap and is the device
selected for this project. Many studies have been conducted regarding potential of sample
contamination to which the inclusion of a saliva trap has all but eliminated the concern.
Medications. While no study was identified addressing a relationship between steroid use
and biomarker suppression the use of steroids will be noted for subjects participating in this
study. Asthmatic patients have been a specific population used to address the potential of
influence of ingested or inhaled steroids on 8-isoprostane production. Several studies
demonstrate that despite treatment with oral or high doses of inhaled glucocorticoids patient with
severe asthma have the highest concentrations of 8-isoprostane in EBC, indicating that this
marker is relatively resistant to glucocorticoids, inhaled or ingested (Montuschi et al., 1999).
Kostikas et al, (2002) reported a similar finding when comparing steroid naïve patients to those
receiving inhaled doses. A study by Antczak et al, (2001) aspirin-tolerant asthma demonstrated
in increase in 8-isoprostane following treatment of inhaled glucocorticoids. This finding
demonstrates the possibility of a phenotype influence on biomarker response. The use of
antioxidant supplements will be recorded; however, a study by Green and McElvaney (2009) the
use of a variety of antioxidant therapies, none of which resulted in a reduction of exhaled 8isoprostane. A history of bleomycin therapy will not result in exclusion from study even though
it has inherent consequences to the lungs. The lack of research does not preclude the possibility
of influence on biomarker production and therefore will be addressed during statistical testing.
Condensate storage. Some mediators, such as H2O2, are unstable at room temperature
and therefore require immediate frozen storage. However, the isoprostanes are stable and less
vulnerable to issues of timing. However, for purposes of this study samples will be immediately
placed on dry ice in a cooler with a goal of -70°C.
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8-isoprostane. The 8-isoprostane biomolecule is considered stable in exhaled breath
condensate. Sample reproducibility is achieved with enzyme-linked kits with detection limits of
3.9 pg-ml. The assay was validated directly by gas chromatography/mass-spectrometry
demonstrating a high correlation between added known amounts of the biomarker. GC/MS is
considered the most sensitive method of detection and quantification of 8-isoprostane (Maloney
et al, 2005). Disease states that influence 8-isoprostane concentrations in EBC are asthma,
ARDS, pulmonary sarcoidosis, obstructive sleep apnea, cystic fibrosis, as well as healthy adults
following exposure to ozone-inhalation (Horvath, 2005).
Isofuran. Isofuran is a biosynthetic relative of the isoprostane. It has been detected and
quantified in blood, urine, plasma, CSF and exhaled breath condensate. Currently the GC/MS
has been the only method utilized to detect and quantify its presence.
Safety concerns. The collection device utilized in this study will be the RTube™, a
disposable device, which will eliminate any concern of contamination from one subject to the
next. There are no reported risks associated with use of the device.
Content and compounds in EBC. Depending on the existing pathology respective
compounds can be present within the alveoli when collected by a variety of collection devices
made of glass, polystyrene, or polypropylene (see Table 3) (Mutlu et al., 2001). Compounds
within EBC are detected and measured via liquid/gas chromatography and are most commonly
quantified via mass spectrometry or enzyme-linked immunoassays. EBC does not currently
represent all of the compounds detected in ALF; however, as assays or tools of measurement
become more sensitive and a better understanding of the ionic composition of lung lining is
gained this non-invasive test could prove invaluable (Hunt 2002).
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Table 3
Compounds found in EBC
Pathology

Compound

Cigarette Smoking

H2O2, 8-Isoprostane

COPD

H2O2, 8-Isoprostane, serotonin, cytokines (IL-1, sIL2R, TNF-α

Asthma

H2O2, 8-Isoprostane, nitrotyrosine thiobarbituric acidreactive products, leukotrienes, pH

Chronic bronchitis

Leukotrienes

Bronchiectasis

H2O2

Cystic Fibrosis

H2O2, nitrite, 8-Isoprostane, IL-8

ALI/ARDS

H2O2, 8-Isoprostane, PGE3

EBC Measurement
Several methods are used to measure the presence of compounds within exhaled breath
condensate, to include gas or liquid chromatography, mass spectrometry, and enzyme-linked
immunoassays.
An assay is “the analysis of a substance or mixture to determine its constituents or their
level” (Webster online dictionary, 2013). Specific assays have been developed to detect and
quantify the presence of target compounds within a mixture. Due to the inherent reactivity of
biological assays, chemical analysis can become complex creating a challenge for controlling
variability. This unpredictability can create challenges when interpreting the data. As such, care
and attention must be given during testing so that variance is avoided.
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Reproducibility of EBC Collection Methods
A method is considered reliable when the results are reproducible. In a study by van
Beurden et al, (2002) 20 stable COPD patients breathed into a condensing device twice for a
period of 10 minutes each time. Hydrogen peroxide was measured following collection and then
again after freezing at -70° C for a period of 10, 20 and 40 days. The study concluded that the
exhaled air volume and condensate volumes were strongly correlated with reproducible H2O2
even on samples stored for 40 days.
In a pilot study performed by Hoffmeyer et al, (2007) the methodology of EBC sampling
and processing was evaluated to measure field assessments. Sixteen healthy adults were
evaluated for four days over two consecutive weeks to determine the effects of sample collection
(time vs. volume, with vs. without nose clip) and sample processing on volume, pH, NO, and
LTB4. Within-day, between-day, and between-week reproducibility were assessed. Results
demonstrated that no significant differences existed with utilization of a nose clip; storage at 46°C for 24 hours had not significant effects on NO and LTB4 concentrations but did result in
increases in pH. The study result demonstrated “good” within and between-day reproducibility;
however, between-week showed elevated results on the Mondays of each week.
Compound Detection and Measurement
Enzyme-linked immunosorbant assay (ELISA). The enzyme-linked immunosorbant
assay (ELISA) is a type of assay that allows for the detection of a substance in a liquid or wet
sample (Lequin, 2005). Perlmann and Engvall of Sweden developed the ELISA technique in
1971. The ELISA evolved from the radioactive-immunoassay (RIA) developed by Berson and
Yalow in 1960 when evaluating endogenous plasma insulin. Radioactive labeling became very
popular; however, growing concern of personnel over-exposure to radioactive materials, as well
as the need to build and maintain safe appropriate laboratories and waste management, prompted
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change. Initially, weaker radioactive iodine, iodine-125, was developed to address these
concerns. However, the European RadioimmunoAssay Club (ERIAC) held meetings in the
1970’s to approach the issue; it was during this time that the idea of using enzyme labels was
born. Skepticism of how such a large and bulky molecule could attach to an antigen or antibody
without sterically impeding the necessary chemical reaction was addressed through careful
planning and execution of experiments. In 1971 Pearlman and Engvall published their first paper
utilizing the ELISA by measuring rabbit serum IgG with alkaline phosphatase as the biomarker
label.
Essentially, all microbial species have at least one antigen that is unique. As a result these
antigens can be purified and used to produce specific monoclonal antibodies. Both the antibodies
and the purified antigens can then be used as a diagnostic tool. The ELISA is such a diagnostic
tool. There are two forms of this assay: 1) the direct ELISA uses monocolonal antibodies to
detect the presence of a specific antigen in a sample; and 2) the indirect ELISA is used to
determine the presence of a specific antibody in a sample.
Concerns expressed by Il’yasova et al, regarding the use of ELISA when quantifying
isoprostanes is the cross-reactivity of the polyclonal antibodies used to bind with the IsoPs will
bind to other similar molecules resulting in a potentially inflated quantification. They also
purport that other biological impurities in the sample can interfere with antibody binding with the
ELISA analysis, which impacts specificity, etc.
Mass spectrometry. Mass spectrometry (MS) is a technique that measures the mass-tocharge ratio of charged particles by separating them according to their masses. This technique is
used to determine the masses of particles, the elemental composition of a sample or molecule, as
well as revealing the chemical structures of molecules achieved by ionizing chemical compounds
to generate charged molecules, ultimately resulting in mass-to-charge ratios. A mass
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spectrometer consists of three modules: an ion source, a mass analyzer and a detector. The ion
source converts gas phase molecules into ions. The mass analyzer sorts the ions by their masses
through the use of an electromagnetic field. The detector measures the value of an indicator
quality providing the raw data for calculating amounts of each ion present.
Mass spectrometry generally follows the following steps:
1. Loading a sample into the MS to undergo vaporization
2. Sample ionization through electron beam impaction
3. Ion separation by electromagnetic fields
4. Ion detection
5. Ion signal processing through mass spectra
A mass spectrometer has both qualitative and quantitative capabilities, such as identifying
unknown compounds, determining the isotopic composition of elements in a molecule,
determining the structure of a compound, quantifying the amount of a compound in a sample or
studying the fundamentals of gas phase ion chemistry (Sparkman, 2000).
Chromatography. Chromatography is a method of physically separating mixtures for
the purpose of identifying compounds and is achieved through two phases: mobile and
stationary. The mobile phase consists of dissolving the sample mixture into a fluid. The resulting
solution is then delivered into a holding structure with another predetermined mixture and
becomes fixed in place, or the stationary phase. The compounds within the mobile mixture
travel at varying speeds depending on their inherent properties, causing a separation. Differential
partitioning of the compounds occurs between the mobile and the stationary phase, resulting in
measurability of the compounds present in the mixture. Chromatography can either be used as a
purification process for further analysis or for the analysis of smaller amounts of material to
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determine relative proportions of analytes. Chromatography techniques include gas and liquid
media.
Many techniques of chromatography can be employed to achieve separation, such as
displacement, planar, paper, and thin layer chromatography. There is also column
chromatography in which the stationary bed is within a tube or column. Sample identification is
determined by the interaction/retention times occurring between the particles of the mobile phase
and the content lining the column. Chromatography that employs techniques by physical state of
mobile phase is called gas-liquid chromatography (GLC). Gas chromatography (GC) is based on
a partition-equilibrium of an analyte between a solid stationary phase and a mobile gas phase.
Liquid chromatography (LC) is a separation technique in which the mobile phase is a liquid
rather than a gas.
High performance liquid chromatography. High performance liquid chromatography
(HPLC) is an improved form of column chromatography. Rather than a mobile phase solvent
dripping through a column under gravity the HPLC utilizes high pressure, up to 400
atmospheres, resulting in a much faster process. The HPLC also utilizes much smaller particle
sizes for the column packing material giving it a much larger surface area for interaction between
the stationary phase and the mobile phase for enhanced separation of the components of the
mixture. The methods employed by the HPLC are highly automated and extremely sensitive.
Measurable compounds include amino acids, proteins, nucleic acids, hydrocarbons,
carbohydrates, drugs, terpenoids, pesticides, antibiotics, steroids, metal-organic species, as well
as a variety of inorganic substances.
Gas chromatography. Gas chromatography is an instrument used to separate chemicals
in a complex sample for the purposes of identification and quantification. Often the gas
chromatograph is used in conjunction with mass spectrometry to achieve a much finer degree of
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substance identification than can be achieved when used in isolation. Using these techniques in
tandem reduces the likelihood of error, as it is very unlikely that two different molecules will
behave in the same manner in both a gas chromatograph and a mass spectrometer.
Gas chromatographic techniques vaporize liquid samples as a means of separating them
based on boiling points. Vaporization of the compound can occur without inciting decomposition
of the compound. Typical uses of GC include testing the purity of a particular substance, or
separating the different components of a mixture. In some situations GC can be used to identify a
compound.
Gas chromatography is principally similar to column chromatography and HPLC with
some notable differences. Separation of compounds is carried out between a liquid stationary
phase and a gas mobile phase, rather than a solid stationary phase and liquid mobile phase used
with column and HPLC techniques. The column through which a gas travels is located in an
oven where the temperature of the gas can be controlled. GC uses the boiling points of
compounds as a means of detecting their presence and identification.
Gas chromatography analysis requires a predetermined volume of analyte be injected into
the entrance of a column. As the carrier sweeps the analyte through the column movement is
inhibited by the adsorption of the analyte molecules by either the column walls or the packing
materials. The rate of movement along the column is dependent upon the strength of adsorption.
The total time it takes to travel the length of the column is referred to as the retention time. A
detector is located at the distal end of the column and measures the outlet stream from the
column. The time it takes each component to teach the outline and the concentration of that
component can be determined. Substances are generally identified in the order they elute from
the column and by the retention time of the analyte in the column.
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For purposes of this study only gas chromatography-mass spectrometry will be
addressed, as this will be the technique employed to detect and quantify isofurans in exhaled
breath condensate.
Physical components. The following are specific components are required to carry out
the individual functions of gas chromatography and mass spectrometry.
Autosamplers: to introduce a sample automatically into the inlet of the analyzer. Automatic,
rather than manual, insertion enhances reproducibility and maximizes time.
Inlets: provides the means to introduce a sample into a continuous flow of carrier gas.
Detectors: component responsible for detecting the presence of the desired compound. The most
commonly used detectors are the flame ionization detector (EID) and the thermal conductivity
detector (TCD). Both are considered sensitive to a wide range of components, and both work
over a wide range of concentrations.
Chromatogram: A detector responds to the presence of an analyte placed at the end of the
column, the signal is plotted as a function of time (or of volume of the added mobile phase), and
a series of peaks is obtained and plotted. This is referred to as a chromatogram. The position of
peaks on the time axis may serve to identify the components of the sample; the areas under the
peak provide a quantitative measure of the amount of each component. Once the analyte is
injected into the system the time it takes to peak once it reaches the detector is referred to as the
retention time.
Individual analyte particles during migration through the column will undergo thousands
of transfers between the mobile and stationary phases. The amount of time spent in either phase
is initially highly irregular and depends upon the thermal energy gained during the process to
reverse the transfer. The residence time spent in each phase may be transitory or long. The
particle is only eluted during the mobile phase contributing to irregular migration times. The
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consequence of random individual processes is a symmetric spread of velocities around the mean
value, which represents the behavior of the average and most common particle. The breadth of a
band (time phenomenon) increases as it moves down the column due to the time allowed for
spreading to occur. As a result the zone breadth is directly related to the residence time in the
column and inversely related to the velocity at which the mobile phase flows.
Experiments must occur to enhance separation and improve particle resolution. Chromatographic
separation is optimized once the components of a mixture are separated cleanly with minimum
expenditure. Optimization experiments are aimed at either reducing zone broadening or altering
relative migration rates of the components. Column resolution is a quantitative measure of the
columns ability to separate two analytes. Quantitative analysis is the comparison of either the
height or the area of the analyte peak with that of one or more standards. Analysis based on peak
height can be achieved by connecting the base lines, on either side of the peak, with a straight
line then measuring the perpendicular distance from this line to the peak. Peak heights are
inversely related to peak widths. Therefore, accurate peak heights are only accurate if variations
in column conditions do not alter the peak widths during the period required to obtain
chromatograms for sample and standards. Variables that must be closely controlled for are
column temperature, eluent flow rate, and the rate of sample injection. The effect of sample
injection rate is particularly critical for early peaks of a chromatogram. Analysis based on peak
areas are not affected by column temperature, eluent flow rate, or the rate of injection and, as a
result, are a more satisfactory analytical parameter than peak heights.
Calibration occurs through the preparation of standards for comparison. Chromatograms
for the standards are then obtained and peak heights or peak areas are plotted as a function of
concentration. The major source of error in this process is the uncertainty of the sample volume
and can be the rate of injection. The volumes for this process are small (~1µL); uncertainties
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related to the injection of a reproducible volume of this size with a microsyringe may amount to
several percent relative. This issue can be handled through the use of a rotate sample valve.
The utilization of internal standards enhances precision. With this process, a carefully
measured quantity of an internal substance is introduced into each standard and sample, and the
ration of analyte to internal standard peak areas or heights serves as the analytical parameter.
However, in order for this method to be successful it is imperative that the internal standard peak
be well separated from the peaks of all other components of the sample. The standard peak
should be close to the analyte peak. A suitable internal standard will yield precisions better than
1% relative.
There are over 5000 identifiable substances in exhaled breath. As a result, the
combination of gas chromatography and mass spectrometry provide an ideal mechanism for
detection and quantification of IsoP’s and IsoF’s in exhaled breath. For purposes of this study
GC/MS methodology will be discussed for the detection and quantification of isofuran.
Method development. Currently there are no commercially available kits or standards
for the measurement of isofurans. The labs at Vanderbilt University have developed and retain
exclusive right to the process of detecting and quantifying the presence of isofuran. Since this
research study is questioning the potential of chronic exposure to supraatmospheric
concentrations of oxygen in inducing oxidative stress, isofuran is the only appropriate biomarker
identified to answer that question. Therefore, Vanderbilt University labs will be employed to
analyze the exhaled breath condensate collected for this study.
Data Analysis
The objective of this study is to determine if LFDO as a treatment modality in COPD
superimposes oxidative lung damage. The specific aims of this study are 1) assess for isofuran in
the EBC of COPD patients on LFDO; 2) determine if a correlation exists between standard
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diagnostic spirometry (FEV1/FVC ratio) and exhaled breath condensate (EBC) biomarker
(isofuran); 3) determine if relationships exist between age, gender, height, weight, length of
smoking history, length and concentration of oxygen exposure and EBC biomarkers (isofuran
levels).
Following a data collection period necessary to achieve an adequately powered sample
statistical analyses utilizing a Student’s t-test will be utilized to assess mean differences in
exhaled isofuran levels between the active control and active treatment groups. Significant mean
differences in isofuran levels between the groups will begin to address the potential of chronic
exposure to low flows of domiciliary oxygen as a mechanism of in oxidative stress Significance
will be set at a P-value of <0.05, a confidence interval of 95 and an α= 0.5 to reduce the
occurrence of a Type I error, detecting an effect that does not exist.
Next, linear regression analyses will be performed to determine if a relationship exists
between the study variables (age, gender, height, weight, ethnicity, smoking history, length of
time and concentration of oxygen therapy, FEV1, FEV1/FVC, FEF25-75% and isofuran levels).
Should a relationship be detected correlational testing, utilizing the Pearson’s r, will be
performed to determine the strength of the relationship. As it relates to obstructive disease the
FEV1, FVC and the FEV1/FVC ratio are standard to assessing the stage of COPD. It is well
understood that the results of spirometric testing vary with effort and may produce inconsistent
values as a result. Therefore, participants will be instructed to maximize effort for these specific
tests to ensure accuracy. It is the desire of this researcher to determine if the isofuran biomarker
has a future in predicting degree of obstructive disease states.
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Chapter 3 – Methodology

Purpose
Chronic obstructive pulmonary disease in an advanced state often requires oxygen
supplementation to ameliorate distress. It is well established that prolonged exposure to
increased oxygen tensions contributes to oxidative stress and subsequent tissue damage. The
purpose of this study is determine if the level of a specific biomarker of oxidative stress is
elevated in the presence of exposure to low flow domiciliary oxygen (LFDO) in patients with
COPD.
Research Questions
The research questions guiding this study are:
1.

Does chronic exposure to LFDO contribute to oxidative stress as evidenced by
elevated isofuran levels within the lungs of COPD patients?

2. Does a relationship exist between FEV1, FEV1/FVC, and FEF25-75% isofuran
levels?
3. Is there a correlation between length of oxygen exposure and concentration of oxygen
to isofuran levels?
Donabedian’s Structure-Process-Outcome Model
Donabedian states, “the assumption is made that given the proper settings (structure) and
instrumentalities (process), good medical care will follow” and, therefore, good and desired
outcomes. Quality outcomes are only valid if it can be directly linked to the structure and/or
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process (Donabedien, 1966). The results of the planned methodology and data collection will
render results that will allow us to assess whether the structure in which care is provided, and the
treatment modalities it prescribes to their patient’s results in desirable outcomes. Consistent with
the Donabedian process-structure-outcome model, the purpose of outcomes research is to
determine if healthcare modalities and/or treatment management optimize patient and societal
end results (Clancy and Eisenberg, 1998). With this in mind the following hypotheses were
developed.
Hypotheses
The following hypotheses were formulated in response to findings within the literature review:
1. Ha: Chronic exposure to LFDO will demonstrate ongoing oxidative stress in the lungs
of COPD patients as evidenced by increased isofuran levels.
2. Ha: A relationship between FEV1 and isofuran levels will be demonstrated in patients
diagnosed with moderate to advanced stages of COPD using LFDO
3. Ha: A relationship between FEV1/FVC ratios and isofuran levels will be
demonstrated in patients diagnosed with moderate to advanced stages of COPD using
LFDO.
4. Ha: A relationship between FEF25-75% and isofuran levels will be demonstrated in
patients diagnosed with moderate to advanced stages of COPD using LFDO
5. Ha: A positive correlation between oxygen concentration and isofuran levels will be
demonstrated on the day of sampling in patients diagnosed with advanced stages of
COPD using LFDO.
6. Ha: A positive correlation between length of oxygen exposure and isofuran levels will
be demonstrated in patients diagnosed with advanced stages of COPD using LFDO.

100

This chapter will describe the research design, study setting, health care providers,
sample selection process, sample characteristics, instruments, data collection procedures, and
statistical analyses employed to address the research questions guiding this study.
Research Design
This research study utilized a non-experimental cross-sectional prospective data
collection design to assess for the presence of oxidative stress for those individuals diagnosed
with advanced stages of COPD requiring LFDO therapy. The active control group will consist of
individuals diagnosed with advanced stages of COPD and managed with the standard therapeutic
agents predetermined by their physician with the exception of LFDO therapy. The study did not
impact the care or management of the study participants as no manipulation occurred to an
already prescribed treatment plan. No risks are imposed on the patient as a result of this study.
No patient identifying information will leave the confines of the clinic in which care is provided
to the study participant. A coding system will be utilized to identify samples to relevant study
variables.
Noted in the writings of Donabedian, healthcare provision variables are antecedents to
healthcare outcomes and, therefore, study variables such as administrative demographics and
mission, patient demographics, healthcare provider variables, pulmonary function test results,
medicinal regimen, and isofuran biomarker measurements will be considered when evaluating
outcomes. Those health care providers whose services impact patient care and process will be
described. Patient demographics, such as age, gender, ethnicity, past and current smoking history
are potentially confounding variables.
Independent and dependent variables. The treatment (independent) variable in this
study is LFDO; the effect (dependent) variable is oxidative stress, represented by the biomarker
isofuran. Also being assessed for are relationships between the independent variables of FEV1,
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FVC, FEV1/FVC, FEF25-75, length of oxygen exposure (hrs/day and years), concentration of
oxygen therapy (L/min), smoking history and isofuran levels (see Table 4).
Table 4
Study Variables
Variable

Variable

Measurement

Statistical Analysis

Unit of Measure

LFDO

IV

Continuous

t-test

L/min

DV

Continuous

Linear Regression

Length of Oxygen

Hrs/day

Exposure

Years
Pearson’s r
Linear Regression

Concentration of
DV

Continuous

Pearson’s r

Oxygen Therapy

Liters/minute

Length of Smoking

Linear Regression
DV

Continuous

years

History

Pearson’s r
Linear Regression

Isofuran

IV/DV

Continuous

1-tailed

Pg/ml

Student’s t-test
Linear Regression
FEV1

DV

FVC

DV

Continuous

L/sec
Pearson’s r
Linear Regression

Continuous

L/sec
Pearson’s r
Linear Regression

FEV1/FVC

DV

FEF25-75%

DV

Continuous

L/sec
Pearson’s r
Linear Regression

Continuous

L/sec
Pearson’s r
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Study setting. The setting for this study is a moderately sized medical center in
Midwestern United States. This 236-bed facility offers acute care services as well as obstetrics,
pediatrics, oncology services, long term care, skilled nursing facility, inpatient rehabilitation,
outpatient clinic services and psychiatric treatment. The ethnic breakdown of the town of the
medical center was as follows, with overall U.S. statistics in parentheses: Males: 55% (50%),
Females: 45% (50%); Average age: 26 years (36.8); Caucasian: 84.8% (72.4%), Asian: 5.7%
(4.8), African-American: 4% (12.6%), Hispanic: 2.6% (16.3%); two or more races: 2.4% (2.9%).
The demographics between this Midwestern town and the United States were similar with the
exception of average age and Hispanic population. Patients diagnosed with COPD and receiving
services from an outpatient clinic at Phelps County Regional Medical Center will be recruited for
participation in the study.
Population and Recruitment Strategy
In collaboration with Dr. James, Chief Medical Officer at Phelps County Regional
Medical Center, a convenience sampling will be utilized to recruit participants. A review of
patient records will be made to identify those patients with advanced stages of COPD, both
receiving and not receiving LFDO as qualifiers. As qualifying patients are identified on site
PCRMC staff to determine interest in participating in the study will approach them. Once interest
has been solicited I will explain the study and provide a study participation outline. Informed
consent will be obtained prior to sample collection. The population of interest for this study is
those COPD patients with advanced symptoms of COPD confirmed by pulmonary lung volume
measurements, specifically an FEV1/FVC ratio of < 70%, indicating obstructive disease of
predicted normal volume for age, gender, height and weight. The goal of recruitment is to create
closely matched comparison groups to avoid confounding variables. A convenience sample of
patients with COPD and managed on an outpatient basis from the dates of March 10, 2015 to
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May 7, 2015 was utilized. Group AC, or the active control group, consisting of those COPD
patients diagnosed with advanced COPD but not receiving supplemental oxygen therapy, for
Group AT, or the active treatment group, consisting of those COPD patients diagnosed with
advanced disease requiring supplemental oxygen therapy.
Upon arrival to the outpatient clinic patients were provided a detailed explanation of the
study outlining participation requirements including study goals and exhaled breath collection
requirements as well as another opportunity to have any questions answered.
Inclusion/Exclusion Criteria
Eligibility for study participation was guided by inclusion/exclusion criteria.
Inclusion/exclusion criteria served to control for variability and to aid in creating equivalent
groups.
Inclusion criteria for the study were as follows:
1. >18 years of age
2. Mentally competent to provide informed consent (not currently under the care
of a physician for such disabilities that preclude ability to consent).
3. Outpatient status
4. Diagnosed with advanced stage COPD as evidenced by spirometric FEV1
<70% of predicted normal for age and gender, height and weight, smoking
history
5. With or without supplemental oxygen >6 hours/day depending on group
assignment
Exclusion criteria for the study were as follows:
1. < 18 or > 89 years of age
2. Pregnant women
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3. Mentally incapable of providing informed consent (currently under the care
of a physician for such disabilities that preclude ability to consent).
4. Refusal to participate
5. Active, systemic, oral or nasal infections
6. Patients diagnosed with amyotrophic lateral sclerosis, Huntington’s,
Alzheimer’s, Parkinson’s or Lewey body disease.
Data Collection Procedures
Following Institutional Review Board (IRB) approval from the participating research
institutions, Virginia Commonwealth University and Phelps County Regional Medical Center,
study participants will be assigned to either an active control group or an active study group
based on long-term low flow domiciliary oxygen therapy utilization. The active control group,
Group AC, will consist of patients diagnosed with moderate to advanced stage COPD not
receiving supplemental oxygen therapy; the active treatment group, Group AT, will consist of
patients diagnosed with moderate to advanced COPD receiving supplemental oxygen therapy for
a minimum of 6 hours/day. According to the American Thoracic Society guidelines, once criteria
for oxygen therapy has been met the recommendation for oxygen therapy is for 24 hour use;
however, in an effort to capture enough study participants a minimum oxygen usage has been of
6 hours has been selected, as supported by the Nocturnal Oxygen Treatment Trial and the
Medical Research Council study.
Data Collection and Analysis Instruments
The following instruments and chemicals will be utilized for this study:
1. Futuremed Discovery II Spirometer™
2. The Rtube™ EBC collection device (Respiratory Research, Inc., manufacturer)
3. Gas chromatograph/Mass spectrometry
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a. Capillary Gas chromatography column (DB-1701. Agilent: Cat. No. 21512067)
b. Gas chromatograph/mass Spectrometer (with capabilities for negative-ion
chemical ionization (NICI) mass spectrometry. (Agilent 5973)
4. Isofuran quantification methods (owned by Vanderbilt University Labs)
Collection of exhaled breath condensate (EBC) is a noninvasive means of obtaining
samples from lungs in order to assess pathologic processes. Due to the portability and ease of
use the EBC devices can be used in a variety of settings, such has hospitals, clinics and even in
the home. For the purposes of this study, a commercially manufactured, FDA approved EBC
device, the Rtube™, will be used for collecting and storing as the EBC sample can be easily
removed for storage and transport. The collection tube resides within an aluminum sleeve that is
cooled by placing it in a freezer maintained at a temperature of -70°. The sleeve results in the
condensation and collection of the exhaled gas. General guidelines for EBC collection suggest
10-15 minutes of normal tidal breathing as sufficient for collecting ~3mls of condensate;
however, the diminished capacity of individuals with COPD may result in an increased time
requirement to achieve the same volume. Also, in an effort to ameliorate fatigue during the EBC
collection phase patients may be allowed to maintain nasal cannula oxygen delivery.
Pulmonary Function Testing
Phelps County Regional Medical Center population recruitment target sites include, but
are not limited to, the Internal Medicine Clinic and the Cardiology clinic. Neither location
participates in routine pulmonary function testing. Participants identified for study inclusion
require current pulmonary function testing for comparison to same day IsoF levels. PFTs will be
obtained using the portable Discovery II Spirometer™ by Futuremed. The Discovery II
Spirometer ™ measure parameters include the parameters targeted for this study, FEV1, FVC,
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FEV1/FVC and FEF25-75. The device has a range volume of 12 liters, flow of 0.03-20 l/s, a
flow resistance of <0.70 cm H20/l/s @ 12 l/s, and an accuracy of ± 2%.
EBC Sample Collection and Preparation
Once group assignment is determined, consistent with the most current guidelines offered
by the European Respiratory Society (ERS) and the American Thoracic Society study, with
respect to determining a FEV1/FVC ratio of <70% predicted value, participants will be
instructed to breath into an exhaled breath collection device, the Rtube™, with the following
methods employed:
1. Normal tidal breathing into a mouthpiece attached to a collection chamber wrapped
by a cooling sleeve for approximately 10-15 minutes, or until ~2-3 milliliters of
condensate will be obtained. Sleeves will have been cooled over night in a -70°
freezer maximizes analyte collection volume. The cooling sleeve will be wrapped
with a protective cover.
2. Utilization of a nose clip will be employed for those who can tolerate it and/or
required its use for adequate sample retrieval.
3. Utilization of a saliva trap to minimize salivary contamination of the analyte.
4. Storage of analyte in a -70° freezer until analysis can be made. Samples cannot be
frozen, thawed and refrozen.
Approximately 5-15 minutes of normal breathing into the device should result in a
volume adequate for measuring exhaled biomarkers. Nose clips can be utilized to minimize
escape of exhaled air through the nose; however, compliance is of concern because they can be
perceived as uncomfortable. Utilization of a saliva trap is necessary to minimize salivary
contamination of the analyte; however, salivary contaminants have not proven to have significant
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effects on the biomarkers of interest (Hutterman et al., 2011). A cooling sleeve is placed around
the collection chamber to facilitate condensation.
The Rtube™ is designed to provide maximum sample collection with minimal time.
Exhaled air is directed through a one-way valve and into a cooled collection chamber where
vapors, aerosols and moisture in the breath condense along the protected walls. The one-way
valve is then used as a plunger that collects droplets stuck to the inside wall. The samples are
conveniently stored and shipped in the collection sleeve. No risks are introduced to the study
participant as a result of breathing into the condensate collector.
The clinic staff and the PI will share in the responsibility of overseeing adherence to
collection techniques and timing. Samples will be labeled to identify group membership.
Samples will be logged with identifying code along with the relevant demographics of age,
gender, race, height, weight, LFDO concentration, and oxygen exposure timeline. Samples will
be securely sealed in transport coolers at a temperature of -70° C for transport to lab until
analysis can be made.
Laboratory Analysis
The labs at Vanderbilt University will be employed to analyze the exhaled breath
condensate, as there currently are no commercially available isofuran standards available for
public acquisition. The technique utilized by Vanderbilt University to detect the presence and
quantification of isofuran in exhaled breath is through GC/MS, currently the only method
established for detecting and quantifying isofurans. Therefore, the methods employed to perform
this test are described below.
Gas chromatography permits the separation of closely related components of complex
mixtures. The GC method is noted for its sensitivity, adaptability to accurate quantitative
determinations, its suitability for separating nonvolatile species or thermally fragile species, and
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its widespread applicability to substances that are of prime interest to the industry, science and
the public.
Chromatography methods occur in two phases: mobile and stationary. In column
chromatography, which will be used in this study, the stationary phase is held in a narrow,
coiled, heated tube through which the mobile phase travels. As the mobile phase comes in
contact with the stationary phase and separation of compounds occurs. This separation results in
the ability to identify and quantify targeted substances. The use of mass spectrometry adds
sensitivity and specificity as it identifies the compounds based on molecular weight.
Sensitivity is achieved by the GC/MS technique through the ability to resolve the peaks.
Resolution occurs by adjusting flow rates and mobile phase composition. Adjusting flow rates
allows for the separation of peaks for accurate identification. Mobile phase packing allows for
the separation of polar from non-polar compounds, thus enhancing sensitivity. When using the
GC/MS for detection of both IsoPs and IsoFs quantification can only occur when they are in the
free acid form. In tissues a plasma arachidonic acid oxidation products are generally esterified in
glycerophospholipids. The glycerophospholipids must be subjected to alkaline hydrolysis to
release the compounds into the free fatty acid form to ready them for GC/MS analysis (Milne, et
al., 2013).
The GC/MS methodology is considered robust and has been used for over 20 years.
According to Milne et al (2013) “this particular method offers the lowest limit of quantification
of any reported mass spectrometric methodology for IsoPs.” Due to the fact that these particular
molecules are measured in terms of picograms (or similar derivations) in plasma, CSF, EBC and
other biological fluids in which low levels of IsoPs are found the GC/MS is ideal as a means of
detection and quantification of these groups of molecules. The low limit of detection for
isoprostane is 5 pg/ml.
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For the purposes of compound identification many reagents may be employed, as well as
the equipment necessary to perform the functions. A detection and quantification standard for
isofuran is not currently available to the public for purchase and use. Researchers at Vanderbilt
University discovered isofuran and the methods for its detection and quantification the list
provided are those reagents commonly used when identifying by-products of non-enzymatic
lipid peroxidation, such as the IsoPs, at the Vanderbilt Laboratory. The following agents have
been provided regarding the identification process for IsoPs, which can be applied to the
identification of IsoFs with the delineating difference being the eluting times.
Instrumentation. The following instruments were used to identify and quantify IsoF:
•

Capillary gas chromatography column (DB-1701, Agilent)

•

Gas chromatograph/mass spectrometry (GC/MS, with capabilities for negativeion chemical ionization (NICI) mass spectrometry)

While many different means can be utilized to detect the presence and amount of IsoPs,
such as LC/MS and immunoassays, only GC/MS has been identified as accurately detecting and
measuring IsoFs. Identifying and quantifying the F2-IsoPs by mass spectrometry has advantages
over immunoassay procedures, such as the ELISA. While the ELISA methodology is cost
effective and provides quality analysis, the antibodies used to bind to the F2-IsoPs may exhibit
cross-reactivity with many other molecules similar in structure, confounding the result. Also,
biological impurities can interfere with antibody binding. Mass spectrometry offers high
sensitivity and specificity resulting in enhanced detection and accuracy of desired compounds.
Once specimens arrive in the lab GC/MS analysis will be performed in triplicate to gain
accurate results of the isofuran biomarker. The three results will be averaged in an effort to most
accurately represent the results. The results then will be logged into a data bank to include group
membership, age, gender, race, LFDO concentration utilized, and oxygen exposure timeline.
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Data Analysis
The objective of this study is to determine if LFDO as a treatment modality in COPD
superimposes oxidative lung damage. The specific aims of this study are 1) assess for isofuran in
the EBC of COPD patients on LFDO; 2) determine if there is a correlation between standard
diagnostic spirometry and exhaled breath condensate (EBC) biomarker (isofuran) levels; and 3)
determine if relationships exist between duration and concentration of oxygen exposure and EBC
biomarker isofuran levels.
Following a thorough literature review evaluating methodologies described in this paper
for this study it was determined that a large effect size exists between control and treatment
groups regarding the generation of isoprostanes, consistent with oxidative stress. Since isofurans
are derived from isoprostanes the assumption holds that the effect of the treatment, LFDO, will
result in a large effect size regarding isofuran production.
To determine the significance of isofuran in the EBC of the active treatment group,
severe stage COPD patients on LFDO, compared to the active control, severe stage COPD
patients not receiving LFDO, a Student’s t-test will be performed, with the assumptions of
bivariate independent variables, a continuous dependent variable, independent observations of
the dependent variable, and normal distribution being met. A power analysis was performed
utilizing the software G*Power Analysis for a 1-tail t-test to compare group means of the active
control and active treatment groups with a α=0.5 to control for Type I errors and a ß= 0.80 to
control for Type II errors with an effect size of 0.8, and generated an n = 52.
Pulmonary function testing includes a variety of assessments that provide for the specific
interpretation of their results, such as changes in lung volumes and capacities, respiratory flow
patterns and rates, as well as diffusion capacity, or the exchange of nutrients between the alveoli
and the capillary beds. In an effort to better assess where oxidative stress exerts its derangement
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it is necessary to determine a relationship between the presence of oxidative stress and the
parameters most affected by its presence. This study will directly assess for the relationship
between isofuran, a validated biomarker of oxidative stress, and the standard diagnostic
pulmonary function parameter of FEV1 and FEV1/FVC. However, all spirometry parameters
will be collected and evaluated as a mechanism of discovery and future evaluation. Linear
regression will be performed to determine if a relationship between FEV1/FVC exists, and the
strength of that relationship determined with correlation analysis. Assumptions of linear
regression include linearity and additivity, statistical independence of the errors,
homoscedasticity of the errors and normality of the error distribution will be met. If a
relationship is identified through linear regression a Pearson’s r will be utilized to assess for
strength of the relationship between the demographic independent variables and the dependent
variable, isofuran. Considerations may have to be made when assessing isofuran levels and the
age demographic as senescence can result in diminished antioxidant ability.
In order to better understand the impact of LFDO on COPD patients with regard to
ongoing oxidative stress relationships between duration of oxygen therapy (hours/day of use) and
concentration of oxygen (L/min flow) need to be explored. Linear regression will be performed
to determine if a relationship between length of exposure and concentration of oxygen relates to
isofuran levels. Should a relationship be identified the strength of that relationship will be
determined through correlation analysis, the Pearson’s r. Assumptions of linear regression
include linearity and additivity, statistical independence of the errors, homoscedasticity of the
errors and normality of the error distribution will be met.
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Chapter 4 – Results

Introduction
The purpose of this study was to determine if oxidative stress is occurring in the
lungs of individuals with COPD as a result of chronic exposure to low flow domiciliary
oxygen (LFDO) therapy as evidenced by a specific biomarker, isofuran (IsoF). A
methodology was developed to address this phenomenon and statistical analyses
employed to interpret the findings. Each result will be preceded by the research question
it intended to address.
A power analysis, utilizing scientific Graph Pad Prism 6.0 software, revealed a
sample size of 52 necessary to sufficiently power this study. A convenience sample of 54
subjects was identified at Phelps County Regional Medical Center, collected from March
12, 2015 to May 7, 2015 that met study inclusion criteria. Two subjects were removed
from the active treatment (AT) group due to insufficient exhaled breath condensate
sample volume necessary to detect and quantify IsoF. The active control (AC) group
consisted of 26 participants, 15 males (58%) and 11 females (42%); and 26 participants
in the active treatment, 10 males (38%) and 16 females (62%) individuals all of whom
had an FEV1/FVC <0.70 and FEV1 <80% of predicted normal (See Table 5). The AT
group utilized LFDO for a minimum of 7 hrs/day. No current research exists regarding
risks of prescription LDFO therapy, therefore, duration of oxygen (hrs/day) exposure did
not impact study inclusion. All study participants were Caucasian.
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Table 5
Study Participant Demographics
Control (COPD no Oxygen)
Treatment (COPD with Oxygen)
Number
26
26
Age (years)
62 ± 29
65± 16.5
Male/Female
15/11
10/16
Height (inches)
66 ± 5
65 ± 7.5
Weight (lbs)
190 ± 87.5
217 ± 119
Caucasian
26
26
Smoking History
22/26
22/26
Current Smokers
13/26
0/26
*Age, height and weight are reported as the mean ± standard deviation

P value
0.3655
0.1717
0.3079
0.0900

Study participants enrolled in the study from the cardiology clinic received
pulmonary function testing the day of data collection by the PI utilizing the Discovery II
Spirometer™. Study participants enrolled in the pulmonary function lab received
pulmonary function testing the day of data collection by certified respiratory therapists.
Vmax Encore Software v21-2A by CareFusion is utilized by the PCRMC to interpret
pulmonary function test results. A t-test was performed to compare group means between
the AC (COPD without LFDO) and the AT (COPD with LFDO) (see Table 6).
Table 6
Study Participant Spirometry Results

FEV1
FVC
FEV1/FVC
FEF25-75

Control (COPD no Oxygen)
Mean + SEM

COPD (w/ Oxygen)
Mean + SEM

P value

60.19 ± 2.73
75.81 ± 3.67
64.63 ± 2.86
34.93 ± 3.99

60.08 ± 3.92
70.42 ± 4.60
68.38 ± 2.81
51.38 ± 6.06

0.9819
0.3615
0.3544
0.0265

It was the intention of this study to create closely matched study groups with
regard to age, gender, height, weight, ethnicity and the spirometric tests FEV1, FVC,
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FEV1/FVC and FEF25-75, (with the notable exception of LFDO therapy) to enhance
interpretability of the results. Student’s t-tests were performed to compare group means
for each parameter. No significant differences were noted between any of the parameters
in the AC and AT groups with the exception of the FEF25-75 results, which
demonstrated a P = 0.0265. This difference warrants future investigation.
The following research questions were addressed through statistical analyses.
Research Question 1
Does chronic exposure to LFDO contribute to oxidative stress as evidenced by elevated
isofuran levels within the lungs of COPD patients?
Using the statistical software package, Graph Pad Prism 6, a one-tailed t-test was
performed to determine the mean difference in exhaled breath IsoF levels between the
AC and AT groups. The descriptive statistics are provided below (see Table 7).
Significance was set at a P value <0.05, an α=0.05, with a 95% CI. The results
demonstrated a t=1.61, with df=50, and a nonsignificant P = 0.056 with a SEM 35.81±
4.91 of IsoFs in the active control, and a SEM 51.35±8.27 of IsoFs in the treatment group
(see Table 8). The R2 value of 0.049 suggests that only 4.9% of the variance could be
explained by LFDO therapy. An F test to compare variances was performed resulting in a
P=0.0115, indicating significant differences in variances between groups. An unpaired ttest with a Welch’s correction for unequal standard deviations was performed generating
a nonsignificant P=0.0569 (see Table 9, Figure 1). Based on these findings it cannot be
supported that LFDO therapy results in statistically significant increases in exhaled
breath IsoF levels in COPD patients.
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Table 7
Descriptive Statistics
N

Mean

Standard Deviation

Std Error Mean

Active Control
26
IsoFs
Active Treatment
26
IsoFs

35.81

25.062

4.908

51.35

42.170

8.270

Table 8
Unpaired One-Tailed t-test comparing group means, 95% Confidence Interval
One-Tailed
t-test table
Control
Group
Treatment
group

Isofuran
Mean ±SEM
35.81±4.91

df

Difference
between the
Mean ±SEM

25

15.54±9.62

51.35±8.27

25

P value
P = 0.0562

Table 9
Unpaired One-tailed t-test with Welch’s correction
One-Tailed
t-test table
Control
Group
Treatment
group

Isofuran
Mean ±SEM
35.81±4.91

t

Difference
between the
Mean ±SEM

df

1.616

40.67 15.54±9.62

51.35±8.27
AC IsoF & AT IsoF Mean Comparison
80

pg/ml

60
40
20

A

A

T

C

Is

Is

oF

oF

s

s

0

Mean ± SEM

Figure 1: AC IsoF & AT IsoF Means Comparison
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P value
P = 0.0569

The t-test descriptive statistics revealed an AC group standard deviation (SD) of
25.03 and an AT SD of 42.17. Clearly, a larger SD is noted in the AT group, meaning a
wider dispersion of obtained values. A between groups data dispersion comparison was
made (see Table 10). Evidenced by the dispersion data a significant difference is noted
between the maximum values obtained between the groups. No a priori knowledge
existed suggesting cause for exclusion of the 181pg/ml sample obtained and, therefore,
the result remained.
Table 10
Between Groups Data Dispersion

Minimum
25% Percentile
Median
75% Percentile
Maximum

AC pg/ml
10.0
16.75
27.5
44.0
96.0

AT pg/ml
11.0
18.75
33.5
79.25
181.0

The mean AC group exhaled breath IsoF level was 35.82 pg/ml with a one SD
range of 10.78 to 60.84 pg/ml, and a relatively small SEM (4.91) suggesting less
variation in the AC group when compared to the AT group. The AT group mean exhaled
breath isofuran level was 51.35 pg/ml with a one SD range of 9.18 to 93.52 pg/ml, a
comparatively larger SEM (8.27), suggesting more unexplained variance in the AT group
than in the AC group.
Research Question 2
Does a relationship exist between FEV1, FVC, FEV1/FVC, FEF25-75% and isofuran
levels?
The following relationships were explored through simple linear regression
utilizing the statistical software package SPSS, version 23. An analysis of the statistical
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results, including a Pearson’s r correlation, coefficients, model summary and ANOVA is
provided. Tables, graphs and figures may accompany the explanation to enhance clarity
of the findings. It is the intention of the PI to determine the clinical application of IsoF as
replacement for standard pulmonary function testing. Therefore, in the following analyses
IsoF is the situated as the predictor variable, while the PFTs are the outcome variables.
The results of the linear regression analysis are reported below.
A simple linear regression was calculated to determine if a relationship exists
between FEV1 in COPD patients receiving LFDO therapy and exhaled breath isofuran
levels. A line of best-fit analysis revealed a relatively flat slope of -0.07314 to 0.3125 and
a goodness of fit R2=0.075 indicating a very weak correlation to the best-fit line (see
Figure 2), an assessment supported the B value revealing that every 1 unit of increase in
isofuran would only generate a 0.132 unit of change in the FEV1. According to the R2
coefficient of determination only 7.5% of the model variation could be explained by
exhaled breath IsoF levels, leaving approximately 92.5% of the variance unexplained. A
model summary was performed revealing a Pearson correlation (r =0.274) (see Table 11),
synonymous with the Beta coefficient (see Table 12), demonstrating a weak relationship
between IsoF levels and FEV1. A subsequent ANOVA analysis of the model summary
was performed with a resulting nonsignificant P=0.176, confirming that isofuran levels
do not correlate to FEV1 values (see Table 13). In summary, no significant correlation
was established between IsoF levels from individuals with COPD on LFDO to FEV1.
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Figure 2: AT IsoFs & AT FEV1
Table 11
AT IsoF and FEV1 Model Summary
Model

R

R Square

Adjusted
R Square

1

.274

.075

.036

Change Statistics
R Square
Change
F Change
.075
1.941

df1
1

Table 12
AT IsoF and FEV1 Regression Coefficients

Model
1
(Constant)
Active Treatment IsoF

Unstandardized
Coefficients
B
Std. Error
54.147
6.244
.132
.095

Standardized
Coefficients
Beta

t
1.941

Sig
.176

.274

Table 13
AT IsoF and FEV1 ANOVA for Regression Analysis
Model
1

Regression
Residual
Total

Sum of Squares

df

774.173
9571.673
10345.846

1
24
25
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Mean
Squares
774.173
398.820

F
1.941

Sig
.176

A simple linear regression was calculated to determine if a relationship exists
between IsoF levels and the FVC in COPD patients receiving LFDO therapy. A line of
best-fit analysis revealed a relatively flat slope of -0.1937-0.2732 and a goodness of fit
R2=0.001 indicating a very weak correlation to the best-fit line (see Figure 3), assessment
supported by the B value revealing that every 1 unit of increase in IsoF levels would only
generate a 0.015 unit of change in the FVC. According to the R2 coefficient of
determination only 0.1% of the model variation could be explained by exhaled breath
IsoF levels, leaving approximately 99.9% of the variance unexplained. A model summary
was performed revealing a Pearson correlation (r =0.028) (see Table 14), synonymous
with the Beta coefficient (see Table 15), demonstrating a weak relationship between
isofuran levels and FVC. A subsequent ANOVA analysis of the model summary was
performed showing no statistical difference (P=0.892), confirming that IsoF levels do not
correlate to FVC values (see Table 16). No significant correlation was established
between IsoF levels from individuals with COPD on LFDO to FVC.
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Figure 3: AT IsoFs & AT FVC
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Table 14
AT IsoF and FVC Model Summary
Model

R

R Square

Adjusted
R Square

1

.028

.001

-0.041

Change Statistics
R Square
Change
F Change
.001
0.019

df1
1

Table 15
AT IsoF and FVC Regression Coefficients

Model
1
(Constant)
Active Treatment IsoF

Unstandardized
Coefficients
B
Std. Error
69.212
7.396
.015
.112

Standardized
Coefficients
Beta

t
9.358

Sig
.000
.892

.028

Table 16
AT IsoF and FVC ANOVA for Regression Analysis
Model
1

Regression
Residual
Total

Sum of Squares

df

10.462
13429.538
13440.000

1
24
25

Mean
Squares
10.462
559.564

F

Sig
.019

.892

A simple linear regression was calculated to determine if a relationship exists
between FEV1/FVC in COPD patients receiving LFDO therapy and exhaled breath
IsoF levels. A line of best-fit analysis revealed a relatively flat slope of -0.08833-0.1949
and a goodness of fit R2=0.051 indicating a very weak correlation to the best-fit line (see
Figure 4), an assessment supported the B value revealing that for every 1 unit of increase
in IsoF levels would only generate a 0.076 unit of change in the FEV1/FVC. According
to the R2 coefficient of determination only 5.1 % of the model variation could be
explained by exhaled breath IsoF levels, leaving approximately 94.1% of the variance
unexplained. A model summary was performed revealing a Pearson correlation (r
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Figure 4: AT IsoFs & AT FEV1/FVC
=0.227) (see Table 17), synonymous with the Beta coefficient (see Table 18),
demonstrating a weak relationship between IsoF levels and FEV1/FVC. A subsequent
ANOVA analysis of the model summary was performed showing no statistical difference
(P=0.265), confirming that IsoF levels do not correlate to FEV1/FVC values (see Table
19). No significant correlation was established between exhaled breath IsoF levels from
individuals with COPD on LFDO to FEV1/FVC.
Table 17
AT IsoF and FEV1/FVC Model Summary
Model
1

R
.227

R Square
.051

Adjusted
R Square
0.012

Change Statistics
R Square
Change
F Change
.051
1.302

df1
1

Table 18
AT IsoF and FEV1/FVC Regression Coefficients

Model
1
(Constant)
Active Treatment IsoF

Unstandardized
Coefficients
B
Std. Error
64.091
4.399
.076
.067
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Standardized
Coefficients
Beta
.227

t
14.570
1.141

Sig
.000
.265

Table 19
AT IsoF and FEV1/FVC ANOVA for Regression Analysis
Model
1

Sum of Squares

Regression
Residual
Total

df

275.732
4750.268
5008.000

1
24
25

Mean
Squares
257.732
197.928

F

Sig

1.302

.265

A simple linear regression was calculated to determine if a relationship exists
between FEF25-75% in COPD patients receiving LFDO therapy and exhaled breath IsoF
levels. A line of best-fit analysis revealed a relatively flat slope of -0.1784-0.4298 and a
goodness of fit R2=0.038 indicating a very weak correlation to the best-fit line (see Figure
5), an assessment supported the B value revealing that for every 1 unit of increase in IsoF
levels would only generate a 0.146 unit of change in the FEF25-75. According to the R2
coefficient of determination only 3.8 % of the model variation could be explained by
exhaled breath IsoF levels, leaving approximately 96.2% of the variance unexplained. A
model summary was performed revealing a Pearson correlation r =0.194 (see Table 20),
synonymous with the Beta coefficient (see Table 21), demonstrating a weak relationship
between IsoF levels and FEF25-75%. A subsequent ANOVA analysis of the model
summary was performed showing no statistical difference (P=0.265), confirming that
IsoF levels do not predict FEF25-75% values (see Table 22). While significant between
group differences were noted on pulmonary function test FEF25-75 parameters no
significant between group differences were noted with regard to exhaled breath IsoF. No
significant correlation was established between IsoF levels from individuals with COPD
on LFDO to FEF25-75.
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Figure 5: AT IsoFs & FEF25-75
Table 20
AT IsoF and FEF25-75% Model Summary
Model
1

R

R Square

.194

.038

Adjusted
R Square
-.003

Change Statistics
R Square
Change
F Change
.038
.935

df1
1

Table 21
AT IsoF and FEF25-75% Regression Coefficients

Model
1
(Constant)
Active Treatment IsoF

Unstandardized
Coefficients
B
Std. Error
44.710
9.934
.146
.151

Standardized
Coefficients
Beta
.194

t
4.501
.967

Sig
.000
.343

Table 22
AT IsoF and FEF25-75% ANOVA for Regression Analysis
Model
1

Regression
Residual
Total

Sum of Squares

df

943.994
24224.045
25168.038

1
24
25
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Mean
Squares
943.994
1009.335

F

Sig
.935

.343

Research Question 3
Is there a correlation between length of smoking history, and length of oxygen exposure
and concentration of oxygen to isofuran levels?
The following relationships were explored through simple linear regression
utilizing the statistical software package SPSS, version 23. An analysis of the statistical
results, including a Pearson correlation, coefficients, model summary and ANOVA is
provided. Tables, graphs and figures may accompany the explanation to enhance clarity
of the findings. The results of the linear regression analysis were as follows:
A simple linear regression was calculated to determine if a relationship exists
between length of smoking history (yrs) in COPD patients receiving LFDO therapy and
exhaled breath IsoF levels. A line of best-fit analysis revealed a relatively flat slope of
-1304-0.2243, and a goodness of fit R2= 0.012 indicating a very weak correlation to the
best-fit line (see Figure 6), an assessment supported the B value revealing that every 1
unit of increase in IsoF levels would only generate a 0.047 unit of change in the smoking
history. According to the R2 coefficient of determination only 1.2% of the model
variation could be explained by exhaled breath IsoF levels, leaving approximately 98.8%
of the variance unexplained. The model summary revealed a Pearson correlation r =0.111
(see Table 23), synonymous with the Beta coefficient (see Table 24), demonstrating a
weak relationship between IsoF levels and length of smoking history. A subsequent
ANOVA analysis of the model summary was performed showing no statistical difference
(P=0.590), confirming that IsoF levels are not significantly correlated with length of
smoking history (see Table 25). Not all individuals in the AT group had a history of
smoking. Four individuals reported having never smoked. No significant correlation was
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Figure 6: AT IsoFs & Length of Smoking History
Table 23
AT IsoF and Length of Smoking History Model Summary
Model

R

R Square

Adjusted
R Square

1

.111

.012

-.029

Change Statistics
R Square
Change
F Change
.012
.299

df1
1

Table 24
AT IsoF and Length of Smoking History Regression Coefficients

Model
1
(Constant)
Active Treatment IsoF

Unstandardized
Coefficients
B
Std. Error
27.049
5.665
.047
.086

Standardized
Coefficients
Beta
.111

t
4.775
.547

Sig
.000
.590

Table 25
AT IsoF and Length of Smoking History ANOVA for Regression Analysis
Model
1

Regression
Residual
Total

Sum of Squares

df

98.144
7878.317
7976.462

1
24
25
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Mean
Squares
98.144
328.263

F

Sig
.299

.590

established between IsoF levels from individuals with COPD on LFDO to length of
smoking history (yrs).
A simple linear regression was calculated to determine if a relationship exists
between length of daily oxygen exposure (hours/day) in COPD patients receiving LFDO
therapy and exhaled breath IsoF levels. A line of best-fit analyses revealed a relatively
flat slope of -0.03538-0.09946 and a goodness of fit R2=0.039, indicating a very weak
correlation to the best-fit line (see Figure 7), an assessment supported the B value
revealing that every 1 unit of increase in IsoF levels would only generate a 0.032 unit of
change in the length of oxygen therapy (hrs/day). According to the R2 coefficient of
determination only 3.9% of the model variation could be explained by exhaled breath
IsoF levels, leaving approximately 96.1% of the variance unexplained. A model summary
was performed revealing a Pearson correlation r =0.196 (see Table 26), synonymous with
the Beta coefficient (see Table 27), demonstrating a weak relationship between IsoF
levels and length of daily oxygen exposure (hours/day). A subsequent ANOVA analysis
of the model summary was performed showing no statistical difference (P=0.590),
confirming that IsoF levels are not correlated to length of daily oxygen exposure (hrs)
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Figure 7: AT IsoFs & AT Length of Daily Oxygen Exposure (hrs)
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Table 26
AT IsoF and Length of Daily Oxygen Exposure (hrs) Model Summary
Model

R

R Square

Adjusted
R Square

1

.196

.039

-.002

Change Statistics
R Square
Change
F Change
.039
.962

df1
1

Table 27
AT IsoF and Length of Daily Oxygen Exposure (hrs) Regression Coefficients

Model
1
(Constant)
Active Treatment IsoF

Unstandardized
Coefficients
B
Std. Error
12.739
2.154
.032
.033

Standardized
Coefficients
Beta
.196

t
5.916
.547

Sig
.000
.336

(see Table 28). No significant correlation was established between isofuran levels from
individuals with COPD on LFDO to length of daily oxygen exposure (hrs).
Table 28
AT IsoF and Length of Daily Oxygen Exposure (hrs) ANOVA for Regression Analysis
Model
1

Regression
Residual
Total

Sum of Squares

df

45.646
1138.508
1184.154

1
24
25

Mean
Squares
45.646
47.438

F

Sig
.962

.336

A simple linear regression was calculated to determine if a relationship exists
between oxygen delivery (L/min) in COPD patients receiving LFDO therapy and exhaled
breath IsoF levels. A line of best-fit analysis revealed a relatively flat slope of -0.003896
-0.007623 and a goodness of fit R2=0.018 indicating a very weak correlation to the bestfit line (see Figure 8), an assessment supported the B value revealing that every 1 unit of
increase in IsoF levels would only generate a 0.002 unit of change in the oxygen delivery
(L/min). According to the R2 coefficient of determination only 1.8% of the model
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Figure 8: AT IsoFs & AT Oxygen Delivery (L/min)
variation could be explained by exhaled breath IsoF levels, leaving approximately 98.2%
of the variance unexplained. A model summary was performed revealing a Pearson
correlation r =0.135 (see Table 29), synonymous with the Beta coefficient (see Table 30),
demonstrating a weak relationship between IsoF levels and oxygen delivery (L/min). A
subsequent ANOVA analysis of the model summary was performed showing no
statistical difference (P=0.511), confirming that IsoF levels are not correlated to oxygen
delivery (L/min) (see Table 31). No significant correlation was established between IsoF
levels from individuals with COPD on LFDO to oxygen delivery (L/min).
Table 29
AT IsoF and Oxygen Delivery (L/min) Model Summary
Model
1

R
.135

R Square
.018

Adjusted
R Square
-.023
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Change Statistics
R Square
Change
F Change
.018
.446

df1
1

Table 30
AT IsoF and Oxygen Delivery (L/min) Regression Coefficients

Model
1
(Constant)
Active Treatment IsoF

Unstandardized
Coefficients
B
Std. Error
2.366
.184
.002
.003

Standardized
Coefficients
Beta
.135

t
12.861
.668

Sig
.000
.511

Table 31
AT IsoF and Oxygen Delivery (L/min) ANOVA for Regression Analysis
Model
1

Regression
Residual
Total

Sum of Squares

df

.154
8.307
8.462

1
24
25

Mean
Squares
.154
.346

F

Sig
.446

.511

A simple linear regression was calculated to determine if a relationship exists
between duration of oxygen therapy (yrs) in COPD patients receiving LFDO therapy and
exhaled breath IsoF levels. A line of best-fit analysis revealed a relatively flat slope of
0.06711 -0.01327 and a goodness of fit R2=0.074 indicating a very weak correlation to
the best-fit line (see Figure 9), an assessment supported the B value revealing that every 1
unit of increase in IsoF levels would only generate a -0.027 unit of change in the duration
of oxygen therapy (yrs). According to the R2 coefficient of determination only 7.4% of
the model variation could be explained by exhaled breath IsoF levels, leaving
approximately 92.3% of the variance unexplained. A model summary was performed
revealing a Pearson correlation r =0.272 (see Table 32), synonymous with the Beta
coefficient (see Table 33), demonstrating a weak relationship between IsoF levels and
duration of oxygen therapy (yrs). A subsequent ANOVA analysis of the model summary
was performed showing no statistical difference (P=0.180), confirming that IsoF levels
are not correlated to duration of oxygen delivery (L/min) (see Table 34). No significant
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Figure 9: AT IsoFs & AT Length of Oxygen Therapy (yrs)
Table 32
AT IsoF and Duration of Oxygen Therapy (yrs) Model Summary
Model

R

R Square

Adjusted
R Square

1

.272

.074

.035

Change Statistics
R Square
Change
F Change
.074
.1.911

df1
1

Table 33
AT IsoF and Duration of Oxygen Therapy (yrs) Regression Coefficients

Model
1
(Constant)
Active Treatment IsoF

Unstandardized
Coefficients
B
Std. Error
4.799
1.284
-.027
.019

Standardized
Coefficients
Beta
-.272

t
3.738
-1.382

Sig
.000
.180

Table 34
AT IsoF and Duration of Oxygen Therapy (yrs) ANOVA for Regression Analysis
Model
1

Regression
Residual
Total

Sum of Squares

df

32.215
404.610
436.825

1
24
25
131

Mean
Squares
32.215
16.859

F
1.911

Sig
.180

correlation was established between isofuran levels from individuals with COPD on
LFDO to duration of oxygen therapy (yrs).
Secondary Findings
In an effort to better understand whether “years” of exposure of LFDO influenced
the IsoF levels, “time” (years of exposure) was subdivided into three categories: 0-2 years
(n=14), 3-6 years (n=8), and 7-20 years (n=4) (see Figure 10). An ANOVA was
performed to compare group means between the three established time frames. A P value
was set at a significance level of 0.05 at a CI 95%. The results generated were means of
65.57, 33.63 and 37.00 respectively, with a P = 0.1795 (see Table 35). In summary,
“time” in terms of years of exposure showed no statistical significance with regard to
exhaled breath IsoF levels in the lungs of COPD on LFDO therapy.
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132

Table 35
One-way Analysis of Variance for Years of Oxygen Exposure
ANOVA table
Treatment
(between
columns)
Residual
(within
columns)

SS

DF

MS

F(DFn, DFd)

P value

6169

2

3084

F (2,23) =
1.853

P = 0.1795

Total

44458 25

38289 23

1665
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Chapter 5 – Summary & Discussion

Introduction
This chapter summarizes the results of this research study and provides discussion
regarding the findings. The results were examined in the context of the literature review and the
theoretical framework guiding this study. Description of the data collection site and population
demographics is presented first with the integration of the theoretical framework to follow.
Quantitative results are discussed as they relate to the individual research questions and the
theoretical framework. A methodological review will be presented. Finally, limitations,
implications of the study and suggestions for future research are presented.
Purpose
The purpose of this study was to elucidate whether or not LFDO contributes to ongoing
oxidative stress in the lungs of COPD patients. Supplemental oxygen is a known inducer of
oxidative stress. Oxidative stress is a central mechanism in the pathologic processes resulting in
the parenchymal changes in the lungs commensurate with chronic bronchitis and emphysema. It
is understood that oxygen therapy clearly improves symptomatic dyspnea associated with the
disease in individuals with COPD; however, the medical research community would be remiss to
ignore the nocuous potential of chronic oxygen exposure.
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Synthesis of Quantitative Results
No research to date has been conducted utilizing IsoF as a marker of oxidative stress in
the lungs of COPD patients. Actually, no research has been conducted utilizing any biomarker to
determine if LFDO presents an oxidative risk. This study is foundational in that regard. The
results of this study provide benchmark information about baseline IsoF levels in the COPD
population subset, with and without LFDO. Isofuran is a biosynthetic relative to the validated
oxidative stress biomarker, IsoP, whose formation is favored in the presence of elevated oxygen
tensions. This particular sensitivity to oxygen tension makes it an ideal biomarker to examine the
potential of oxygen therapy. A simple first step approach to uncovering this potential was to
create closely matched groups with regard to age, gender, COPD diagnosis and ethnicity and to
compare the mean IsoF levels between the active control (no LFDO) and treatment groups (with
LFDO).
Research Question 1. The first research question asks if chronic exposure to LFDO
contributes to oxidative stress in the lungs of COPD patients as evidenced by elevated exhaled
breath IsoF levels. The resulting study groups demonstrated no statistically significant
demographic differences, which serves to minimize threats to internal validity. No statistical
difference in mean IsoF levels was determined between the AC and AT groups (P=0.057);
therefore, the null hypothesis was accepted.
While inferences may not be drawn from this result, questions are raised. What is
responsible for IsoF levels greater than one standard deviation from the mean in four participants
in the control group and five participants in the treatment group? Are there other factors, such as
concomitant comorbidities, that contribute to IsoF formation detectable in exhaled breath? How
long does it take for IsoF levels to return to basal following cessation of therapy? Is IsoF an
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appropriate biomarker to address supplemental oxygen as a contributor of oxidative stress? Does
length or concentration of oxygen exposure explain these variations? The latter question will be
addressed in a subsequent section; however, regarding relevant comorbidities, little information
has been established in exhaled breath biomarker research implicating known sources of
confounding IsoF results with the exception of those with known mitochondrial diseases, such as
amyotrophic lateral sclerosis (ALS), Alzheimer’s, Lewy body and Parkinson’s diseases (Fessel
et al., 2003). Even then, what is understood about the significant presence of IsoF in these
diseases was tested in the substantia nigra of individuals diagnosed with Parkinson’s and Lewy
body disease, not exhaled breath. As a result, minimal exclusions were imposed except for those
diagnosed with ALS, Alzheimer’s, Lewy body and Parkinson’s diseases.
When considering significant sources of increased tissue oxygen tension alveolar
macrophages (AMs) must be included, as they responsible for producing large quantities of
ROS. According to Barnes (2004) the conditions imposed by AM activation in the lungs leads to
a cascade of processes that “together could account for all of the pathophysiological features of
COPD.” A mechanism of defense incited by AMs is respiratory burst, a marked increase in
superoxide (an oxygen radical) to serve as a bactericide. Vacchiano et al (1997) demonstrated in
rat culture a mean 8-IsoP macrophage production of 14 ± 1 pg/ml when exposed to air, and a 25
± 2 pg/ml when exposed to 100% oxygen. This evidence supports macrophage contributions to
increased oxidant load, and, subsequently, oxidative stress when unchecked. Relevant to note in
the same study, however, are the findings that show no increase from baseline in mean
macrophage production of 8-IsoP following exposure to 50% oxygen. This finding supports that
concentrations ≤ 50% FiO2 do not contribute to ongoing oxidative stress at normal partial
pressures (at sea level or 1 ATA). When compared to the current study, it suggests this IsoF
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levels obtained are likely a result of the original disease process and not the addition of LFDO
therapy as no study participants were exposed to >36% at 1 ATA.
A significant challenge, with regard to accurately interpreting the results, in the current
study is that no data exists defining baseline exhaled breath IsoF levels in healthy subjects or in
individuals diagnosed with COPD. Only three studies to date have employed exhaled breath IsoF
as a biomarker of oxidative stress, all of which utilized different study groups (refer to Table 36).
The three studies are presented below with comparisons made in order to discern any existing
inferences between them.
A study by Dworski et al (2009) demonstrated a basal exhaled breath IsoF level of 3.9 ±
3.3 pg/ml (mean ± SD) in known human allergic asthmatics. The study demonstrated that
asthmatics who were exposed to an inhaled antigen challenge (IAC) showed an increase in
exhaled breath IsoFs at all time points, with significance being reached at 2 h (P=0.036) and 4 h
(P=0.025) post challenge (7.7 ± 6.7 and 6.8 ± 4.7 pg/ml respectively). While the population for
the current study (adults with COPD) differed from the Dworski study (children with asthma) it
is the only published study utilizing exhaled breath as a medium for which to evaluate and
compare the results of the oxidative stress biomarker, IsoF. The mean exhaled breath IsoF level
for the control group in the Dworski study (3.9 pg/ml) was significantly lower than that the mean
obtained in the active control group in the current study (35.8 pg/ml). The disparity in control
means may reflect an overall disparity in disease states of the participants: adults with advanced
COPD compared to asthmatic children in a quiescent state.
In an unpublished study by Vacchiano (2005) the EBC IsoF levels of naval pilots who
were exposed to 100% oxygen intermittently during high altitude flight over the course of their
flying careers were compared to age, gender and smoking matched naval pilot candidates
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(control group) whom had never been exposed to supplemental oxygen (personal
communication). The control group mean EBC IsoF levels obtained from the pilot candidates
was reported to be 3.1 ± 3.5 SD pg/ml. The results obtained are very similar to the control mean
obtained in the Dworski study, 3.9 ± 3.3 SD pg/ml, suggesting they may be reflective of basal
IsoF levels in healthy lungs. The AC group (COPD patients without LFDO) mean EBC IsoF
value obtained in the current study of 35.8 ± 25.0 SD represents diseased lungs. The oxygen
exposed pilot group in the Vacchiano study generated a mean EBC IsoF level of 38.8 ± 116.5 SD
(15.86 SEM) pg/ml, similar to the AC group EBC IsoF values obtained in the current study (see
Table 36). In addition, there was a further marked increase in EBC IsoF levels, from their
already increased baseline levels, in the actively flying pilot group following a training flight
during which 100% oxygen was inspired for an average of 1.5 hours. It was reported in the
personal communication that the oxygen exposed pilots percent (%) predicted FVC and FEV1
values were lower than expected for the entire aviator group at 3 measurement periods (preflight
and 2 post-flight periods). There was also a statistically significant decrease compared to
preflight baseline in both % predicted FVC and FEV1 at the 1st post flight measurement period in
aviators with 2200 to 3500 hours of total flight time breathing 100% oxygen. This suggests that
this group of aviators had developed signs of restrictive lung disease during the course of their
careers. It can be speculated that chronic intermittent high concentration supplemental oxygen
exposure is central to that development. The control group for the current study and the treatment
group for the Vacchiano study reflect basal IsoF levels in diseased lungs. Both have incurred
lung damage but from different instigators of oxidative stress. The COPD patients have
developed their disease due to first or second hand smoke, or environmental pollutants while the
pilots appear to have incurred lung damage as a result of inspiring sufficient supplemental
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Table 36.
Exhaled Breath Isofuran Studies
Study

N

Control
IsoF Mean ± SD
pg/ml

Treatment
IsoF Mean ± SD
pg/ml

Dworski
(2009)

27

3.9 ± 3.3

7.7 ± 6.7
6.8 ± 4.7

Vacchiano
(2005)

48

3.1 ± 3.5

38.8 ± 116.5

Stulce
(2015)

52

35.8 ± 25.0

51.4 ± 42.2

Population
Children with
human allergic
asthma
Naval pilot
candidates
Naval pilots
COPD w/o
LFDO
COPD with
LFDO

oxygen required to achieve a blood oxygen partial pressure to maintain normal cognitive
function at high altitude. Explanations for the increased exhaled breath IsoF mean (51.4 ± 42.2)
in the current study treatment group remains unclear; however, they follow a similar trend as in
the Vacchiano study, increasing from baseline following oxygen therapy, possibly indicating that
supplemental oxygen may be responsible for the observed increases in exhaled breath IsoF.
As reported in the literature review, no medications are known to impact IsoP formation
in humans, and, presumably then IsoF, as it is a biosynthetic relative of IsoP would similarly not
be affected. Corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic
acid (ASA) inhibit prostaglandin synthesis via the cyclooxygenase pathway. Prostanoid isomers,
such as the isoprostanes, are produced as a result of non-enzymatic processes and, therefore,
corticosteroids, NSAIDs and ASA presumably have no significant impact on their formation.
However, it has been demonstrated that ASA significantly reduced 8-IsoP production by primary
cultures of rat alveolar macrophages under laboratory conditions but has not been substantiated
in human studies (Vacchiano, Osborne and Tempel, 1997). This finding suggests an alternative
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mechanism of ASA in regard to ameliorating oxidant load, such as scavenging of reactive
oxygen species (ROS) or through the NADPH oxidase inhibition, the enzyme responsible for the
production of superoxide as a result of respiratory burst. In the current study ASA use did not
preclude study participation. Medication lists were reviewed as a method of confirming comorbidities, however, no subjects were excluded due to medication use. The six participants in
the active control group that reported daily low dose aspirin use generated an IsoF range of 15-42
pg/ml; in the active treatment group the six participants reporting daily low dose aspirin use
generated an exhaled breath IsoF range of 11-77pg/ml. The AC IsoF group mean ± SEM was
35.81 ± 4.92; the AT group mean ± SEM was 51.35 ± 8.27. Daily aspirin use did not appear to
exert a negative influence on IsoF synthesis in either group, suggesting that ASA may not have
ROS scavenger or NADPH oxidase inhibitor capabilities in this population subset likely due to
the degree of lung pathology.
In summary, the lack of significant findings in this study are a result of 1) the
methodology employed was not suitable to address the research questions; 2) IsoF, a biomarker
influenced by multiple sources, lacks specificity with regard to source, rendering it unsuitable for
purposes of evaluating LFDO as an instigator of oxidative stress; or 3) LFDO at concentrations
less than 36% do not contribute to ongoing oxidative stress in the lungs of individuals of COPD.
The contribution of this study to the large gap in literature on IsoF as a biomarker of oxidative
stress is, however, as a benchmark with which to compare future research. The comparison of the
three studies (Dworski, Vacchiano, Stulce) begins to shed light on baseline EBC IsoF in a variety
of populations. Exhaled breath biomarker analysis is in its infancy, with exhaled breath IsoF
analysis nearly non-existent. A recent PubMed search reported 692 research studies since 1992
utilizing “exhaled breath” as a search term; of those, 58 studies were conducted in 2015. A
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PubMed search utilizing “isofuran” as the search term yielded 21 studies, only one of which
evaluated exhaled breath as the medium for IsoF analysis. The current study may provide insight
into the scope of its value.
Research Question 2. The second research question asks whether or not a relationship
exists between FEV1, FVC, FEV1/FVC, FEF25-75% and IsoF levels. The noninvasive nature of
exhaled breath condensate collection makes it an ideal method for the assessment of pathologic
processes occurring in individuals in fragile health states, such as those with advanced COPD. In
light of this concept, multiple studies have been conducted to correlate exhaled breath
biomarkers to those pulmonary function test parameters consistent with diagnosing and
quantifying disease states of individuals with COPD, but without real success. Until this study
none had attempted to correlate exhaled breath IsoF levels to standard diagnostic spirometry,
such as FEV1, FVC, FEV1/FVC, and FEF25-75%.
To address this question current PFTs were obtained to compare and correlate to exhaled
breath IsoF levels to assess for clinical application. In order to obtain accurate PFT results
maximal effort is required, and often times multiple maneuvers, all of which can be very
challenging for the individual with COPD, particularly those with advanced disease. If an actual
correlation between a validated exhaled breath biomarker and pulmonary function parameters
could be identified, individuals could theoretically be spared from this rigorous PFT process.
IsoF was selected as the predictor variable with the intention of replacing conventional
pulmonary function testing.
A linear regression statistical model was employed to explore possible relationships
between FEV1, FVC, FEV1/FVC, and FEF25-75% and exhaled breath IsoF levels. No
significant relationships were revealed between any of the tested pulmonary function parameters
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and exhaled breath IsoF. As mentioned, multiple studies have been performed to determine if a
correlation exists between exhaled breath oxidative biomarkers and pulmonary function test
results without success with the exception of a study conducted in 2010 by Carraro et al, which
evaluated 20 children diagnosed with asthma, comparing their exhaled breath 8-IsoPs to
FEV1/FVC and FEF25-75% parameters to identify whether or not a correlation exists. The
analysis demonstrated that 8-IsoP in the exhaled breath condensate was significantly increased in
children with problematic asthma (p=0.05) with a negative correlation to both the FEV1/FVC
and FEF25-75% (r= -0.5), and both statistically significant (P=0.03). Although these findings did
not utilize IsoF as the oxidative stress biomarker, it is closely related to 8-IsoP, suggesting a
potential relationship could be established in the same setting. As such, support for continued
research and refinement in determining whether or not exhaled breath biomarker analysis as a
noninvasive means of predicting disease states has a place as a diagnostic tool should continue.
While no correlation was established in the current study between IsoF and FEF25-75%
(r=0.194, P=0.34) it is of interest to note a significant difference in FEF25-75% existed between
the AC and AT groups (P=0.0265). Two methods were employed to collect PFT data, the
Discovery II Spirometer™ conducted by the PI, and in the PFT lab conducted by certified
respiratory therapists. Error may have been introduced as a result; however, no significant
differences in the remaining test parameters were noted.
In summary, studies have failed to consistently correlate standard spirometric testing with
validated oxidative stress biomarkers. The current study also failed to identify a correlation
between FEV1, FVC, FEV1/FVC and FEF25-75% parameters and the oxidative stress
biomarker, IsoF. However, the ideal noninvasive conditions offered by exhaled breath analysis to
individuals with advanced lung disease make it desirable as a diagnostic and prognostic tool.
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Exhaled breath biomarker analysis is still in the early stages; as more research is conducted and
methodologies improved there may come a time when correlations can be made between exhaled
breath biomarkers and current standard diagnostic testing.
Research Question 3. The third research question asks whether or not exhaled breath
IsoF levels were correlated to length of oxygen exposure, smoking history and/or concentration
of oxygen delivery (L/min). Understanding the relationships between the relevant variables of
time of exposure and concentration of oxygen delivery to IsoF levels could provide crucial
insight into the potential of LFDO as a mechanism of ongoing oxidative stress. It is intuitive that
time would be a relevant factor in promoting oxidative stress as longer exposure provides more
opportunity to incite oxidative stress. However, in the current study, chronicity did not result in
significant elevations in exhaled breath IsoF levels. In fact, an individual who had been on
oxygen for 20 years generated an exhaled breath IsoF level of 13 pg/ml, one of the lowest values
obtained in the study, while the individual generating the highest exhaled breath IsoF level (181
pg/ml) reported oxygen use for only 3 weeks. Perhaps the crucial assessment period, with regard
to “time”, is at the initiation or introduction of LFDO therapy.
It is also intuitive to believe that dose (or concentration) would influence IsoF production,
as more of the offending substance is available to incite pathology. The relevance of
concentration may exist, however, with the higher concentrations/doses. There are many studies
implicating high concentrations (≥ 50%) of supplemental oxygen exposure to oxidative stress,
however, there are no studies evaluating low flow/concentration (L/min) of oxygen therapy for
individuals on LFDO therapy as a mechanism of oxidative stress. The L/min flows of oxygen
therapy reported in the current study were between 2-4 L/min (28-36% concentration). Two
L/min was the lowest reported concentration of oxygen therapy in the current study, it generated
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both the lowest and the highest IsoF values at 11 pg/ml after LFDO 12 hrs/day for 3 years and
181 pg/ml with LFDO 24 hrs/day for 3 weeks. The single participant reporting 4 L/min of daily
oxygen use (9 hrs/day for 5 years) generated an exhaled breath IsoF of 77 pg/ml. The disparity in
the range in IsoF compared to concentration suggests LFDO does not influence oxidative stress.
It is well established, particularly in diving and aviation literature, that oxygen is toxic
when breathed at a partial pressure in excess of 0.4 ATA (40% O2 at atmospheric pressure) for a
sufficient period of time. As partial pressures exceed 0.4 ATA, oxidant load increases and
pathology ensues. Nagatomo et al (2012) exposed male Wistar rats to 14.4%, 20.9%, 35.5%,
39.8%, 62.5% and 82.2% oxygen at 1 ATA for 24 hours. Derivatives of reactive oxygen
metabolites (dROMs) in plasma were utilized as an index of oxidative stress. It was concluded
that 14.4%, 20.9% and 35.5% oxygen did not affect dROM levels; however, rats exposed to
39.8% 62.5% and 82.2% oxygen had significant (P<0.05) increases in dROMs, with the highest
level in the 82.2% oxygen exposure group. Vacchiano et al (1997) had a similar finding with no
significant increase in alveolar macrophage mean concentration of 8-IsoP at 50% oxygen
exposure at 1 ATA. These studies demonstrate safe oxygen therapy administration <40% oxygen
at 1 ATA. With regard to the current study, these findings support LFDO concentrations ranging
from 28-36% as a safe therapy. Concentrations this low minimally impact blood oxygen partial
pressures, particularly in the presence of diseased lungs with a decreased diffusion capacity.
There is evidence, however, that brief exposure (30-60 minutes) to low concentrations of
oxygen (28%) results in significant increases (P<0.05; P<0.001) in validated exhaled breath
oxidative stress biomarkers (BMAC; 8-Isoprostane and IL-6) in healthy adults (Phillips, 2003;
Carpagnano, 2004). The target population in the Phillips study was exclusively healthy adults
while the Carpagnano included both healthy adults and adults with COPD. Both studies
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employed a pre and post EBC analysis after breathing ambient air and 28% supplemental
oxygen. While these time points (30-60 minutes) do not represent chronicity they do address the
concept “low concentrations/flow” as a mechanism of oxidative stress. The results from the
Phillips and Carpagnano studies are in conflict with what is currently understood about minimal
oxidant load occurring as a result of concentrations <40% at sea level. With regard to the current
study, there may be some similarities to those reporting brief or sporadic exposure generating the
highest results. The individual reporting sporadic use in the two months prior to sample
collection generated an exhaled breath IsoF of 148 pg/ml. The individual reporting three weeks
of 24 hrs/day 2L/min of oxygen use reported 181 pg/ml. These results, along with those reported
in the Phillips and Carpagnano study, support investigating oxidative stress associated with an
introductory phase of LFDO therapy, and subsequently, the mechanisms responsible for return to
baseline in its continued presence.
To explore the concept of “time” further to determine if IsoF levels were influenced by
length of exposure in terms of years a one-way analysis of variance (ANOVA) was performed.
Lengths of exposure were defined as 0-2 years (n=14), 3-6 years (n=8) and 7-20 years (n=4).
These range bins were determined to meet the criteria necessary to perform an ANOVA.
Significance differences between groups was not found (P = 0.1795), meaning time in terms of
years of exposure did not implicate LFDO as a mechanism of oxidative stress. Consistently the
variables of potential influence on oxidative stress have not been substantiated in this study.
Again, indicating that the IsoF levels obtained in the study are likely a result of preexisting
diseases, not LFDO.
In summary, with what is currently understood regarding IsoF as a biomarker sensitive to
elevated tissue oxygen tensions it could not be demonstrated that concentration of oxygen
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delivery (L/min), or duration of therapy in terms of hours/day or years predictably influenced its
production. Low flow domiciliary oxygen prescription flow rates fall between 1-5 L/min (2444%). It has been substantiated that concentrations < 40% oxygen delivery at 1 ATA are safe.
The current study had no participants utilizing greater than 36%; therefore, it would not be
expect to observe an elevation in IsoF. There may be evidence suggesting oxidative stress may
occur during an initiation phase of oxygen therapy. As more is understood regarding the
variables influencing oxidative stress, and hence the biomarkers of oxidative stress, the more
specific methodologies can be developed and employed, bringing healthcare provision closer to
quality outcomes. Until then, the current study suggests that LFDO does not contribute to
ongoing oxidative stress, but rather that the IsoF levels are a reflection of disease.
Theoretical Framework
The overarching goal, as it relates to health sciences research, is patient safety. An
organized and methodological approach is ideal when attempting to determine if practice
modalities/treatments are optimal in promoting, maintaining and restoring health. Donabedian’s
Structure-Process-Outcome framework postulates that if the institutional “structure” and
“process” are constructed and conducted in the appropriate way then quality outcomes will
certainly follow. To assess whether LFDO therapy is appropriately prescribed and managed at
Phelps County Regional Medical Center the Structure-Process-Outcome model was utilized.
Qualitative Observations. Donabedian’s model of Structure-Process-Outcome provides
a framework by which to evaluate the effectiveness and/or quality of healthcare. “Structure”
refers to the context in which care is delivered, such as hospital buildings, administration, staff,
economic resources and equipment. Phelps Country Regional Medical Center is active in and
supportive of research as a mechanism by which to provide those they serve with the most
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appropriate and effective care. The Chief Medical Officer at PCRMC supported this research
endeavor in the form of allowing the PI access to all areas of the hospital that offered and
managed the care of individuals with COPD in an effort to better understand any potential risks
associated with the use of prescribed LFDO therapy as a treatment modality. This level of
engagement demonstrated the administration’s attitude and commitment toward providing
quality care.
Areas accessed for this research project included the cardiology, internal medicine, and
the pulmonary function clinics. The clinics were appropriately staffed with licensed practical
nurses, registered nurses, and nurse practitioners, registered physical therapists, and certified
respiratory therapists and physicians. All areas were equipped with emergency equipment and
protocols to address untoward medical emergencies. The cardiac and internal medicine clinics
were housed in the Medical Office Building directly attached to the hospital, while the
pulmonary function lab was housed within the hospital itself. The location of the clinics
facilitated ease of transport and quick access to acute care. The “structure” aspect, which
promotes quality outcomes, was sufficient.
“Process” refers to the sum of all interactions between patients and providers throughout
the delivery spectrum that translates to healthcare. It is during the “process” phase that diagnoses
are made, treatments are formulated and delivered, and patient education takes place. The
manner in which care is delivered significantly influences patient satisfaction and perception of
quality. The “process” of delivery at PCRMC is collaborative between disciplines per protocol.
Phelps County is committed to the evolution of improved communication to enhance outcomes.
Witness to this process was observed firsthand during the data collection phase. This assessment
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was not only made as a primary observer, but also as a result as the consistent feedback obtained
from client surveys of the respective clinics as part of their quality assurance commitment.
“Outcome” refers to those measurable or discernable changes in health status, behavior,
or knowledge as well as overall patient satisfaction and health-related quality of life
improvements. Improving health states is the primary goal of healthcare; therefore, assessing
outcome with regard to this central parameter is necessary. Health “state” can be defined broadly
or narrowly. With regard to this study, a very specific assessment of a prescribed treatment was
utilized to determine the “outcome” of said treatment. The benefits of LFDO therapy are well
understood; however, until recently, there had not been a specific mechanism by which to assess
for pathology related to LFDO. Utilizing new techniques to measure IsoF allowed us to examine
the outcome of a prescribed treatment of LFDO offered by PCRMC to their constituents.
In summary, according to Donabedian, outcome is conceptually defined as the end result
of the process of care to include “those things, either favorable or adverse, in the actual or
potential health status of persons, groups, or communities that can be attributed to medical care”
(Donabedian, 1985, p.256). Based on the results of this study, when utilizing IsoF as an outcome
measurement of LFDO, quality can be assumed, as ongoing oxidative stress as a result of LFDO
therapy was not substantiated.
Methodologic Review
The final inquiry for this study is whether or not the methodology employed is suitable
for future research. The response is a mixed yes and no. The exhaled breath condensate
collection protocol utilized in the current study is consistent with recommendations by the
American Thoracic Society and European Respiratory Society (ATS/ERS), and consistent with
the protocol at Vanderbilt Eicosanoid Core labs, currently the only known lab in the United

148

States equipped to identify and quantify IsoFs. Therefore, no changes are currently indicated
with regard to the actual sample collection, storage and analysis methodology.
Refinement of inclusion/exclusion criteria for participant selection is required. Greater
insight is warranted regarding the impact acquired mitochondrial disease and alveolar
macrophages contributes to increased tissue oxygen tensions and, thus, IsoF formation. Until this
is realized it will be difficult to precisely assess exogenous oxygen as the mitigator of oxidative
stress when utilizing the IsoF biomarker.
Confounding study results circle around the highest IsoF values obtained (181 and 148
pg/ml) by individuals reporting either less than a month or sporadic use of LFDO in the two
months prior to data collection. Is it a function of time? Are there compensatory mechanisms that
explain the lack of findings? Are there particular disease processes that result in greater IsoF
synthesis? As a result of these, and other questions, a methodology addressing these confounders
requires development.
Exhaled breath condensate analysis was included in the methodology in the current study
to evaluate LFDO as a mechanism of ongoing oxidative stress due to its noninvasive low risk
profile. Historical approaches to diagnosing and prognosing pulmonary disease states include
bronchoscopy with bronchoalveolar lavage and/or biopsy. Risks associated with the procedure
vary depending on the overall health state of the individual. Individuals with COPD who are
chronically hypercarbic with symptomatic shortness of breath are at risk for post procedure
ventilatory support (Rand et al, 2013). As COPD progresses even mild insults can result in
exacerbations. Exhaled breath condensate collection as an approach of assessing disease states in
this fragile population makes it desirable.
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Limitations
A significant limitation of this study was the lack of a standardized protocol for exhaled
breath condensate collection. Due to the inherent nature of the individual biomarker compounds
being assessed, the varying storage practices and the specimen assessment tool (assays vs. mass
spectrometry) makes establishing a singular methodology for exhaled breath condensate
collection and biomarker detection challenging. As a result, the ATS/ERS have only developed
recommendations versus a standardized protocol. Recently, Mastrigt et al (2015) conducted an
extensive literature search utilizing the Medline, Embase and PubMed databases on the analysis
and applications of volatile organic compounds (VOCs) in exhaled breath (EB) and EBC on
children. They retrieved 1165 papers, nine of which contained original data on VOCs in EB and
84 on biomarkers in EBC. Following an analysis of the studies obtained it was concluded that,
while EBC analysis adds value to the diagnostic process and follow-up care of individuals with
respiratory disease, the lack of standardization of collection methods and analysis techniques
impedes the introduction of EBC use into clinical practice. This assessment is consistent with
those determined by Horvath et al in 2005, Montuschi in 2007 and supported by the ATS/ERS.
After approximately 13 years of EBC research clinical application has not been achieved. The
results of the current study did not substantiate clinical use of EBC analysis with regard to either
LFDO as an instigator of oxidative stress or as a substitute for pulmonary function testing.
Currently no studies have been conducted that define basal levels of exhaled breath IsoF
in individuals diagnosed with COPD, making the inability to interpret the obtained results is a
crucial limitation. Not only are there no exhaled breath basal IsoF levels established in
individuals with COPD, there are no exhaled breath IsoF levels established in healthy individuals
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either. While this is considered a significant limitation of this study, the obtained results will aid
in establishing that benchmark knowledge for future studies to compare.
Isofuran production is currently understood to occur in response to elevated oxygen
tensions (Roberts et al, 2004). Elevated oxygen tension levels within the body can occur from
both endogenous and exogenous sources. This study aimed to discern if oxidative stress was
occurring as a result of prescribed LFDO therapy, an exogenous source of reactive oxygen
species production. Endogenous sources of molecular oxygen can result from genetic or acquired
mitochondrial diseases, such as amyotrophic lateral sclerosis (ALS), Huntington’s, Alzheimer’s,
Lewy body and Parkinson’s diseases (Fessel et al, 2003). Study candidates were surveyed for
these particular diseases with none reported or observed. However, other more common diseases
that are linked to mitochondrial dysfunction, such as diabetes and hypertension, were not
controlled for.
Acquired mitochondrial dysfunction occurs as a result of adverse effects from drugs,
infections or other environmental factors (Ellinas and Frost, 2011). Diseases of the mitochondria
appear to cause the most damage to cells of the brain, heart, liver, skeletal muscles, kidney and
the endocrine and respiratory systems (Ellinas and Frost, 2011). The most common comorbidities reported by the participants in this study were COPD (100%), hypertension (87%),
diabetes (40%), coronary artery disease (56%), and hyperlipidemia (56%). Oxidative stress is
central to many of these disease processes with acquired mitochondrial dysfunction as a
contributing factor. It is unknown at this time to what degree, if any, these disease processes
contribute to elevated IsoF levels as a result of liberated molecular oxygen from disrupted
mitochondria. The limited understanding of contributing sources of elevated tissue oxygen
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tensions make it challenging to interpret which source, endogenous or exogenous, is responsible
for and to what degree of IsoF synthesis in this study.
A limitation of biomarker analysis is the lack of specificity with regard to which tissue it
represents. It has not been established that biomarker levels are exclusive to specific disease
processes when obtained via blood, plasma or urine. It is speculated that compounds collected in
exhaled breath condensate are representative of the alveolar lining, but, it does not necessarily
preclude the possibility that portions of a particular biomarker aren’t representative of other
systemic oxidative stress processes. As a result, it is recommended that exhaled breath analysis
of oxidative stress should not occur in the presence of an active infection, specifically sepsis and
pneumonia. No individuals with either current or recent pneumonias or other systemic infections
were considered for study inclusion. Candidates were excluded for active oral infections and
current use of antibiotics. Those who reported current antibiotic therapy were excluded for
concern of lingering inflammatory processes that might contribute to an oxidant load and
confound the result.
Limitations of this study with regard to PFT testing were the mixed-provider mixed-tool
methodology. Multiple clinic sites (Cardiology Clinic, Internal Medicine Clinic, Pulmonary
Rehab Clinic, Pulmonary Function Lab) were available for recruiting participants. Only the PFT
lab provided same day PFT testing; all other recruitment sites required obtaining PFT utilizing a
portable spirometer. This mixed provider approach utilizing two different tools introduced a
potential measurement error, a threat to internal validity. Ensuring consistent effort provided by
study participants during PFT testing outside of the pulmonary function lab was difficult. The
portable Discovery II™ spirometer, while considered sensitive and accurate, lacked the
sophistication of the software employed in the PFT lab. The lack of previous experience with
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administering pulmonary function testing by the PI introduced an initial limitation; however,
proficiency was realized early on.
The sample size generated for this study was based on an effect size determined through
examining 8-IsoP research. Isofuran may have a smaller effect size requiring a larger N with
which to power a study. A larger sample size would allow for the detection of patterns in
comorbidities as it relates to IsoF levels as well as possible explanation of the significant outliers
in the active treatment group.
Recommendations for Future Research
While known genetic mitochondrial diseases (Lewy body, Alzheimer’s and Parkinson’s
Diseases) were excluded from this study, current research implicates mitochondrial pathology in
many of the same diseases correlated to oxidative stress, such as diabetes and hypertension, etc.
Acquired mitochondrial mutations manifest within the human in the form of cellular senescence,
such as aging, heart disease, and diabetes, etc. Cytochrome c oxidase is responsible inside the
mitochondria for converting molecular oxygen to two molecules of water. In the presence of
cytochrome c oxidase mutations this feature is retarded and molecular oxygen goes unchecked,
contributing to oxidative stress within the cell. Future research to aid in a better understanding
the relationships between mitochondrial disease, cytochrome c oxidase mutations and IsoF
production could lead to an enhanced understanding of the origin of IsoF synthesis and
validating it as a useful tool in oxidative stress research.
It is of interest to consider that IsoF concentrations may decline at some undefined point
in time following initiation of LFDO. It would be of value to know the mechanism(s) responsible
for stabilizing isofuran synthesis following an “introductory phase” of therapy. Tolerance or
adaptation within the body manifests in many different ways. Mechanisms of systemic
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tolerance/adaptation, such as endogenous free radical scavenging systems activity, up and down
regulation, or potential reductions in cytokine activity, as a mechanism of stabilizing IsoF levels
following prolonged LFDO use, should be explored.
Identified contributors of increased oxidant load include mitochondrial disease, AM
activity and supplemental oxygen. With what is currently understood about IsoF there is no way
of discerning which source of ROS is responsible for IsoF synthesis. Currently, over 250
isomers of IsoFs have been identified. Continued research in delineating these isomers could
provide insight into their unique qualities regarding specificity and sensitivity to specific
processes/diseases. Until then, in light of what is currently known, IsoF is not a sensitive
biomarker of supplemental oxygen therapy.
A methodology recommendation would be to utilize a longitudinal repeated measures
pre-post test design. Develop a study design that targets individuals being prescribed LFDO,
obtaining baseline IsoF levels prior to LFDO initiation, then again at predetermined time points
following initiation (24 hours after initiation, then at 1, 2, 3, 5 and 6 months). A determination
could be made pending the need for continued IsoF evaluation of IsoF. Such an approach would
be better able to identify whether or not supplemental LFDO is a mechanism of ongoing
oxidative stress.
Summary
The purpose of this chapter was to present the results of this study in such a way that was
meaningful to researchers and healthcare providers. It was intended to encourage the reader to
consider the implications of traditional therapies/practices employed. This study did not
demonstrate LFDO as a mechanism of ongoing oxidative stress; however, as more is learned
about the variables contributing to IsoF synthesis we may be able to optimize its unique feature
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of oxygen tension specificity in gaining greater insight into oxidative stress and related diseases,
specifically COPD.
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Appendix A

Low-flow domiciliary oxygen therapy as a mechanism of ongoing oxidative stress in
COPD patients
Study Participant Data Collection Sheet
Active Control Group ID #___________
Active Treatment Group ID #__________
Age: _____
Gender: M or F
Height: (in feet and inches): _________________________________________
Weight: (in pounds): _______________________________________________
Ethnicity: ________________________________________________________
Current Smoker? Y

N

How long ago did you quit? _________________________________________
How many years did you smoke? ____________________________________
How many packs per day did you smoke? _____________________________
Do you have alpha-1 antitrypsin deficiency? Y
Are you currently on oxygen therapy at home? Y

N
N

If yes, how long have you been on home therapy? ______________________
How much oxygen (liters per minute) are you on? _____________________
Are you currently receiving antibiotics? Y

N

If yes, do you currently have a nose or mouth infection? Y
Please provide a complete list of medications you take daily:
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N

Appendix B

Sample Storage Data Sheet

Sample ID#: ________________________
Sample Collection Date: ______________ Sample Collection Time: ______________
Cooler Temperature: _________________
Ship Date: __________________________
Comments:
___________________________________________________________________

____________________________________________________________________
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Appendix C

Informed Consent
Title of Research: Chronic exposure to low flow home oxygen therapy as a mechanism of
oxidative stress.
Investigators: Jill Stulce, MSN, CRNA
Informed Consent
Before you agree to take part in this study, it is important that you read the following
description of the study. This paper describes the purpose, methods, benefits, and risks of
the study. It is always your right to change your mind and decide not to be in the study at
any time.
Purpose of Research
To determine if home oxygen therapy contributes to ongoing lung inflammation for
people diagnosed with COPD.
Explanation of Procedures
This is a study that compares the exhaled breath of individuals diagnosed with COPD
receiving home oxygen therapy to those individuals diagnosed with COPD not receiving
oxygen therapy to determine if oxidative stress is occurring within the lungs as a result.
There will be two groups of patients. The groups include 1) patients diagnosed with
advanced COPD not receiving home oxygen therapy; and 2) patients diagnosed with
advanced COPD receiving home oxygen therapy. If you are selected to participate in this
study you will be assigned to one of these two groups. Group selection will be decided
by use of home oxygen therapy. A PhD candidate from Virginia Commonwealth
University is conducting this study.
The care given to the patient will not be changed in any way other than the collection
exhaled breath into a collecting device, which will take approximately 10 minutes. The
patient will be asked to breath into a spirometry device to determine lung function.
Information needed for the study will be collected from the principle investigator, project
manager or staff. This information will include but not be limited to age, height, weight,
ethnicity, smoking status and history, oxygen therapy history.
Participants Initials:__________
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Appendix D

Informed Consent
Title of Research: Chronic exposure to low flow home oxygen therapy as a mechanism of
oxidative stress
Investigators: Jill Stulce, MSN, CRNA
Risks
No risks are associated with study participation.
Benefits
There may be no direct advantage to being in this study. Information from this study
may help make the care better for future patients.
Participant Selection
We are asking only those individuals who have been diagnosed with COPD who may or
may not be on oxygen therapy.
Withdrawal Without Prejudice
You do not have to be in this research study. You can agree to be in the study now and
change your mind later. Your decision will not affect your care.
Confidentiality
Information collected will remain private. The information collected from your chart
may be printed for scientific purposes. This information includes the your medication
list, age, height, weight, ethnicity, pulmonary function test results, smoking status and
history, oxygen therapy history. Your identity will not be revealed. The researchers will
be the only ones with access to the study information.
Costs and/or Payment to Subject for Participation in Research
There will be no costs for taking part in the study. Also, you will not be paid to take part
in this study.
Participant’s Initials:__________
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Appendix E

Informed Consent
Title of Research: Chronic exposure to low flow home oxygen therapy as a mechanism of
oxidative stress
Investigators: Jill Stulce, PhDc, CRNA
Questions
Any questions regarding study participation should be made directly to Jill Stulce, PhDc,
CRNA at 314-691-1310.
Agreement
This agreement states that you have received a copy of this informed consent. Your
signature below says that you agree to participate in this study.

_______________________________________
Signature of Participant

__________________
Date

_______________________________________
Participant Name (printed)

_______________________________________
Signature of Researcher or Anesthesia Provider
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___________________
Date

Appendix F

Exhaled Breath Collection Instruction Sheet
To better understand processes occurring within the lungs of COPD patients receiving
oxygen therapy we are asking you to participate in a research project by providing your
exhaled breath for analysis. Below is a list of what is required by you to ensure success in
this evaluation.
Thank you for your participation.
1. Rinse mouth prior to introducing RTube™ mouthpiece into mouth.
2. Secure lips around mouthpiece and breath in and out through your mouth
3. Approximately 10 minutes is required to obtain an adequate amount of exhaled
breath condensate for analysis
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